---
document_datetime: 2025-12-18 11:57:10
document_pages: 116
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/saphnelo-h-c-004975-x-0023-epar-assessment-report-variation_en.pdf
document_name: saphnelo-h-c-004975-x-0023-epar-assessment-report-variation_en.pdf
version: success
processing_time: 111.3466314
conversion_datetime: 2025-12-24 23:18:07.747417
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

16 October 2025 EMA/348230/2025 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

Saphnelo

International non-proprietary name: anifrolumab

Procedure No. EMEA/H/C/004975/X/0023

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                              | ..............................................8                                                           |
|-------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier....................................................................................      | 8                                                                                                         |
| 1.2. Legal basis and dossier content............................................................................        | 8                                                                                                         |
| 1.3. Information on Paediatric requirements.................................................................            | 8                                                                                                         |
| 1.4. Information relating to orphan market exclusivity                                                                  | ................................................... 8                                                     |
| 1.4.1. Similarity                                                                                                       | ....................................................................................................... 8 |
| 1.5. Scientific advice................................................................................................. | 8                                                                                                         |
| 1.6. Steps taken for the assessment of the product                                                                      | ....................................................... 9                                                 |
| 2. Scientific discussion                                                                                                | ..............................................................................10                          |
| 2.1. Problem statement...........................................................................................       | 10                                                                                                        |
| 2.1.1. Disease or condition.......................................................................................      | 11                                                                                                        |
| 2.1.2. Epidemiology                                                                                                     | ................................................................................................ 11       |
| 2.1.3. Clinical presentation, diagnosis prognosis..........................................................             | 11                                                                                                        |
| 2.1.4. Management.................................................................................................      | 12                                                                                                        |
| 2.2. About the product ............................................................................................     | 12                                                                                                        |
| 2.3. Type of Application and aspects on development                                                                     | .................................................. 12                                                     |
| 2.4. Quality aspects ................................................................................................   | 12                                                                                                        |
| 2.4.1. Introduction .................................................................................................   | 12                                                                                                        |
| 2.4.2. Active Substance...........................................................................................      | 13                                                                                                        |
| 2.4.3. Finished Medicinal Product ..............................................................................        | 13                                                                                                        |
| 2.4.4. Discussion on chemical, pharmaceutical and biological aspects.............................                       | 18                                                                                                        |
| 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects                                               | ..................... 19                                                                                  |
| 2.5. Non-clinical aspects..........................................................................................     | 19                                                                                                        |
| 2.5.1. Introduction .................................................................................................   | 19                                                                                                        |
| 2.5.2. Pharmacology...............................................................................................      | 19                                                                                                        |
| 2.5.3. Pharmacokinetics                                                                                                 | .......................................................................................... 19             |
| 2.5.4. Toxicology....................................................................................................   | 20                                                                                                        |
| 2.5.5. Ecotoxicity/environmental risk assessment........................................................                | 21                                                                                                        |
| 2.5.6. Discussion on non-clinical aspects....................................................................           | 21                                                                                                        |
| 2.5.7. Conclusion on the non-clinical aspects..............................................................             | 21                                                                                                        |
| 2.6. Clinical aspects ................................................................................................  | 22                                                                                                        |
| 2.6.1. Introduction .................................................................................................   | 22                                                                                                        |
| 2.6.2. Clinical pharmacology ....................................................................................       | 23                                                                                                        |
| 2.6.3. Discussion on clinical pharmacology .................................................................            | 36                                                                                                        |
| 2.6.4. Conclusions on clinical pharmacology ...............................................................             | 39                                                                                                        |
| 2.6.5. Clinical efficacy .............................................................................................  | 39                                                                                                        |
| 2.6.6. Discussion on clinical efficacy ..........................................................................       | 72                                                                                                        |
| 2.6.7. Conclusions on the clinical efficacy...................................................................          | 77                                                                                                        |
| 2.6.8. Clinical safety ...............................................................................................  | 77                                                                                                        |
| 2.6.9. Discussion on clinical safety                                                                                    | ...........................................................................102                            |
| 2.6.10. Conclusions on the clinical safety                                                                              | ..................................................................107                                     |
| 2.7. Risk Management                                                                                                    | Plan.....................................................................................107              |
| 2.7.1. Safety concerns                                                                                                  | ...........................................................................................107            |

<div style=\"page-break-after: always\"></div>

2.7.2. Pharmacovigilance plan  .................................................................................  107

2.7.3. Risk minimisation measures  ...........................................................................  110

2.7.4. Conclusion  ...................................................................................................  110

2.8. Pharmacovigilance...........................................................................................  110

2.8.1. Pharmacovigilance system  .............................................................................  110

2.8.2. Periodic Safety Update Reports submission requirements ...................................  111

2.9. Product information  .........................................................................................  111

2.9.1. User consultation..........................................................................................  111

3. Benefit-Risk Balance............................................................................  111

3.1. Therapeutic Context ........................................................................................  111

3.1.1. Disease or condition......................................................................................  111

3.1.2. Available therapies and unmet medical need ....................................................  111

3.1.3. Main clinical studies  ......................................................................................  112

3.2. Favourable effects  ...........................................................................................  112

3.3. Uncertainties and limitations about favourable effects ..........................................  112

3.4. Unfavourable effects  ........................................................................................  112

3.5. Uncertainties and limitations about unfavourable effects .......................................  113

3.6. Effects Table ..................................................................................................  113

3.7. Benefit-risk assessment and discussion ..............................................................  115

3.7.1. Importance of favourable and unfavourable effects ...........................................  115

3.7.2. Balance of benefits and risks  ..........................................................................  115

3.7.3. Additional considerations on the benefit-risk balance .........................................  115

3.8. Conclusions  ....................................................................................................  116

4. Recommendations ...............................................................................  116

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| CR       | American College of Rheumatology                                                      |
|----------|---------------------------------------------------------------------------------------|
| ADA      | Anti-drug antibody                                                                    |
| AE       | Adverse event                                                                         |
| AESI     | Adverse event of special interest                                                     |
| AI       | autoinjector                                                                          |
| ALB      | Serum albumin                                                                         |
| ANA      | antinuclear antibody                                                                  |
| APFS     | Accessorised pre-filled syringe                                                       |
| APS      | antiphospholipid syndrome                                                             |
| AUC      | Area under the concentration-time curve                                               |
| AUC sd   | AUC during the first dosing interval                                                  |
| AUC inf  | area under concentration-time curve from time zero extrapolated to infinity           |
| AUC last | area under concentration time curve from time zero to last quantifiable concentration |
| AUC ss   | AUC at steady state                                                                   |
| BICLA    | British Isles Lupus Assessment Group-2004-based Combined Lupus Assessment             |
| BILAG    | British Isles Lupus Assessment Group                                                  |
| BMI      | body-mass index                                                                       |
| B4SIGENE | 4-gene signature status                                                               |
| C ave,sd | Average concentration after first administration                                      |
| C ave,ss | Average concentration at steady state                                                 |
| CDL      | clinical data lock                                                                    |
| CI       | Confidence interval                                                                   |
| CL       | Clearance                                                                             |
| CL/F     | apparent total body clearance of drug after extravascular administration              |
| C ave    | average concentration                                                                 |
| CHMP     | Committee for Medicinal Products for Human Use                                        |
| CLASI    | Cutaneous Lupus Erythematosus Disease Area and Severity Index                         |
| C max    | maximum concentration                                                                 |
| C max,sd | Maximum concentration after first administration                                      |
| C max,ss | Maximum concentration at steady state                                                 |
| CHM      | Cochran-Mantel-Haenszel                                                               |
| C min    | minimum concentration                                                                 |
| C min,sd | Minimum concentration after first administration                                      |

<div style=\"page-break-after: always\"></div>

| C min,ss   | Minimum concentration at steady state                                                                 |
|------------|-------------------------------------------------------------------------------------------------------|
| COVID-19   | Coronavirus disease 2019                                                                              |
| CrCL       | Creatinine clearance                                                                                  |
| CSP        | clinical study protocol                                                                               |
| CSR        | clinical study report                                                                                 |
| C trough   | trough concentration                                                                                  |
| CV         | Coefficient of variation /Cardiovascular                                                              |
| CV-EAC     | Cardiovascular Event Adjudication Committee                                                           |
| CWRES      | Conditional weighted residuals                                                                        |
| EAIR       | exposure-adjusted incidence rate                                                                      |
| eGFR       | estimated glomerular filtration rate                                                                  |
| D          | Day                                                                                                   |
| DB         | double-blind                                                                                          |
| DCO        | Data cut-off                                                                                          |
| DMC        | Data Monitoring Committee                                                                             |
| dsDNA      | double-stranded deoxyribonucleic acid                                                                 |
| EMA        | European Medicines Agency                                                                             |
| E-R        | Exposure-response (model)                                                                             |
| EULAR      | European Alliance of Associations for Rheumatology                                                    |
| F          | bioavailability                                                                                       |
| FAS        | full analysis set                                                                                     |
| FDA        | Food and Drug Administration                                                                          |
| GCP        | Good Clinical Practice                                                                                |
| GOF        | Goodness-of-fit                                                                                       |
| HCP        | Health Care Professionals                                                                             |
| HCV        | hepatitis C virus                                                                                     |
| HR         | hazard ratio                                                                                          |
| IA         | Interim analysis                                                                                      |
| ICE        | intercurrent event                                                                                    |
| ICF        | informed consent form                                                                                 |
| IFN        | interferon                                                                                            |
| IFNAR1     | subunit 1 of the type I interferon receptor                                                           |
| IMP        | Investigational medicinal product                                                                     |
| IP         | investigational product                                                                               |
| IPRED      | Individual prediction                                                                                 |
| IV         | Intravenous                                                                                           |
| K a        | first-order absorption rate constant                                                                  |
| K m        | The concentration at which elimination of 50% of the maximum is achieved in Michaelis Menten equation |

<div style=\"page-break-after: always\"></div>

| L         | Liter                                                                                       |
|-----------|---------------------------------------------------------------------------------------------|
| LS        | least squares                                                                               |
| LLOQ      | lower limit of quantification                                                               |
| ULOQ      | upper limit of quantification                                                               |
| mAb       | monoclonal antibody                                                                         |
| MACE      | major acute cardiovascular events                                                           |
| MI (MAR)  | multiple imputation (missing at random)                                                     |
| MRT       | mean residence time of the unchanged drug in the systemic circulation from zero to infinity |
| NA        | not applicable                                                                              |
| nAb       | neutralizing antibody                                                                       |
| NC        | noncompliance                                                                               |
| NR        | non-responder                                                                               |
| NSAID     | non-steroidal anti-inflammatory drug                                                        |
| OCS       | oral corticosteroids                                                                        |
| OLE       | open-label extension                                                                        |
| ORR       | Objective response rate                                                                     |
| OS        | Overall survival                                                                            |
| pAb       | polyclonal antibody                                                                         |
| pcVPC     | Prediction corrected visual predictive check                                                |
| PD        | pharmacodynamic(s)                                                                          |
| PEOT      | premature end of treatment                                                                  |
| PGA       | Physician's Global Assessment                                                               |
| PK        | Pharmacokinetic(s)                                                                          |
| PPK       | Population pharmacokinetic(s)                                                               |
| PT        | Preferred term                                                                              |
| PY        | Patient years                                                                               |
| Q         | Intercompartmental clearance                                                                |
| Q2W       | Once every 2 weeks                                                                          |
| Q3W       | Once every 3 weeks                                                                          |
| Q4W       | Once every 4 weeks                                                                          |
| QW        | Once per week                                                                               |
| RM        | restricted medication                                                                       |
| RSE       | Relative standard error                                                                     |
| SAP       | statistical analysis plan                                                                   |
| SC        | subcutaneous                                                                                |
| SD        | standard deviation                                                                          |
| SLE       | Systemic Lupus Erythematosus                                                                |
| SLEDAI-2K | Systemic Lupus Erythematosus Disease Activity Index 2000                                    |

<div style=\"page-break-after: always\"></div>

| SoC        | Standard of care                                                                                 |
|------------|--------------------------------------------------------------------------------------------------|
| SOC        | System organ class                                                                               |
| SRI(4)     | Systemic Lupus Erythematosus Responder Index of ≥ 4                                              |
| t 1/2      | half-life                                                                                        |
| t 1/2 λ z  | half-life associated with terminal slope ( λ z) of a semi-logarithmic concentration time curve   |
| TE-ADA     | treatment-emergent anti-drug antibody                                                            |
| t last     | time of last quantifiable concentration                                                          |
| USA        | United States of America                                                                         |
| V c or V 2 | Volume of distribution of the central compartment                                                |
| V max      | The maximal elimination rate constant of Michaelis Menten equation                               |
| V p or V 3 | Volume of distribution of the peripheral compartment                                             |
| VPC        | Visual predictive check                                                                          |
| VAS        | visual analog scale                                                                              |
| V z /F     | apparent volume of distribution following extravascular administration (based on terminal phase) |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

AstraZeneca AB submitted on 18 December 2024 an extension of the marketing authorisation to introduce a new pharmaceutical form (solution for injection) associated with a new route of administration (subcutaneous use) and a new strength (120 mg).

Furthermore, the PI is brought in line with the latest QRD template version 10.4.

## 1.2. Legal basis and dossier content

The legal basis for this application refers to:

Article 19 of Commission Regulation (EC) No 1234/2008 and Annex I of Regulation (EC) No 1234/2008, (2) point(s) (c) (d) (e) - Extensions of marketing authorisations

## 1.3. Information on Paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/0149/2023 covering the application on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0149/2023 was not yet completed as some measures were deferred.

## 1.4. Information relating to orphan market exclusivity

## 1.4.1. Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## 1.5. Scientific advice

<div style=\"page-break-after: always\"></div>

Table 1: Scientific advice and protocol assistance

| Date       | Topic (quality/ non-clinical/ clinical)   | Reference number / Coordinator(s)   | Brief summary of the advice                                                                                                                                                                                                                                                                                                                                                 |
|------------|-------------------------------------------|-------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2016-05-26 | Clinical                                  | EMEA/H/SA/2903/2/2016/II            | The Scientific advice pertained to the following non-clinical, and clinical aspects: Clinical development, Phase II, Study drug, Dose, Pharmacokinetics, Primary endpoints, Composite / Co- primary, Secondary endpoints, Methodology, Statistical Analysis, Sample size, Population, Inclusion, Exclusion, Special population                                              |
| 2018-07-26 | Non-Clinical, Clinical                    | EMEA/H/SA/2903/3/2018/III           | The Scientific advice pertained to the following non-clinical, and clinical aspects: Pre-clinical development, Clinical development, Phase III, Comparability, Study drug, Dose, Pharmacokinetics, Methodology, Statistical Analysis,                                                                                                                                       |
| 2023-02-23 | Clinical                                  | EMA/SA/0000121096                   | The Scientific advice pertained to the following clinical aspects: clinical and statistical alignment with the Agency on the acceptability of a Bayesian borrowing methodology                                                                                                                                                                                              |
| 2022-08-29 | Clinical                                  | EMA/SA/0000095558                   | The Scientific advice pertained to the following and clinical aspects: design of the proposed global, single, Phase III study of anifrolumab to obtain an indication for the treatment of systemic sclerosis. Details of the study design, including intended target population, primary and key secondary efficacy endpoints, as well as the proposed statistical approach |

## 1.6. Steps taken for the assessment of the product

The Rapporteur appointed by the CHMP was:

Rapporteur: Outi Mäki-Ikola

<div style=\"page-break-after: always\"></div>

| The application was received by the EMA on                                                                                                                                               | 18 December 2024   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| The procedure started on                                                                                                                                                                 | 23 January 2025    |
| The CHMP Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on                                                                                             | 14 April 2025      |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC and CHMP members on                                                                                             | 28 April 2025      |
| The CHMP agreed on the consolidated List of Questions to be sent to the MAH during the meeting on                                                                                        | 22 May 2025        |
| The MAH submitted the responses to the CHMP consolidated List of Questions on                                                                                                            | 16 July 2025       |
| The CHMP Rapporteur circulated the CHMP Assessment Report on the responses to the List of Questions to all CHMP and PRAC members on                                                      | 25 August 2025     |
| The CHMP Rapporteur circulated the updated CHMP Assessment Report on the responses to the List of Questions to all CHMP and PRAC members on                                              | 11 September 2025  |
| The CHMP agreed on a list of outstanding issues in writing and/or in an oral explanation to be sent to the MAH on                                                                        | 18 September 2025  |
| The MAH submitted the responses to the CHMP List of Outstanding Issues on                                                                                                                | 23 September 2025  |
| The CHMP Rapporteur circulated the CHMP Assessment Report on the responses to the List of Outstanding Issues to all CHMP and PRAC members on                                             | 01 October 2025    |
| The CHMP Rapporteur circulated the updated CHMP Assessment Report on the responses to the List of Outstanding Issues to all CHMP and PRAC members on                                     | n/a                |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Saphnelo on | 16 October 2025    |

## 2. Scientific discussion

## 2.1. Problem statement

This application is a line extension concerning the development of a subcutaneous (SC) formulation of anifrolumab administered once weekly (QW).

<div style=\"page-break-after: always\"></div>

## 2.1.1. Disease or condition

Systemic  lupus  erythematosus  is  a  complex,  chronic,  and  heterogeneous  autoimmune  disease  of unknown etiology that affects multiple organ systems.

The sought indication is: ' Saphnelo is indicated as an add on therapy for the treatment of adult patients with  moderate  to  severe,  active  autoantibody  positive  systemic  lupus  erythematosus  (SLE),  despite standard therapy ', which is identical to the approved wording for IV anifrolumab.

## 2.1.2. Epidemiology

The incidence and prevalence rates of SLE across the world are generally estimated at 0.3 to 23.7 cases per 100.000 person-years and 6.5 to 178.0 cases per 100.000 persons, respectively, although these types of estimates can be considered conservative as they do not capture cases of mild, undiagnosed, or misdiagnosed disease. There are wide geographical variations in the incidence and prevalence of SLE based on sex, age, and ethnicity. Systemic lupus erythematosus disproportionally affects females over males (~9:1) and primarily affects women of childbearing potential. Incidence and prevalence rates in people of African or Asian descent are 2 to 3 times higher than in Caucasian populations. In addition, non-Caucasians often have more severe clinical manifestations, such as increased haematological, serosal, neurological, and renal manifestations, and accrue more damage over time and at a faster pace. In about 15%-20% of cases, disease onset occurs during childhood and tends to be more severe with faster and more severe damage accrual.

Compared to the general population, the overall mortality in SLE is elevated, with a standardised mortality ratio (defined as the ratio of the number of deaths observed to deaths expected) of 2.4 reported in a large international cohort of 9.457 subjects followed for over 70.000 subject-years.

## 2.1.3. Clinical presentation, diagnosis prognosis

SLE is a chronic, multisystemic, disabling autoimmune rheumatic disease of unknown aetiology. Clinical manifestations of SLE can include constitutional symptoms, alopecia and rashes, serositis, inflammatory arthritis, renal disease, systemic vasculitis, lymphadenopathy, splenomegaly, haemolytic anaemia, cognitive dysfunction, and other central nervous system involvement. Arthritis and photosensitive skin rash are common presenting features. Patients may present with a single or a variety of clinical manifestations and the most frequent serologic finding (an abnormal anti-nuclear antibody (ANA) test) is sensitive but not specific for the diagnosis. This can make diagnosis and management of the disease challenging.

The manifestations and progression of SLE are unpredictable and include periods of chronic activity, clinically inactive periods, and phases with heightened disease activity ('disease flares'). Due to the variable nature of the disease and its treatment, patients experience reduced physical function, loss of employment, and significantly worse health-related quality of life. According to a recent survey of over 2000 SLE patients, severe fatigue was ranked as one of their most burdensome symptoms. Increased hospitalisations and side effects of medications add to the disease burden.

Uncontrolled, ongoing disease activity over time has been associated with poorer outcomes, such as organ damage and coronary artery disease in SLE. Higher doses of medications to control disease activity are associated with cumulative and irreversible organ damage (such as premature cataracts, retinopathy, osteoporotic fractures, cardiovascular damage, avascular necrosis, and infections and early mortality from causes such as infection and cardiovascular disease), shortening lifespan by about 10 years.

<div style=\"page-break-after: always\"></div>

## 2.1.4. Management

Until the approval of the 2 available targeted therapies for SLE (belimumab, IV or SC) and IV anifrolumab, treatments were based on non-targeted therapies such as OCS and other immunosuppressive drugs. These  remain  a  major  component  of  SLE  therapy.  However,  chronic  steroid  use,  nonsteroidal  antiinflammatory drugs, and immunosuppressive agents have known safety concerns that contribute to longterm morbidity and mortality in SLE patients.

There continues to be a need for improvement in SLE treatment through enhanced convenience for patients.

## 2.2. About the product

Anifrolumab is a human IgG1 κ mAb that inhibits binding of type I IFNs to IFNAR1. By blocking type 1 IFN signaling, anifrolumab reduces multiple innate and adaptive downstream inflammatory pathways.

The currently approved wording for IV anifrolumab is as follows: ' Saphnelo is indicated as an add on therapy  for  the  treatment  of  adult  patients  with  moderate  to  severe,  active  autoantibody  positive systemic lupus erythematosus (SLE), despite standard therapy. '

The same SLE population as for IV use is targeted for SC use; therefore, there is no proposed change to the approved indication. The recommended dose is 120 mg by SC administration QW.

The extension application concerns SC route of administration with new delivery devices, accessorised prefilled  syringe  (APFS)  or  prefilled  pen/autoinjector  (AI),  with  the  options  of  administration  by healthcare professionals and for at-home use (self-administration or by caregiver).

## 2.3. Type of Application and aspects on development

This submission refers to a type of application which is an extension of marketing authorisation of a complete and independent application.

The anifrolumab SC clinical programme included a pivotal global, multicenter, randomized, double-blind (DB), placebo-controlled, Phase III study (D3465C00001; TULIP SC). TULIP SC was an ongoing study during the procedure evaluating the safety and efficacy of anifrolumab SC administered by accessorised pre-filled syringe (APFS) in adults with moderate to severe SLE despite receiving standard of care.

The independent Data Monitoring Committee (DMC) made a recommendation that the interim analysis (IA) met the pre-specified efficacy criteria with no new safety findings. The MAH considered the data to provide  substantial  evidence  that  anifrolumab  SC  showed  a  positive  benefit-risk  profile  that  was consistent with the established profile of the approved IV treatment.

## 2.4. Quality aspects

## 2.4.1. Introduction

The finished product (FP) is presented as a solution for injection containing 150 mg/ml of anifrolumab as active substance.

Other ingredients are: histidine/ histidine hydrochloride monohydrate, lysine hydrochloride, trehalose dihydrate, polysorbate 80 (E 433), water for injections.

<div style=\"page-break-after: always\"></div>

The product is available in pre-filled pen [also referred to as autoinjector (AI)] and in pre-filled syringe [also referred to as accessorised pre-filled syringe (APFS)].

The objective of this extension application is to add subcutaneous (SC) route of administration to be administered with new delivery devices, accessorised prefilled syringe or prefilled pen/autoinjector. The recommended dose and dosing regimen will be different than the currently approved intravenous (IV) administration, however the formulation and concentration of 150 mg/ml remain the same.

## 2.4.2. Active Substance

The  active  substance  (AS),  anifrolumab,  a  human,  immunoglobulin  G1  kappa  (IgG1 κ) monoclonal antibody produced in mouse myeloma cells (NS0) by recombinant DNA technology.

There are no changes to the active substance.

## 2.4.3. Finished Medicinal Product

## 2.4.3.1. Description of the product and pharmaceutical development

## Description of the product

The  finished  product  is  a  sterile,  preservative-free,  liquid  dosage  form  intended  for  subcutaneous injection.

The finished product is supplied:

- -as a single-dose pre-filled pen: 120 mg of anifrolumab per AI with a 0.8 mL label-claim volume
- -as a single-dose accessorised pre-filled syringe (APFS): 120 mg of anifrolumab per APFS with a 0.8 mL label-claim volume.

The finished product contains 150  mg/mL  anifrolumab  in  L-histidine/L-histidine hydrochloride monohydrate,  L-lysine  hydrochloride, α,α -trehalose  dihydrate,  polysorbate  80,  pH  5.9.  The  finished product  is  aseptically  filled  into  a  1  mL  long-staked  needle  glass  syringe  and  stoppered  with  an elastomeric plunger stopper.

The active substance is provided ready to fill into syringes for manufacture of the finished product. The AS composition is the same as the finished product composition. All excipients present in the anifrolumab finished product are of compendial grade and are commonly used in the manufacturing of parenteral pharmaceutical preparations.

## Formulation development

A summary of the finished product history from clinical to commercial development is provided. The 120 mg/syringe  sterile  finished  product  was  developed  to  ensure  anifrolumab  quality  over  the  intended finished  product  shelf  life  and  to  enable  and  provide  convenience  for  a  subcutaneous  route  of administration. The development of the formulation is described, and characterization of the intended commercial formulation is evaluated.

Overall, sufficient formulation development studies were conducted and in general the conclusions drawn by  the  applicant  can  be  agreed.  The  results  indicate  that  the  formulation  possessed  appropriate robustness.

<div style=\"page-break-after: always\"></div>

No formula overages are included. Overfill to ensure the deliverable volume of the finished finished product is included and is considered acceptable.

## Manufacturing process development

Overview of the development history of the manufacturing processes including a summary description of the processes used to manufacture materials for all anifrolumab clinical studies has been provided.

The Applicant has conducted comparability assessments to evaluate the impact of the changes between the finished product manufacturing processes.

In  conclusion,  release  test  data,  and  for  some  comparability  exercises  also  stability  data,  has  been provided. As the Applicant has compared commercial PFS-SA material to all relevant materials: PFS-SA (clinical), vial (authorised), and vial, (clinical) and all provided test results demonstrate comparability, the comparability of the commercial PFS-SA to clinical FPS-SA and previously approved presentations, can be considered sufficiently demonstrated.

## Process characterisation

Manufacturing process characterisation studies for finished product manufacturing process have been performed  to  assess  the  effects  of  manufacturing  process  parameters  and  environmental  factors (product-contact materials and light exposure) on product quality to identify critical process parameters (CPPs). Results of the studies are presented in acceptable detail. Based on risk assessment and the cumulative potential leachables level calculated based on the total organic carbon results of the medium or high-risk materials, the materials used in the finished product manufacturing process were found to pose a low risk to patient safety.

Analytical  equivalency  characterization  studies  and  device  equivalency  characterization  studies  were performed between prefilled syringe sub-assembly and accessorised prefilled syringe (PFS-SA/APFS) as well as between prefilled syringe sub-assembly and autoinjector (PFS-SA/AI). The purpose of analytical equivalency characterization studies is to assess potential impact of APFS or AI assembly process on anifrolumab product quality profile, and to support using PFS-SA as an equivalent material to APFS or AI for product quality lot release. The studies demonstrated that the assembly process does not impact anifrolumab product quality. Based on the studies, the testing of PFS-SA is supported.

Device equivalency characterization studies between the PFS-SA and APFS demonstrate that the device performance attributes could be tested at the PFS-SA intermediate stage as representative of the final APFS  product. Also, device equivalency characterization studies  between  the  PFS-SA  and  AI demonstrated that the device performance attributes could be tested at the PFS-SA intermediate stage as representative of the final AI product. Thus, assembly, labelling, and packaging processes do not meaningfully  impact  these  device  performance  attributes.  The  functionality  of  the  assembled  APFS delivery devices over the claimed shelf life is adequately demonstrated.

## Microbiological attributes

Sterility and endotoxin of the FP are tested as part of batch release, and sterility and container closure integrity  are  tested  as  part  of  the  FP  stability  program.  This  is  considered  adequate.  No  failures  of sterility, endotoxin, or container closure integrity tests have been observed to date in the FP container closure system. The container closure integrity of the intended commercial FP manufactured at the FP fill facility was qualified as part of the fill-finish validation program to demonstrate proper stoppering of the syringes.

## Compatibility

<div style=\"page-break-after: always\"></div>

Saphnelo FP is ready to use solution for injection in PFS (APFS) or solution for injection in pre-filled pen (AI) for subcutaneous administration. No reconstitution diluent(s) is used. Compatibility is adequately presented.

## 2.4.3.2. Manufacture of the product and process controls

## Manufacture

The  site  responsible  batch  release  in  EEA  of  both  PFS  and  AI  finished  product  presentations  is AstraZeneca AB, Gärtunavägen, Sweden. Valid proof of GMP compliance has been provided.

The  standard  manufacturing  process  is  comprised  of  active  substance  thawing,  pooling  and  mixing, bioburden  reduction  filtration  and  in-process  hold,  sterile  filtration,  aseptic  filling  into  ready-to-use syringes and aseptic stoppering with ready-to-use plungers, visual inspection, and assembly, labeling and  packaging.  The  assembly  of  PFS-SA  is  done  either  in  autoinjector  and  accessorised  pre-filled syringes. A narrative description of the full manufacturing process was provided, accompanied by a flow chart  describing  each  step  of  the  process  including  material  inputs,  critical/non-critical  process parameters and in-process controls. Acceptable ranges for critical/non-critical process parameters and in-process controls were presented in tabulated form. The description of the manufacturing process and process controls is considered sufficient and meets relevant guideline. There are no reprocessing or reworking steps indicated in the finished product manufacturing process and the batch numbering system was explained.

## Process controls

Control  of  critical  finished  product  manufacturing  process  steps  is  described  through  critical  process parameters, in-process controls and in-process hold time. Summaries of critical process parameters and in-process controls with acceptance criteria are provided and are considered appropriate. The limits for bioburden are in accordance with the relevant ' Guideline of Sterilisation of the Medicinal Drug Products (EMA/CHMP/QWP/850374/2015) '. Filter integrity limits were defined during filter validation studies.

The finished product manufacturing process was validated with consecutive commercial scale process validation (PV) lots for PFS-SA finished product at the proposed commercial manufacturing site.

Manufacturing process validation covered all manufacturing steps and the data included critical and noncritical process parameters, in-process controls and additional in-process testing. Overall, all PV batches were successfully validated and the acceptance criteria were met thus demonstrating the consistency and reliability of the finished product manufacturing process.

The  proposed  hold  time  for  thawed  and  mixed  AS  process  intermediate  after  bioburden  filtration  is supported by the process validation data.

The aseptic process validation (media fills) was carried out with commercial filling line to demonstrate that the aseptic condition is maintained during the filling process. Media fill data was provided but was not assessed since it is considered to be covered by GMP.

Filters are used in sterile filtration and were validated using worst case conditions The validation results demonstrated that the formulation does not compromise the integrity of the filters.  Furthermore, filters are compatible with the AS and according to the applicant the extractables are below the Threshold of Toxicological Concern for genotoxic impurities described in ICH M7. Overall, adequate and acceptable data of filter validation was presented.

<div style=\"page-break-after: always\"></div>

The  process  validation  of  label,  assembly  and  packing  manufacturing  for  AI/APFS  was  executed  on consecutive batches in accordance with the process validation protocol. No major or critical deviations were encountered during the process validation execution. All process validation acceptance criteria were met. Therefore, the assembly, labelling, and packaging process is capable of consistently producing packaged AI/APFS with acceptable attributes and has been successfully validated.

Shipping  qualification  of  anifrolumab  autoinjector  device  when  packaged  as  a  unitized  load  included simulated transportation in air and road modes that are representative of the commercial supply chain. Shipping validation data demonstrated that quality of finished product and functionality of AI were not affected when exposed to the supply chain routes from the filling site, to the label and pack site, and to the distribution centres. The shipping qualification included thermal and container integrity operational qualification and performance qualification studies. The provided data is considered acceptable.

## 2.4.3.3. Product specification

## Specifications

Comprehensive panel of specification in accordance with ICH Q6B principles are set for PFS-SA including tests for general properties, identity, purity and impurities, safety, potency and quantity. Additionally, functionality tests are performed on PFS-SA and AI.

Overall,  specifications  cover  all  relevant  characteristics  of  the  finished  product.  Additionally,  the acceptance criteria for all specification tests are considered acceptable and appropriately justified.

## Analytical procedures

Analytical procedures utilized in the specification tests of the finished product included both compendial and non-compendial methods. The validation data of in-house tests was provided in the dossier and are considered acceptable. Summaries of the analytical method transfer test results of in-house methods have been provided and are considered acceptable.

## Batch analysis

Batch analytical data was provided for clinical batches and commercial scale batches. Overall, all batches met the acceptance criteria of release specification in place at the time indicating adequate batch-to-batch consistency and controlled manufacturing process.

## Characterization of impurities:

Based on the risk assessment it can be concluded that it is not necessary to include any elemental impurity controls in the finished product specification. The information on the control of elemental impurities is satisfactory.

A risk evaluation concerning the presence of nitrosamine impurities in the finished product has been performed (as requested) considering all suspected and actual root causes in line with the 'Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products' (EMA/409815/2020) and the ' Assessment report- Procedure under Article 5(3) of Regulation EC (No) 726/2004- Nitrosamine impurities in human medicinal products ' (EMA/369136/2020). Based on the information provided it is accepted that no risk was identified on the possible presence of nitrosamine impurities in the active substance or the related finished product. Therefore, no additional control measures are deemed necessary.

## Container closure

<div style=\"page-break-after: always\"></div>

Finished product in the primary packaging is referred to as the pre-filled syringe sub-assembly (PFSSA). Device components are attached to the PFS-SA and do not contact the finished product solution. For the accessorised pre-filled syringe (APFS), the needle guard, finger flange and plunger rod are added to  the  PFS-SA to produce the APFS. For the autoinjector (AI), the PFS-SA is assembled with device components (drive unit and syringe) unit to produce the fully assembled AI.

The  primary  container  closure  system  components  and  device  components  (accessories)  have  been adequately described. Material compliances to pharmacopoeias, specifications for incoming inspection schematic drawings and suppliers are stated. Certificates of analysis have been provided for syringes, stoppers and needle and considered adequate. The rationale for choosing the container closure system was provided and is considered acceptable. The safety and compatibility of the finished product PFS-SA were adequately evaluated.

The finished product contacting primary container components come pre-sterilized. Secondary packaging components include an opaque paperboard carton to protect the finished product from light exposure and  an  internal  paperboard  partition  to  secure  the  labelled  device  during  transportation.  Carton components  are  constructed  from  coated,  bleached  paper  stock,  with  pre-printed  artwork.  This information is sufficient.

Devices have been further described in Section 3.2.R. This covers: Rationale for Regulatory Classification of the Product, Regulatory Compliance and Quality Systems, Device Description, Principles of Operation and Mode of Action, Device Components and Raw Materials, Design Changes from Clinical to Commercial, Design Verifications and Human Factors Engineering (HFE).

Notified body opinions on the conformity of the device part of a pharmaceutical product, with the relevant general safety and performance requirements (GSPR) for APFS and AI have been provided according to Annex I of Regulation (EU) 2017/745.

Overall, the provided data (P.7) as well as data from other CTD sections covering suitability of the CCS (P.2.4), confirmation of container closure integrity (P.2.5 and P.3.5.) and stability tests (P.8.1) indicate that the selected container closure systems are in general appropriate and enable adequate protection from microbial contamination.

## 2.4.3.4. Stability of the product

The proposed shelf life for the finished product is 48 months and is based on real time stability data from the PFS-SA batches at the long-term storage condition of 2-8°C.

Stability  is  monitored  at  three  conditions:  2-8°C  (recommended  long-term  storage  condition),  2327°C/55-65%  RH  (accelerated  condition)  and  38-42°C/70-80%  RH  (stress  condition).  The  testing intervals are in line with ICH Q5C.

Overall, the finished product stability program designed by the Applicant follows ICH Q1A and ICH Q5C guidelines and the stability study protocols have been provided for all presentations and conditions. The presented stability data supports the shelf-life of 48 months (4 years) for PFS-SA.

As there is no contact between the solution and the components of the delivery device, it is considered sufficient to test APFS and AI stability from PFS-SA. However, functionality of the assembled delivery device over the whole claimed shelf life should be demonstrated. 48 months device functionality data is provided for APFS and AI and the functionality of the assembled APFS as well as the AI delivery devices over the claimed shelf life is adequately demonstrated.

<div style=\"page-break-after: always\"></div>

Furthermore, design verification testing, presented in section R.2, includes performance testing after accelerated aging preconditioning to assure adequate performance of the APFS/AI device throughout the shelf life of the product.

The photostability study results for APFS and for AI demonstrate that the finished product commercial marketing packs are effective in protecting the finished product material from light exposure.

In-use stability studies to determine the suitability of a 7 days in-use duration at room temperature have been presented and support the statement in section 6.3 of the SmPC.

## 2.4.3.5. Adventitious agents

Adventitious agents evaluation of Saphnelo vial (iv) has been approved in previous submissions. Microbial control of the proposed finished product presentations have been adequately demonstrated and ensured throughout the finished product manufacturing process. No adventitious agents section has been provided in this extension application submission, which is considered acceptable.

## 2.4.4. Discussion on chemical, pharmaceutical and biological aspects

The objective of this extension application is to add subcutaneous (SC) route of administration to be administered with new delivery devices, accessorised prefilled syringe (APFS) or prefilled pen/autoinjector (AI). The currently approved Saphnelo IV product is not affected by this extension application. The recommended dose and dosing regimen will be different than the currently approved IV administration, however the formulation and concentration of 150 mg/ml remain the same. There are no changes to the active substance.

Overall,  the  provided  quality  dossier  is  of  good  quality,  and  all  the  relevant  sections  has  been satisfactorily covered. The Applicant has compared Commercial PFS-SA material to all relevant materials: PFS-SA  (clinical),  vial  (authorised),  and  vial  (clinical),  and  all  provided  test  result  demonstrate comparability. The comparability of the commercial PFS-SA to clinical FPS-SA and previously approved presentations,  can  be  considered  sufficiently  demonstrated.  The  manufacturing  process  and  control strategy  have  been  adequately  presented.  Manufacturing  process  validation  data  demonstrated  the consistency  and  reliability  of  the  finished  product  manufacturing  process.  Release  and  shelf-life specifications cover all relevant characteristics of the finished product and the acceptance criteria for all specification tests are considered acceptable and appropriately justified.

Finished product in the primary packaging is referred to as the pre-filled syringe sub-assembly (PFSSA). Device components are attached to the PFS-SA and do not contact the finished product solution. For the accessorised pre-filled syringe (APFS), the needle guard, finger flange and plunger rod are added to  the  PFS-SA to produce the APFS. For the autoinjector (AI), the PFS-SA is assembled with device components (drive unit and syringe)  unit  to  produce  the  fully  assembled  AI.  The  primary  container closure system components and device components (accessories) have been adequately described. The safety and compatibility of the finished product PFS-SA were adequately evaluated.

Medical  devices  have  been  further  described  in  Section  3.2.R.2.  Notified  body  opinions  have  been provided for the accessorised prefilled syringe (APFS) and for the autoinjector (AI) according to Annex I of Regulation (EU) 2017/745, with the relevant general safety and performance requirements (GSPR).

Long-term storage shelf-life at 2-8°C has been proposed for both APFS and AI. The presented stability data supports the proposed shelf-life of 48 months for PFS-SA. The functionality of the assembled APFS and AI delivery devices over the claimed shelf life are adequately demonstrated.

<div style=\"page-break-after: always\"></div>

## 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way.

## 2.5. Non-clinical aspects

## 2.5.1. Introduction

No new nonclinical data was submitted in this extension application to support the proposal to add the new route of administration (subcutaneous (SC)). To support anifrolumab SC administration, summaries of the previous studies in cynomolgus monkey submitted for the original MAA were provided and are shortly  summarised  below.  The  non-clinical  data  for  anifrolumab  has  been  reviewed  in  previous procedures.

The  information  in  sections  4.6  and  5.3  of  the  SmPC  remain  unchanged,  except  substituting  the information of safety margins via IV and SC routes of administration under the fertility .

## 2.5.2. Pharmacology

## 2.5.2.1. Primary pharmacodynamic studies

N/A

## 2.5.2.2. Secondary pharmacodynamic studies

N/A

## 2.5.2.3. Safety pharmacology programme

N/A

## 2.5.2.4. Pharmacodynamic drug interactions

N/A

## 2.5.3. Pharmacokinetics

Following SC injection, absorption of anifrolumab from the dosing site was slow, with the peak serum concentration occurring approximately 2 days after administration in cynomolgus monkeys. The slopes of the terminal phases for IV infusion and SC injection were similar.

The maximum observed serum concentration (Cmax) after SC and IV dosing was dose proportional. The nonlinear drug exposure (AUC) was likely the result of the receptor mediated clearance of anifrolumab at lower doses. The elimination half-life (t1/2) of anifrolumab increased with dose and was at lower doses &lt; 1 week and at higher doses &gt; 2 weeks.

<div style=\"page-break-after: always\"></div>

## 2.5.4. Toxicology

## 2.5.4.1. Single dose toxicity

N/A

## 2.5.4.2. Repeat dose toxicity

A GLP 9-month (39-week) repeat IV infusion or SC injection dose toxicity study in cynomolgus monkeys was conducted using anifrolumab 15 and 60 mg/kg/week SC dose levels (and 5 and 50 mg/kg/week IV dose) in cynomolgus monkeys (Study 7140-129). The findings noted were similar in the IV and SC route of administration groups. The NOAEL for female cynomolgus monkeys was 60 mg/kg SC (resulting a mean Cmax of 3,230 ± 1,120 μ g/mL and mean AUC0-7d  19,500 ± 5,620 μ g·d/mL), the highest doses tested in comparison, the NOAEL after IV dosing was 50 mg/kg IV (resulting in a mean Cmax of 4,510 ± 1,200 μ g/mL and mean AUC0-7d 21,600 ± 5,780 μ g·d/mL). Based on the arterial inflammation observed, the NOAEL for males was &lt; 15 mg/kg SC (and &lt;5 mg/kg IV). Of note, non-SLE vasculitis has not been a clinical safety finding attributed to anifrolumab in the clinical studies. The estimated safety margins for SC administrated anifrolumab (at NOAEL 15 mg/kg) and the MRHD of 120 mg SC every week were approximately 52 for AUC and 51 for Cmax for the 39-week study.

## 2.5.4.3. Genotoxicity

N/A

## 2.5.4.4. Carcinogenicity

N/A

## 2.5.4.5. Reproductive and developmental toxicity

N/A

## 2.5.4.6. Toxicokinetic data

See section 2.5.4.2. on repeat dose toxicity.

## 2.5.4.7. Local tolerance

No anifrolumab-related adverse changes were observed at the infusion/injection sites as assessed by dermal Draize scoring, macroscopic, and histopathology examinations in cynomolgus monkeys in the repeated-dose toxicity studies.

## 2.5.4.8. Other toxicity studies

N/A

<div style=\"page-break-after: always\"></div>

## 2.5.5. Ecotoxicity/environmental risk assessment

Anifrolumab is a monoclonal antibody, naturally occurring protein which non-hazardous and biodegradable. The environmental risk is negligible. As stated in the EMEA/CHMP/SWP/4447/00 Rev. 1Corr. 2024 guideline, in the case of medicinal products comprised of naturally occurring substances as active  substance,  the  ERA  may  consist  of  a  justification  for  not  submitting  ERA  studies.  Such  a justification was provided in the current variation submission and is acceptable.

## 2.5.6. Discussion on non-clinical aspects

No  new  non-clinical  data  was  submitted  in  this  extension  application  intended  to  add  SC  route  of administration in addition to IV. This was acceptable to the CHMP. The toxicological and toxicokinetic studies  included  in  the  original  MAA  were  considered  adequate  to  support  the  SC  administration anifrolumab of the current application.

The studies with SC route of administration were:

- Non-GLP single IV or SC dose toxicity, pharmacokinetics, pharmacodynamics, and immunogenicity Study of anifrolumab (MEDI -546) in male cynomolgus monkeys (Study 7140142).
- GLP  9-month  (39-week)  repeat  SC  injection  and  IV  infusion  toxicity,  toxicokinetic,  and immunogenicity  study  of  anifrolumab  (MEDI -546)  in  cynomolgus  monkeys  with  a  12 -week recovery period monkeys (Study 7140-129).

Following SC injection, absorption of anifrolumab from the dosing site was slow, with the peak serum concentration occurring approximately 2 days after administration in cynomolgus monkeys. The Cmax after SC and IV dosing was generally dose proportional.

The toxicology findings were similar after SC and IV route of administration in GLP 9-month (39-week) repeated dose study in cynomolgus monkeys with anifrolumab 15 and 60 mg/kg/week SC (and 5 and 50 mg/kg/week IV). The NOAEL for female cynomolgus monkeys was 60 mg/kg SC  (Cmax of 3,230 μ g/mL and AUC0-7d  19,500 μ g·d/mL). Based on the arterial inflammation observed, the NOAEL for males was &lt; 15 mg/kg SC. The estimated safety margins were approximately 52 for AUC and 51 for Cmax. No anifrolumab-related  adverse  changes  were  observed  at  the  infusion/injection  sites  in  cynomolgus monkeys. The safety margin following SC use has been included in the SmPC section 5.3.

The  active  substance  is  a  natural  substance,  the  use  of  which  will  not  alter  the  concentration  or distribution of the substance in the environment. Therefore, anifrolumab is not expected to pose a risk to the environment.

## 2.5.7. Conclusion on the non-clinical aspects

No new non-clinical data was submitted. The nonclinical data including the repeated dose toxicology and toxicokinetic  studies  in  cynomolgus  monkeys  using  the  SC  (and  IV)  route  of  administration  of anifrolumab, was acceptable for the proposed addition of the of the SC route of administration.

<div style=\"page-break-after: always\"></div>

## 2.6. Clinical aspects

## 2.6.1. Introduction

## GCP aspects

The Clinical studies were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical studies conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

A summary of the clinical studies relevant for the current application is shown in Table 2.

Table 2: Summary of clinical studies in the application

| Study number (name)                     | Study design Primary objective Primary endpoint                                                                                                                                                                                                                                                                                                                                                            | Patient population and No. of randomized participants                                                                                                                                                              | Dose and route of administration                              | Study status                                                                                                                                                                         |
|-----------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pivotal Phase III study                 | Pivotal Phase III study                                                                                                                                                                                                                                                                                                                                                                                    | Pivotal Phase III study                                                                                                                                                                                            | Pivotal Phase III study                                       | Pivotal Phase III study                                                                                                                                                              |
| D3465C00001 (TULIP SC)                  | Phase III study of the safety and efficacy of SC anifrolumab in patients with moderate to severe SLE despite standard of care Primary objective To compare efficacy of anifrolumab with placebo on overall disease activity in patients with SLE. Primary endpoint BICLA response at Week 52                                                                                                               | Adult patients 18 to 70 years of age with moderate to severe SLE N = 360 planned 1:1; IA based on first 220/360 planned randomized patients to complete 52- week treatment period or withdraw early from the study | Anifrolumab 120 mg or placebo SC QW administered via APFS     | Ongoing Recruitment of 220 patients for IA was completed July 2023; recruitment of the full study (N = 367) was completed 21 Aug 2024 Interim CSR dated 15 Nov 2024 (Module 5.3.5.1) |
| Device comparability and bridging study | Device comparability and bridging study                                                                                                                                                                                                                                                                                                                                                                    | Device comparability and bridging study                                                                                                                                                                            | Device comparability and bridging study                       | Device comparability and bridging study                                                                                                                                              |
| D3465C00002 Device PK Bridging Study    | A multicenter, randomized, open-label, parallel Phase 1 comparability study of anifrolumab administered using APFS or AI in Healthy Volunteers Primary objective To demonstrate that the PK exposure following single SC administration of anifrolumab by AI is comparable to the PK exposure following single SC administration of anifrolumab using APFS Primary endpoint AUC inf , AUC last , and C max | Adult healthy volunteers 18 to 55 years of age N = 180                                                                                                                                                             | Anifrolumab 120 mg SC single dose administered via APFS or AI | Completed Final CSR, dated 15 Nov 2023 (Module 5.3.3.1)                                                                                                                              |

Abbreviations: AI=Autoinjector; APFS=Accessorised pre-filled syringe; AUC=Area under the concentration-time curve; Cmax=Maximum concentration; CSR=Clinical study report; IA=Interim analysis; QW=Once per week; SC=Subcutaneous

<div style=\"page-break-after: always\"></div>

## 2.6.2. Clinical pharmacology

## 2.6.2.1. Pharmacokinetics

Pharmacokinetics of anifrolumab administered by subcutaneous (SC) route has been studied in four clinical studies. Two clinical studies have been conducted to support the SC administration of the applied dose 120 mg of anifrolumab (Table 2 ). An ongoing pivotal Phase III study (D3465C00001, hereafter referred to as 'TULIP SC study') was conducted to support approval of an SC route of administration with  a  prefilled  syringe  (APFS)  and  a  completed  Phase  I  device  PK  bridging  study  (D3465C00002, hereafter referred to as 'device PK bridging study') to support approval in an autoinjector (AI). Two additional completed clinical studies including SC administration of anifrolumab were submitted in the initial application for marketing authorisation. Phase I study D3461C00006 (study 06) was a randomized, placebo-controlled, double-blind, single-dose study to evaluate the safety, tolerability and pharmacokinetics of SC 300 mg and 600 mg SC anifrolumab doses, and 300 mg IV dose in healthy volunteers. Phase II study D3461C00008 (study 08) was a multicenter, randomized, placebo-controlled study characterizing the PK and PD, safety, and tolerability of SC anifrolumab in 36 SLE patients at doses of SC 150 mg or SC 300 mg or placebo, once every two weeks (Q2W) for 52 weeks (26 doses). The PK and PD data from this study was used to inform dose selection for Phase III clinical study with SLE patients. The PK data from these studies was included in the population PK analyses.

The final SC dose of 120 mg has been administered in 289 subjects including 180 healthy volunteers and 109 SLE patients.

## Formulations of drug product used in the clinical development

The drug product is an APFS or AI is a sterile 150 mg/1 mL solution for injection. Each APFS or AI contains a nominal label claim of 120 mg anifrolumab in a 0.8 mL volume. The formulation is similar to the originally approved for IV infusion. The drug product batches used in pivotal TULIP SC study and device PK bridging study were manufactured using Clinical Process 3. The earlier SC clinical studies (study 06 and study 08) were conducted with drug product manufactured by Process 2. The excipient composition has not changed since the initial development. The drug product originating from Process 2 and from the earlier Process 3 were confirmed comparable in the initial marketing authorisation for IV presentation.  The  comparability  of  the  drug  product  originating  from  the  different  manufacturing processes is based on comparison of the quality and physicochemical properties.

## Bioanalytical methods

The validated MSD-ECL assay for the quantitation of anifrolumab was the same assay as approved in the initial MAA. An additional validation report including additional stability data was provided. The stability of the analyte was demonstrated for nine freeze/thaw cycles and for 2183 days at -80 °C. All other bioanalytical methods were also the same assay as approved in the initial MAA. Bioanalytical reports for both clinical studies were provided including in-run validation results. The results of the incurred sample repeats met the acceptance criteria.

## Pharmacokinetic data analysis

Pharmacokinetic parameters were derived from dense PK data using non-compartmental methods with Phoenix WinNonlin Version 6.2 or 8.1 or higher depending on the study. All descriptive and inferential statistical computations were performed using SAS Version 9.2 or 9.4, or higher. The serum anifrolumab trough concentrations (Ctrough) were reported with descriptive statistics at each visit and time point in those  studies  where  sparse  PK  data  was  collected.  The  statistical  analyses  were  conducted  with appropriate models.

<div style=\"page-break-after: always\"></div>

A population PK (PPK) model was developed to describe the PK anifrolumab following intravenous (IV) and subcutaneous (SC) administration. A total of 14,176 serum PK samples from 1,194 subjects in ten clinical studies were included in the dataset.

## Absorption

In the Phase I PK study 06 in healthy volunteers, bioavailability of single doses of 300 mg SC anifrolumab given  as  two  1  ml  SC  injections,  300  mg  IV  anifrolumab  given  as  30  min  infusion  and  600  mg  SC anifrolumab given as 4 ml SC using an infusion pump were compared following serum concentrations for up to 57 days. The median time to peak concentration Tmax was 4.13 days (range 4.02 to 7.00 days) with mean Cmax of 36.22 µg/ml (SD 11.63) after SC injection of 300 mg dose. The bioavailability in terms of AUCinf after SC administration was approximately 16% lower compared to IV administration. Brief description of PK results and the concentration vs. time profiles were reported in the Saphnelo EPAR of the initial submission. The PK data was included in the population PK analyses.

Based on the population PK modelling, the estimated bioavailability of anifrolumab was 75% 72% after SC administration with a Ka of 0.189 day -1 .

## Relative bioavailability /Device PK-bridging study

Phase  I  study  (D3465C00002)  was  conducted  to  compare  anifrolumab  exposure  after  a  single  SC administration of 120 mg dose of anifrolumab using AI to administration of 120 mg dose using APFS in healthy male and female subjects, aged 18 to 55 years. In total 180 healthy volunteers were randomized 1:1:1:1:1:1 to one of the injection sites (upper arm, abdomen, or thigh) within a device group (APFS or AI) capped at 60 participants in each body weight category (50 to &lt; 70 kg, 70 to &lt; 90 kg, and 90 to 110 kg).

The geometric mean serum concentration vs. time profiles per device group are presented in Figure 1 . The serum concentration of anifrolumab reached maximum concentrations the median tmax being 5.00 days after administration by both AI (range 2.00 to 14.00 days) and APFS (range 2.00 to 11.00 days). Systemic exposure of anifrolumab following SC administration with AI device was comparable to APFS device as the 90% CIs for the geometric mean ratios of Cmax, AUCinf, and AUClast were contained within the interval of 0.8 and 1.25 for the bioequivalence margins (Table 3 ).

In the abdomen, the AI device group showed 15% and 21% larger geometric mean AUCinf and AUClast values than APFS device group. Following SC injection in the thigh and upper arm, the AI device showed 14% and 13% lower AUClast than injections by APFS, respectively. Similarly, Cmax was 21% larger for the AI device in the abdomen compared to the APFS device whereas it was 12% lower in both the thigh and upper arm. All PK parameters were deemed comparable between both device groups for each injection site.

The MAH has not compared exposures between the injection sites within a device (AI or APFS). Summary statistics of the main PK parameters are presented in Table 4 .

<div style=\"page-break-after: always\"></div>

Figure 1: Geometric mean (± gSD) serum concentration (ng/mL) of Anifrolumab versus time by treatment (AI vs. APSF) (linear scale) (PK analysis set)

<!-- image -->

Table 3: Statistical comparison of primary PK parameters (PK analysis set).

| Parameter (Unit)                                      | Comparison                                            | n                                                     | Geometric LS Mean                                     | Comparison of Device Groups                           | Comparison of Device Groups                           |
|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                                                       |                                                       |                                                       |                                                       | Ratio                                                 | 90% CI                                                |
| C max (ng/mL)                                         | AI vs APFS                                            | 90 vs 90                                              | 9402 vs 9617                                          | 0.9777                                                | (0.8880, 1.0764)                                      |
| AUC inf (day*ng/mL)                                   | AI vs APFS                                            | 88 vs 89                                              | 121500 vs 125800                                      | 0.9658                                                | (0.8727, 1.0689)                                      |
| AUC last (day*ng/mL)                                  | AI vs APFS                                            | 90 vs 90                                              | 115700 vs 120000                                      | 0.9644                                                | (0.8669, 1.0730)                                      |
| AI=Autoinjector; APFS=Accessorised pre-filled syringe | AI=Autoinjector; APFS=Accessorised pre-filled syringe | AI=Autoinjector; APFS=Accessorised pre-filled syringe | AI=Autoinjector; APFS=Accessorised pre-filled syringe | AI=Autoinjector; APFS=Accessorised pre-filled syringe | AI=Autoinjector; APFS=Accessorised pre-filled syringe |

<div style=\"page-break-after: always\"></div>

Table 4: Summary statistics (geometric mean and CV%) of anifrolumab PK parameters by injection site and device group.

| Parameter (Unit)    | Summary          | Abdomen (N = 60)   | Abdomen (N = 60)   | Thigh (N = 60)     | Thigh (N = 60)     | Upper Arm (N = 60)   | Upper Arm (N = 60)   |
|---------------------|------------------|--------------------|--------------------|--------------------|--------------------|----------------------|----------------------|
| Parameter (Unit)    | Summary          | AI (N = 30)        | APFS (N = 31)      | AI (N = 31)        | APFS (N = 30)      | AI (N = 29)          | APFS (N = 29)        |
| AUCinf (day*ng/mL)  | gMean            | 134800             | 117200 a           | 131100 a           | 145600             | 101500 b             | 116700               |
| AUCinf (day*ng/mL)  | gCV%             | 44.48              | 59.28              | 35.05              | 46.28              | 39.34                | 58.27                |
| AUCinf (day*ng/mL)  | Median           | 140900             | 119100             | 134600             | 151600             | 100600               | 130600               |
| AUCinf (day*ng/mL)  | Min - Max        | 39600 - 239000     | 34700 - 281000     | 64400 - 254000     | 57600 - 362000     | 55100 - 223000       | 9350 - 180000        |
| AUClast (day*ng/mL) | gMean            | 129800             | 107600             | 122500             | 142100             | 98160                | 112600               |
| AUClast (day*ng/mL) | gCV%             | 46.67              | 73.70              | 39.19              | 46.08              | 39.63                | 58.31                |
| AUClast (day*ng/mL) | Median           | 136000             | 115600             | 128700             | 149000             | 106700               | 127300               |
| AUClast (day*ng/mL) | Min - Max        | 34000 - 239000     | 14500 - 279000     | 64200 - 247000     | 57500 - 334000     | 48700 - 189000       | 9270 - 180000        |
| Cmax (ng/mL)        | gMean            | 10570              | 8768               | 10110              | 11450              | 7816                 | 8865                 |
| Cmax (ng/mL)        | gCV%             | 38.56              | 61.87              | 29.71              | 37.89              | 27.45                | 52.02                |
| Cmax (ng/mL)        | Median Min - Max | 10800 3990 - 19100 | 10000 1730 - 18800 | 10300 4820 - 17500 | 11950 5900 - 24100 | 7990 4630 - 13200    | 10000 981 - 15400    |
| tmax (day)          | Median           | 5.00               | 5.00               | 5.00               | 5.00               | 6.00                 | 5.00                 |
| tmax (day)          | Min - Max        | (2.00 - 11.00)     | (2.00 - 11.00)     | (5.00 - 11.00)     | (2.00 - 7.00)      | (2.00 - 14.00)       | (2.00 - 7.00)        |
| tmax (day)          | gCV%             | 58.33              | 65.29              | 54.37              | 53.05              | 49.07                | 74.88                |

## Distribution

The estimated central volume of distribution (Vc) for anifrolumab was 3.48 L, based on the final PPKmodel including exposures after SC administration, indicating typical distribution for IgG. The value is similar to the Vc of 2.93 L estimated in the population PK analyses following IV administration only.

## Elimination

Based on population PK analysis, the estimated typical (linear) CL was 0.146 L/day ([0.141 to 0.151] 95% CI) which is close to what was reported previously 0.193 L/day for IV anifrolumab only.

Anifrolumab has non-linear elimination caused by antigen sink effect resulting in more rapid elimination at lower concentrations. Therefore, elimination half-life decreases as concentration decreases.

## Dose proportionality and time dependencies

Following IV administration, anifrolumab exposure increased more than dose-proportionally because of increase of elimination at low serum concentrations by target-mediated elimination of anifrolumab. Dose proportionality has not been evaluated after SC administration. Subcutaneous doses of 150 mg, 300 mg and 600 mg in addition to the applied 120 mg dose have been used in the clinical studies.

In  the  PK  study  006  in  healthy  volunteers,  exposure  to  anifrolumab  increased  approximately  doseproportionally following single SC dose administration of anifrolumab when the dose was increased from 300 mg to 600 mg with the arithmetic mean Cmax increasing from 36.22 to 63.86 μ g/mL and AUCinf increasing from 784.6 to 1828 day* μ g/mL (6 subjects per treatment group).

<div style=\"page-break-after: always\"></div>

## Pharmacokinetics in target population

Pharmacokinetics of 120 mg dose of SC anifrolumab in the patients with SLE was investigated in the Phase III pivotal TULIP SC Study. Anifrolumab was administered SC via an APFS into abdomen, thigh or upper arm either by the patient or his/her caregiver at home following training by investigator or study personnel. The SC doses were to be administered at least 5 days apart. The three injection sites were to be rotated. By the cut-of date, 108 patients of 175 randomised patients were included in the PK analysis set.

Following SC administration of 120 mg dose once a week, at 12 week time point the geometric mean serum anifrolumab Ctrough value was 47.873 µg/ml (CV% 143.0%) with median (min, max) 57.711 µg/ml (0.010, 139.254). The steady state was reached between 12 and 24 weeks with geometric mean Ctrough of 57.126 µg/ml (CV% 156.7%) corresponding median (min, max) 70.558 µg/ml (0.010 µg/ml, 208.458 µg/ml) at 24 week time point (n=96). For the Week 57 and 63 time points, the anifrolumab Ctrough were reported  for  those  patients  who  did  not  enter  the  OLE  treatment  period.  Therefore,  anifrolumab concentrations started decline from week 52 onwards as the last SC dose was given on Week 51. The serum Ctrough vs. time profiles for SLE patients up to 63 weeks are presented in Figure 2 .

Figure 2: Serum anifrolumab trough concentrations (Ctrough) (mean ± SD) on linear and semi-logarithmic scale following 120 mg once weekly SC injection by APFS in SLE patients.

<!-- image -->

## Population PK modelling and simulations

The final PPK model was a two-compartment model with parallel first-order and Michaelis-Menten kinetics clearances from the central compartment. Absorption from SC administration site was characterized with estimated  bioavailability  (F1)  and  absorption  rate  constant  (Ka).  Interindividual  variability  was characterized on first-order clearance (CL), central volume (Vc), peripheral volume (Vp), the maximum velocity of saturated clearance process (Vmax), and Ka. The covariates were as follows: on CL, baseline body weight, albumin level, creatinine clearance, IFN 4-gene signature status (B4SIGENE), and sex; on Vc, baseline body weight; on Vmax, race. Parameter estimates are shown in Table 5 .

<div style=\"page-break-after: always\"></div>

Table 5: Parameter estimates for final anifrolumab PPK model

| Parameter            |   Estimate |   RSE (%) | 95% CI               | Shrinkage (%)   | Unit   |
|----------------------|------------|-----------|----------------------|-----------------|--------|
| 1. CL                |   0.146    |     1.7   | [0.141 ; 0.151]      | -               | L/d    |
| 2. V2                |   3.48     |     2.06  | [3.33 ; 3.62]        | -               | L      |
| 3. Q                 |   0.07     |     1.97  | [0.0673 ; 0.0727]    | -               | L/d    |
| 4. V3                |   1.72     |     4.68  | [1.56 ; 1.88]        | -               | L      |
| 5. KA                |   0.189    |     4.16  | [0.174 ; 0.205]      | -               | 1/d    |
| 6. F1                |   0.746    |     1.83  | [0.719 ; 0.772]      | -               | -      |
| 7. VMAX              |   3.22     |     2.23  | [3.08 ; 3.36]        | -               | mg/d   |
| 8. KM                |   0.252    |     3.39  | [0.235 ; 0.268]      | -               | mg/L   |
| CrCL on CL           |   0.287    |    16.1   | [0.197 ; 0.378]      | -               | -      |
| B4SIGENE Low on CL   |  -0.194    |    13.1   | [-0.243 ; - 0.144]   | -               | -      |
| Albumin on CL        |  -1.14     |    11.3   | [-1.39 ; - 0.887]    | -               | -      |
| Body weight on CL    |   0.602    |     9.91  | [0.485 ; 0.718]      | -               | -      |
| Body weight on V2    |   0.475    |    12     | [0.364 ; 0.586]      | -               | -      |
| Black race on Vmax   |   0.000686 |  5590     | [-0.0744 ; 0.0758]   | -               | -      |
| Asian race on Vmax   |  -0.115    |    47.5   | [-0.223 ; - 0.00793] | -               | -      |
| 'Other' race on Vmax |   0.0934   |    44.7   | [0.0116 ; 0.175]     | -               | -      |
| Male sex on CL       |   0.178    |    29.8   | [0.0744 ; 0.282]     | -               | -      |
| ETA CL               |  30.6      |     2.67  | [30.5 ; 30.6]        | 27.7            | %CV    |
| ETA V2               |  35.8      |     1.42  | [35.8 ; 35.8]        | 24.9            | %CV    |
| ETA VMAX             |  30.5      |     3.21  | [30.5 ; 30.5]        | 33.3            | %CV    |
| ETA V3               |  73.2      |     3.52  | [73.1 ; 73.2]        | 43.4            | %CV    |
| ETA KA               |  32.6      |     9.1   | [32.5 ; 32.6]        | 73.3            | %CV    |
| Proportional Error   |  54.9      |     0.141 | [54.9 ; 54.9]        | 8.54            | %CV    |

Anifrolumab concentration-time curves for the first 112 days after 120 mg QW SC and 300 mg Q4W IV dosing regimens are shown in Figure 3 The estimated time to reach steady state was approximately 112 days for both regimens. Simulations indicate that distribution of average concentration at steady state (Cave,ss) is overlapping for the two regimens, whereas maximum concentrations (Cmax,ss) are lower and minimum concentrations (Cmin,ss) are higher for the 120 mg QW SC regimen compared with 300 mg Q4W IV (Figure 4 ). Importantly, Cmin,ss of 120 mg QW SC is less than that of 1000 mg Q4W IV regimen, which was evaluated in phase 2 study CD-IA-MEDI-546-1013 (refer to the initial MAA). The simulated median Cmin,ss are 53.93 and 110.6 mg/L for 120 mg QW SC and 1000 mg Q4W IV, respectively.

<div style=\"page-break-after: always\"></div>

Figure 3: Simulated anifrolumab concentration-time curves of 300 mg Q4W IV and 120 mg QW SC regimens.

<!-- image -->

Solid lines represent the median and shaded areas represent the 95% prediction interval of 1000 simulations

Figure 4: Simulated anifrolumab concentrations at steady state for 120 mg QW SC and 300 mg Q4W IV.

<!-- image -->

Dashed  red  line  represents  the  lower  5 th   percentile  of  simulations  of  1000mg  Q4W  IV  for  Cave,ss,  Cmax,ss,  Cmin ss, respectively

Simulations were performed to assess missed doses during weekly SC dosing (Figure 5 and Table 6 ). A missed dose would obviously result in reduced exposure, however the Cmin would still be higher than

<div style=\"page-break-after: always\"></div>

after IV monthly dosing. Total monthly dose would be reduced from 349 mg (120 mg x 4 doses x 0.728 bioavailability) to 262 mg (120 mg x 3 doses x 0.728 bioavailability), i.e., missing one dose in one month is still 87% of the dose received in one 300 mg IV dose.

Figure 5: Simulation of non-adherence scenarios after subcutaneous administration.

<!-- image -->

Symbol (+) indicates a dosing event

<div style=\"page-break-after: always\"></div>

Table 6: Exposure metrics of non-adherence scenarios after subcutaneous administration.

| Treatment                                                                                                                                                                                                                            | AUC ss,d0-d28 (mg.d/L) Median [90% CI]                                                                                                                                                                                               | C ave,ss (mg/L) Median [90% CI]                                                                                                                                                                                                      | C min,ss (mg/L) Median [90% CI]                                                                                                                                                                                                      | C max,ss (mg/L) Median [90% CI]                                                                                                                                                                                                      |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 120 mg QW SC                                                                                                                                                                                                                         | 1773 [1048-3077]                                                                                                                                                                                                                     | 63.32 [37.43-109.9]                                                                                                                                                                                                                  | 60.48 [34.52-107.3]                                                                                                                                                                                                                  | 64.94 [38.82-110.8]                                                                                                                                                                                                                  |
| 120 mg QW SC - Missed dose                                                                                                                                                                                                           | 1505 [779.6-2783]                                                                                                                                                                                                                    | 53.74 [27.84-99.40]                                                                                                                                                                                                                  | 44.67 [17.79-89.91]                                                                                                                                                                                                                  | 64.20 [37.61-111.1]                                                                                                                                                                                                                  |
| 120 mg QW SC - 3-day interval                                                                                                                                                                                                        | 1735 [991.4-3023]                                                                                                                                                                                                                    | 61.95 [35.41-108.0]                                                                                                                                                                                                                  | 52.78 [25.06-97.78]                                                                                                                                                                                                                  | 67.27 [40.35-112.7]                                                                                                                                                                                                                  |
| AUC ss,d0-d28 =AUC over 28 days at steady state; C ave,ss =Average concentration at steady state; C max,ss Maximum concentration at steady state; C min,ss =Minimum concentration at steady state; QW=Once per week; SC=Subcutaneous | AUC ss,d0-d28 =AUC over 28 days at steady state; C ave,ss =Average concentration at steady state; C max,ss Maximum concentration at steady state; C min,ss =Minimum concentration at steady state; QW=Once per week; SC=Subcutaneous | AUC ss,d0-d28 =AUC over 28 days at steady state; C ave,ss =Average concentration at steady state; C max,ss Maximum concentration at steady state; C min,ss =Minimum concentration at steady state; QW=Once per week; SC=Subcutaneous | AUC ss,d0-d28 =AUC over 28 days at steady state; C ave,ss =Average concentration at steady state; C max,ss Maximum concentration at steady state; C min,ss =Minimum concentration at steady state; QW=Once per week; SC=Subcutaneous | AUC ss,d0-d28 =AUC over 28 days at steady state; C ave,ss =Average concentration at steady state; C max,ss Maximum concentration at steady state; C min,ss =Minimum concentration at steady state; QW=Once per week; SC=Subcutaneous |

Simulations  were  also  performed  to  assess  transition  from  one  route  of  administration  to  the  other (Figure 6 and Table 7 ).

<div style=\"page-break-after: always\"></div>

Figure 6: Simulation of transition from intravenous (300 mg Q4W IV) to subcutaneous (120 mg QW SC) dosing and vice versa.

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 7: Simulated exposure metrics: Transition from intravenous (300 mg Q4W IV) to subcutaneous (120 mg QW SC) dosing and vice versa.

| Treatment             | AUC ,d0- d365 (mg.d/L) Median [90% CI]   | C ave,d0- d365 (mg/L) Median [90% CI]   | C min,ss (mg/L) Median [90% CI]   | C max,ss (mg/L) Median [90% CI]   | C ave,d140- d168 (mg/L) Median [90% CI]   | C max,d140- d168 (mg/L) Median [90% CI]   | C min,d140- d168 (mg/L) Median [90% CI]   |
|-----------------------|------------------------------------------|-----------------------------------------|-----------------------------------|-----------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|
| 1000 mg Q4W IV        | 75010 [47410- 115200]                    | 205.5 [129.9- 315.6]                    | 111.1 [35.69- 223.4]              | 418.8 [281.2- 633.3]              | -                                         | -                                         | -                                         |
| 120 mg QW SC          | 20510 [12920- 32450]                     | 56.19 [35.40- 88.90]                    | 55.55 [34.30- 87.57]              | 65.50 [39.93- 107.9]              | -                                         | -                                         | -                                         |
| 300 mg Q4W IV         | 17000 [10580- 26890]                     | 46.57 [28.99- 73.68]                    | 16.89 [0.2157- 44.71]             | 107.9 [69.63- 173.7]              | -                                         | -                                         | -                                         |
| IV to SC - 2 week gap | 19690 [12010- 30600]                     | 53.95 [32.90- 83.83]                    | 18.12 [0.1714- 44.70]             | 108.1 [69.08- 171.5]              | 58.00 [36.24- 88.04]                      | 100.7 [65.50- 155.3]                      | 41.29 [18.20- 71.75]                      |
| IV to SC - 3 week gap | 19060 [11520- 30810]                     | 52.22 [31.55- 84.40]                    | 17.68 [0.1730- 46.71]             | 107.7 [70.56- 171.5]              | 51.30 [31.35- 84.34]                      | 100.9 [67.18- 154.9]                      | 27.17 [5.313- 60.30]                      |
| IV to SC - 4 week gap | 18460 [11240- 28600]                     | 50.59 [30.78- 78.35]                    | 18.02 [0.1651- 44.78]             | 106.7 [70.41- 166.9]              | 49.02 [29.20- 77.43]                      | 99.96 [66.58- 150.6]                      | 18.02 [0.1655- 45.85]                     |
| SC to IV - 2 week gap | 17730 [10960- 29520]                     | 48.58 [30.02- 80.88]                    | 18.27 [0.1467- 54.30]             | 134.4 [86.84- 204.1]              | 72.68 [46.89- 113.6]                      | 134.4 [86.84- 204.1]                      | 44.98 [19.52- 82.79]                      |
| SC to IV - 3 week gap | 17580 [10400- 27930]                     | 48.18 [28.50- 76.52]                    | 18.45 [0.1578- 51.61]             | 119.9 [77.62- 182.7]              | 60.66 [35.87- 95.70]                      | 119.9 [77.62- 182.7]                      | 31.68 [7.320- 64.44]                      |
| SC to IV - 4 week gap | 17520 [10480- 28960]                     | 48.00 [28.71- 79.33]                    | 18.09 [0.1879- 52.55]             | 111.0 [70.27- 170.9]              | 43.17 [20.28- 78.56]                      | 110.6 [70.02- 170.2]                      | 21.08 [0.4826- 54.76]                     |

AUC,d0-d365=AUC over 365 days; Cave,d0-d365=Average concentration over 365 days; Cave,d140- d168=Average concentration from day 140 to day 168; Cmax,d140- d168=Maximum concentration from day 140 to day 168; Cmax,ss=Maximum concentration at steady state; Cmin,d140- d168=Minimum concentration from day 140 to day 168; Cmin,ss=Minimum concentration at steady state; IV=Intravenous; QW=Once per week; Q4W=Once every 4 weeks; SC=Subcutaneous

## Special populations

The MAH has not conducted specific studies in special populations like patients with renal impairment or hepatic impairment. The covariate effects were evaluated by PPK modelling and simulations.

The impact of the selected covariates in the final PPK model on area under the concentration-time curve at  steady  state  (AUCss)  and  maximum  concentration  at  steady  state  (Cmax,ss)  based  on  a  univariate assessment are presented as tornado plots in Figure 7 and Figure 8 , respectively. Overall, no covariate showed a substantial impact on AUCss and Cmax,ss with the covariate effect being no greater than 23%. Weight had the most pronounced impact with a decrease in AUCss of 22.9% and a decrease in Cmax,ss of 21.31% for the 95 th   percentile  of  the  weight  distribution  (107  kg)  compared  with  reference  subject weighing 68 kg. The pivotal TULIP SC study was considered to include a presentive weight range of SLE patients (median 70.4 kg, min.-max. 43.9-144 kg).

<div style=\"page-break-after: always\"></div>

Figure 7: Impact of covariates on anifrolumab AUC at steady state.

<!-- image -->

Figure 8: Impact of covariates on anifrolumab Cmax at steady state.

<!-- image -->

Reference: 106.92 mg/L. Bars represent the relative change (%) from the reference. Reference is 68 kg female With presence of B4SIGENE, 4.1 g/dL albumin, .113 mL/min creatinine clearance,and white race. Dosing is 300 mg IV Q4W.

## Effect of ADA on PK

In the TULIP SC study, geometric mean anifrolumab serum concentrations (Ctrough) were lower in ADApositive  patients  (N=11)  compared  to  ADA-negative  patients  (N=97).  Mean  anifrolumab  serum concentration time profiles of ADA-positive patients were generally below the median of those in ADAnegative patients, but the concentrations fell within the range of the concentrations seen in the ADAnegative group.

<div style=\"page-break-after: always\"></div>

ADA status was not formally evaluated as a covariate in the PPK analysis because only 3.3% (N=39) of subjects in the dataset were ADA positive at any time.

## Pharmacokinetic interaction studies

Clinical drug-drug interaction studies have not been conducted with anifrolumab due to low interaction potential own to its elimination pathway via proteolytic enzymes and target mediated degradation.

Concomitant medication were tested as covariate in the PPK analyses. The following medication reported to  be  in  use  at  baseline  in  the  TULIP  SC  study  were  tested:  antimalarial  drugs,  azathioprine, methotrexate, mycophenolate, ACE inhibitors, HMG inhibitors and NSAIDs. The PPK modelling showed that this medication had no meaningful impact on steady state AUC and Cmax of anifrolumab.

## 2.6.2.2. Pharmacodynamics

## Mechanism of action

Anifrolumab is a human IgG1 κ mAb that inhibits binding of type I IFNs to IFNAR1. By blocking type 1 IFN signaling, anifrolumab reduces multiple innate and adaptive downstream inflammatory pathways.

## Primary and Secondary pharmacology

The PD effects of SC anifrolumab was investigated as part of the phase III study (TULIP SC). Type I IFNinducible signature in whole blood was assessed by a 21-gene assay to measure the expression of type I IFN-inducible genes in the whole blood. The DCO for PD assessments was 28 May 2024. The analysis were performed using the FAS (n=220).

Anifrolumab 120 mg SC QW treatment resulted in rapid neutralization of the type I IFN gene signature by  Week  4  and  attained  ≥  88%  median  neutrali zation,  which  was  sustained  through  double-blind treatment (Week 52), in patients with high type I IFN PD signature (Figure 9 ).

No OLE data were included in Figure 9 , and thus, Weeks 57 and 63 reflected the post-treatment followup period for patients who did not enter the OLE. At these timepoints, type I IFN PD signature began to return to the baseline levels in the anifrolumab group.

Figure 9: Type I IFN PD Signature as Percent of Baseline Type I IFN PD Signature Among Patients with a High IFN Test Result Over Time, Line Plot (FAS)

<!-- image -->

Change in type I IFN PD signature expression over time is shown as percent of baseline signature levels, which are set to 100%.

<div style=\"page-break-after: always\"></div>

Median levels of type I IFN PD signature for each treatment group are derived based on individual subjects 100 (((baseline-Week X)/baseline)*100) for the 21 genes.

## 2.6.3. Discussion on clinical pharmacology

## Bioanalytical methods

All bioanalytical methods were the same as in the initial MAA.

## Pharmacokinetics

The pharmacokinetics of anifrolumab following subcutaneous administration has been well characterised in healthy volunteers and in the target population, SLE patients. Two clinical studies were conducted with the applied dose of 120 mg. The pivotal phase 3 TULIP SC study in target population, SLE patients was conducted with SC anifrolumab administered using a prefilled syringe, and a relative bioavailability study in healthy volunteers was conducted to bridge exposures between an autoinjector and the prefilled syringe.  Subcutaneous  absorption  of  anifrolumab  is  slow  with  peak  concentrations  reached  within approximately 5 days after SC injection by both devices.

Pharmacokinetics of anifrolumab following SC injection of 120 mg by an autoinjector (AI) was compared to SC injection by prefilled syringe (APFS) in healthy volunteers. The AI batch had lower total protein content compared to the APFS batch producing in average 6% difference in the total dose of anifrolumab (estimated doses 113.6 mg/0.8 ml vs. 120.8 mg/0.8 ml, respectively). However, although the point estimates for the AI vs. APFS GLSM ratios of the primary PK parameters were below unity, the 90% CIs for  the  GLSM  ratios  imply  that  bioequivalence  is  not  compromised  by  the  difference  in  total  protein content, thus, this issue was not pursued further by the CHMP. Furthermore, based on the provided PK data,  non-linear  PK  of  anifrolumab  seemed  to  compromise  calculation  of  terminal  elimination  phase related  PK  parameters  and  accurate  estimation  of  AUCinf,  nevertheless,  AUClast  showed  comparable results. Despite the observed deficiencies, the study was considered sufficiently robust for comparison of the two devices. The 90% CIs for the geometric mean ratios of AI vs. APSF for primary PK parameters showed bioequivalence of the two devices. The MAH has not provided comparison of exposures between the injection sites for each AI and APFS, separately. Among the three injection sites, SC injections with AI into thigh and abdomen produced comparable mean systemic exposures (AUClast) of anifrolumab while SC injection into upper arm produced approximately 25 % to 32 % lower exposure compared to the other two injection sites. The mean exposures following SC injections by APFS into thigh were in average 32 % to 26 % higher than injection into abdomen and upper arm, respectively. Comparison of the range of the exposures between the injection sites indicates overall lower exposures for SC injections to upper arm for both devices compared to the other injection sites. In the SmPC section 4.2, self-administered subcutaneous  injection  of  anifrolumab  is  advised  to  be  injected  into  thigh  or  abdomen.  Healthcare professional or caregiver could administer the injection also in the upper arm. Thus, although slightly lower range of exposures could be observed for SC injections in the upper arm compared to the other injection sites, the overall impact on drug exposures were not considered remarkable if an injection  is occasionally administered into the upper arm by a healthcare professional or a caregiver. Overall, the range of exposures overlapped between the injection sites and the between-subject variabilities were high for both devices, 38-74% for APFS and 27-47% for AI. Therefore, all the three injection sites were considered  acceptable  to  the  CHMP.  The  provided  clinical  data  was  found  adequate  to  support  the instructions for administration of subcutaneous injection in the SmPC section 4.2.

<div style=\"page-break-after: always\"></div>

## Population PK modelling and simulations

PK of anifrolumab following SC and IV administration was evaluated using PPK analysis. The final pooled dataset model was a two-compartment model with two parallel clearances (first-order and MichaelisMenten)  from  the  central  compartment.  Absorption  following  SC  administration  was  described  with estimated  bioavailability  (F1)  and  absorption  rate  constant  (Ka).  Inter-subject  variability  (IIV)  was characterised  on  linear  clearance  (CL),  central  volume  (Vc),  peripheral  volume  (Vp),  the  maximum velocity of Michaelis-Menten kinetics clearance process (Vmax), and absorption rate constant. Residual unexplained variability was described using proportional error model (additive on log scale). Statistically significant covariates that were retained in the final model were as follows: on CL: baseline body weight, albumin level, creatinine clearance, 4-gene type 1 IFN gene signature status, and sex; on Vc: baseline body weight; on Vmax: Race. The non-parametric distribution of the parameter estimates (bootstrap) showed a good agreement with the NONMEM estimates and diagnostic plots indicated no major problems with model performance. The estimates of CL (0.146 L/day), Vc (3.48 L), and Vp (1.72 L) were close to the values estimated previously using a dataset with only IV data. The final PPK model was considered adequate to evaluate clinical relevance of covariates on exposure to anifrolumab and to simulate PK profiles and exposure measures of untested clinical scenarios (e.g., effect of missed dose on exposure).

Simulations using the PPK model showed that at steady state the distribution of average concentration (Cave,ss)  is  overlapping  for  the  regimens  120  mg  QW  SC  and  300  mg  Q4W  IV,  whereas  maximum concentrations (Cmax,ss) are lower and minimum concentrations (Cmin,ss) are higher for the 120 mg QW SC regimen compared with 300 mg Q4W IV. Importantly, Cmin,ss of 120 mg QW SC is less than that of 1000 mg Q4W IV regimen, which was previously evaluated in a phase 2 study (refer to the initial MAA of Saphnelo).

Simulations were performed to assess missed doses during weekly SC dosing (Figure 5 and Table 7 ). A patient may remember to take their dose some days after the expected dose day. Simulations indicate that in this case, the patient can take the dose as soon as they remember and resume dosing on the usual  day  of  administration  providing  that  a  minimum  interval  of  3  days  is  maintained  between  SC injections.

Simulations  were  also  performed  to  assess  transition  from  one  route  of  administration  to  the  other (Figure 6 and Table 8 ). Based on the simulated concentration-time profiles and exposure metrics, the following instructions were derived for transition from one route of administration to the other:

- Transition  from  IV  to  SC  administration:  The  first  SC  injection  should  be  administered approximately 2 weeks after the last IV dose.
- Transition  from  SC  to  IV  administration:  The  first  IV  infusion  should  be  administered approximately 3 to 4 weeks after the last SC dose.

Instructions regarding missed SC doses and transitioning between routes of administration are included in section 4.2 of the SmPC.

## Special populations

Dedicated clinical studies in special populations like patients with renal impairment or hepatic impairment have not been conducted, but covariate effects were evaluated by PPK approach.

The PPK model indicated that SLE patients with mild to moderate decrease in estimated glomerular filtration rate (eGFR) had comparable CL for anifrolumab after SC administration to patients with normal eGFR values. Likewise, baseline hepatic function tests (liver enzymes, total bilirubin) had no statistically significant  effect  on  CL  of  anifrolumab.  These  results  were  consistent  with  the  observations  for  SLE patients with IV administration only. No dose adjustment is considered necessary for patients with renal

<div style=\"page-break-after: always\"></div>

or hepatic impairment. The clinical studies did not include patients with severe renal impairment or with end-stage renal disease (eGFR &lt;30 mL/min/1.73 m 2 ).

PPK  modelling  and  simulations  indicate  that  body  weight  is  the  most  important  covariate  affecting exposure  and  causing  interindividual  variability.  There  was  a  statistically  significant  difference  in weight-adjusted CL between females and males, with males expected to have 15.1% lower AUC than females. The observation is not clinically relevant (see Figure 7 and Figure 8 ) and dose adjustment based on weight or other intrinsic and extrinsic factors is not required. Presence of baseline type I IFN 4-gene signature was observed to decrease AUC by less than 20% in PPK analyses. Disease status had no effect on exposure of anifrolumab with SLE patients showing similar PK compared to healthy volunteers. A slightly higher clearance in male subjects compared to females was observed in the PPK analyses with SC administration, but this not considered as clinically relevant.

Race was a statistically significant covariate for Vmax but did not impact the CL of anifrolumab. Similar steady state AUC and Cmax were observed across regions and ethnicity. The body weight adjusted CL in the Asian population was similar to the non-Asian population.

Age  (median:  40.0 years,  range:  18  to  70 years)  did  not  impact  the  CL  of  anifrolumab  in  the  PPK analyses.  Of  the  patients  with  SLE  exposed  to  anifrolumab  in  clinical  studies,  33/952  (3.466%) participants were ≥ 65 years of age.

Overall, age, race, ethnicity, region, gender, and baseline type I IFN 4-gene signature status had no clinically relevant impact on exposure of anifrolumab. In the SmPC sections 4.2 and 5.2, the proposed information for renal impairment and hepatic impairment, and the information related covariates (age, race,  ethnicity,  region,  gender,  IFN  status,  body  weight)  is  similar  to  the  IV  anifrolumab.  This  was acceptable to the CHMP.

The number of ADA positive patients was low in the clinical studies with SC administration, thus, no definitive  conclusions  on  effect  of  ADA  on  PK  of  anifrolumab  could  be  made.  Exploratory  graphical analyses indicated that ADA are not expected to have clinically relevant effect on exposure.

## PK drug interactions

Commonly used concomitant medications at baseline were tested as covariates in the PPK analysis, none of them was included in the anifrolumab PPK model. The method was not considered robust: changes in concomitant medications after baseline and in their posology were not taken into account. The issue was not pursued because anifrolumab is a large protein and its kinetics is not expected to be affected by small molecule drugs.

The SmPC sections 4.5 and 5.2 concerning drug interactions is the same as for IV anifrolumab, which was acceptable to the CHMP. Particularly, as anifrolumab could suppress levels of some cytokines, the SmPC includes warning for concomitant use of narrow therapeutic medicines that are CYP-substrates.

## Pharmacodynamics

The results using the Type I IFN PD signature demonstrated that SC anifrolumab at 120 mg dose QW suppressed  the  expression  of  Type  I  IFN-inducible  genes.  The  effect  was  rapid  and  sustainable throughout the 52 weeks treatment. The level of suppression was comparable to that seen with 300 mg IV anifrolumab in pivotal 04 and 05 studies, as well as at 300 mg and 1000 mg doses in the 1013 study. Therefore, the proposal in section 5.1 Pharmacodynamic effects that is aligned with the approved text with IV anifrolumab is acceptable (see separate attachment for detailed SmPC comments).

No PK/PD and exposure-response models were provided to support the current application, this was acceptable to the CHMP.

<div style=\"page-break-after: always\"></div>

## 2.6.4. Conclusions on clinical pharmacology

The  pharmacokinetics  of  anifrolumab  following  subcutaneous  administration  has  been  sufficiently characterised in healthy volunteers and in the target population, SLE patients, in the two clinical studies and by the PPK analyses.

In  terms  of  pharmacodynamics,  the  results  using  the  Type  I  IFN  signature  demonstrated  that  SC anifrolumab at 120 mg dose QW suppressed the expression of Type I IFN-inducible genes. The effect was rapid and sustainable throughout the 52 weeks treatment. The level of suppression was comparable to that seen with 300 mg IV anifrolumab in pivotal 04 and 05 studies, as well as at 300 mg and 1000 mg doses in the 1013 study.

## 2.6.5. Clinical efficacy

The anifrolumab SC clinical programme included a pivotal global, multicenter, randomized, double-blind (DB),  placebo-controlled,  Phase  III  study  (TULIP  SC).  TULIP  SC  was  an  ongoing  study  during  the procedure evaluating the safety and efficacy of anifrolumab SC administered by APFS in adults with moderate to severe SLE despite receiving standard of care (Table 8 ).

The efficacy  assessments  are  based  on  an  interim  analysis  (IA)  of  the  first  220  randomized  of  360 planned patients in TULIP SC who completed the 52-week DB treatment period or withdrew early from the study. The study has continued as planned as DB after the data-cut-off (DCO) for the IA (23 July 2024).

<div style=\"page-break-after: always\"></div>

Table 8: Summary of TULIP SC clinical study

| Study number (Acronym) Sponsor EudraCT number NCT Number                              | Study title                                                                                                                                                                                   | Primary objective                                                                                 | Primary endpoint          | Treatments, doses, regimen, route of administration, and number of randomized patients                                                                                                                                                                                                                                                         | Patient population                                               | Duration                                                                                                                                                 |
|---------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|
| D3465C00001 (TULIP SC) AstraZeneca EudraCT No: 2020-004529-22 NCT No: 2022- 502396-28 | A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus | To compare efficacy of anifrolumab with placebo on overall disease activity in patients with SLE. | BICLA response at Week 52 | Anifrolumab 120 mg SC QW N = 109 Placebo SC QW N = 111 IA based on first 220 randomized/360 planned patients to complete 52-week DB treatment period or withdraw early from the study Total randomized patients at the time of the IA DCO (23 July 2024) (N = 346) Total randomized patients at the time of the IA CDL (13 Sep 2024) (N = 367) | Adult patients 18 to 70 years of age with moderate to severe SLE | 52-week DB, placebo-controlled treatment period (ongoing) Additional 52-week OLE period, with anifrolumab 12-week follow-up period after last dose of IP |

<div style=\"page-break-after: always\"></div>

## 2.6.5.1. Dose response study(ies)

No dose-response studies were conducted. The dose of 120 mg QW for TULIP SC study was selected to provide comparable and noninferior (i.e., at least as high as) median Cave to 300 mg IV in a single injection and noninferior PD suppression to that of 300 mg IV. In addition, the Cave of 120 mg SC QW over 52 weeks had minimal overlap with that of 1000 mg IV, which was evaluated for up to a year in patients with SLE in the Phase IIb study 1013. Further, the simulated 120 mg SC QW steady-state Cmax remained below the steady-state Cmax observed for the approved anifrolumab IV dosing regimen.

## 2.6.5.2. Main study

## Title of study

A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus.

## Methods

The Phase III study TULIP SC comprises a 52-week DB treatment period, followed by a 52-week OLE period, and 12-week safety follow-up period (Figure 10 ). The DB portion of the study was designed to evaluate the efficacy, safety, and tolerability of anifrolumab 120 mg SC QW added to standard of care compared with placebo SC QW added to standard to care in adult patients with moderate to severe SLE.

The OLE was primarily designed to collect data on longer-term safety and tolerability.

Figure 10: TULIP SC study

<!-- image -->

BL, baseline; SOC, standard of care

## · Study Participants

The key eligibility criteria are described below. The patients were males or females aged 18 to 70 years of age.

## Key inclusion criteria

- Diagnosis of paediatric or adult SLE according to the ACR 1997 revised criteria for ≥ 24 weeks prior to signing the ICF
- Autoantibodypositive at Screening for at least one of: ANA titer ≥ 1:80, anti -dsDNA, anti-Smith
- Receiving at least one of the following standard therapy regimens

<div style=\"page-break-after: always\"></div>

- -Oral prednisone (or equivalent) monotherapy minimum daily dose ≥ 7.5 mg/day for at least 6 weeks prior to signing ICF, stable for at least 2 weeks before randomization, maximum daily dose ≤ 40 mg/day
- -Antimalarials and/or immunosuppressant(s) with or without OCS with start date ≥ 12 weeks and stable for ≥ 8 weeks prior to signing ICF
- -Permitted medications include: antimalarials, azathioprine, mycophenolate mofetil/mycophenolic acid, methotrexate, mizoribine, cyclosporine and tacrolimus (Note: For  safety  reasons,  combinations  of  mycophenolate  mofetil  or  mycophenolic  acid  or mycophenolate  sodium,  azathioprine,  methotrexate,  tacrolimus  or  cyclosporine  are  not permitted. Combination of mizoribine should be discussed with the medical monitor.)
- -Maximum allowed daily dose: Azathioprine: ≤ 200 mg/day; Mycophenolate mofetil ≤ 2 g/day or  mycophenolic acid ≤ 1.44  g/day;  Oral,  SC,  or  intramuscular  (IM)  methotrexate ≤ 25 mg/week;  Mizoribine ≤ 150  mg/day;  Cyclosporine ≤ 3  mg/kg/day;  Tacrolimus ≤ 0.2 mg/kg/day
- Total SLEDAI2K ≥ 6 points, with ≥ 4 points coming from clinical components ('Clinical' SLEDAI -2K) at Screening AND clinical SLEDAI of ≥ 4 points at Day 1 (randomi sation)
- BILAG-2004 score of severe disease activity in at least 1 organ system [BILAG level A] or moderate disease activity in at least 2 organ systems [BILAG level B])
- PGA score ≥ 1.0 on a 0 to 3 VAS at Screening

## Key exclusion criteria

- History or current diagnosis of a clinically significant non-SLE related vasculitis syndrome
- History or evidence of suicidal ideation or behavior
- Active severe or unstable neuropsychiatric SLE
- Active  severe  SLE-driven renal disease where protocol-specified standard therapy is considered insufficient
- Diagnosis (within 1 year of signing the ICF) of mixed connective tissue disease or any history of overlap syndromes of SLE and systemic sclerosis
- History of, or current diagnosis of, catastrophic antiphospholipid syndrome (APS) within 1 year prior to signing the ICF. Patients with other degrees of APS adequately controlled by anticoagulants or aspirin for at least 12 weeks can be recruited to the study
- History of, or current, inflammatory joint or skin disease other than SLE that, in the opinion of the investigator, could interfere with the inflammatory arthritis or skin assessments and confound the disease activity assessments
- History of any non-SLE disease that has required treatment with oral or parenteral corticosteroids for more than a total of 2 weeks within the last 24 weeks prior to signing the ICF
- History of recurrent infection requiring hospitalization and IV antibiotics
- Known  history  of  a  primary  immunodeficiency,  splenectomy,  or  any  underlying  condition  that predisposes the patient to infection

<div style=\"page-break-after: always\"></div>

- Active hepatitis B infection, as confirmed by central laboratory, for: Hepatitis B surface antigen (HBsAg); or Hepatitis B core antibody (HBcAb) and hepatitis B virus (HBV) DNA detected above the lower limit of quantitation (LLOQ)
- Active hepatitis C infection (defined as positive hepatitis C virus [HCV] antibody and detectable HCV ribonucleotide (RNA)
- Any severe case of herpes zoster at any time prior to Day 1 or any herpes zoster infection that has not completely resolved within 12 weeks prior to signing the ICF
- Any clinical cytomegalovirus (CMV) or Epstein-Barr virus infection that has not completely resolved within 12 weeks prior to signing the ICF
- Opportunistic  infection  requiring  hospitalisation  or  IV  antimicrobial  treatment  within  3  years  of randomization
- Clinically significant chronic infection (ie, osteomyelitis, bronchiectasis, etc) within 8 weeks prior to signing  the  ICF  (chronic  nail  infections  are  allowed);  any  infection  requiring  hospitalisation  or treatment with IV anti-infectives not completed at least 4 weeks prior to signing the ICF
- History of cancer, apart from squamous or basal cell carcinoma with documented success of curative therapy or cervical cancer in situ treated with apparent success with curative therapy
- Receipt of any commercially available biologic agent within 5 half-lives prior to signing of the ICF
- Regular use of &gt; 1 NSAID within 2 weeks prior to Week 0 (Day 1); OR receipt of fluctuating doses of a NSAID within 2 weeks prior to Week 0 (Day 1)
- Receipt of any commercially available Janus kinase (JAK) inhibitor (e.g., tofacitinib or baricitinib) ≤ 12 weeks or Bruton ' s tyrosine kinase (BTK) inhibitor (e.g., ibrutinib, acalabrutinib, zanubrutinib) ≤ 24 weeks prior to signing the ICF

## · Treatments

During the 52-week DB period, patients received anifrolumab 120 mg SC QW added to SoC or placebo SC QW added to SoC in a 1 ml APFS with 0.8 ml volume. During Weeks 8-40, patients with a baseline OCS ≥10 mg/day were required to taper their OCS dose to ≤7.5 mg/day, unless there was worsening of disease activity. Non-protocol permitted changes to SoC medications for SLE were only allowed if necessary to treat an AE or increased disease activity. Further, patients were instructed not to start any new medications/regimens or make changes to any existing medications/regimens, including over-thecounter products, without first consulting the Investigator.

During the 52-week OLE treatment period in the study, the patients received anifrolumab 120 mg QW. Permitted SoC medications included OCS, antimalarials, and immunosuppressants, but the maximally permitted doses were not to be exceeded.

## · Objectives

The primary objective of the study was to compare efficacy of anifrolumab with placebo on overall disease activity in patients with moderate-to severe SLE despite receiving standard therapy.

## Key secondary objectives were:

- To compare the efficacy of anifrolumab with placebo on improvement in overall disease activity and low (or reduced) OCS use.
- To compare the efficacy of anifrolumab with placebo on the onset of a sustained reduction in disease activity.

<div style=\"page-break-after: always\"></div>

- To compare the efficacy of anifrolumab with placebo on the onset of first flare.

## Other secondary objectives were:

- To compare the efficacy of anifrolumab with placebo on maintained reduction in OCS use among patients with moderate or high OCS use at baseline.
- To compare the efficacy of anifrolumab with placebo on the reduction in moderate to severe flares.
- To compare the efficacy of anifrolumab with placebo on an additional measure of overall disease activity.

The statistical analyses were based on demonstrating superiority of anifrolumab against placebo.

## · Outcomes/endpoints

The primary endpoint was the proportion of patients who are BICLA responders at Week 52.

The key instruments used for the assessment of disease activity including the BICLA response were BILAG-2004, SLEDAI-2K and PGA.

The BILAG-2004 is a translational index with 9 organ systems (General, Mucocutaneous, Neuropsychiatric, Musculoskeletal, Cardiorespiratory, Gastrointestinal, Ophthalmic, Renal and Haematology) that is able to capture changing severity of clinical manifestations. It has ordinal scales by design, where it records disease activity across the different organ systems at a glance by comparing the immediate past 4 weeks to the 4 weeks preceding them. BILAG scoring is based on the principle of physicians' Intention-to-Treat and categorises disease activity into 5 different levels from A to E:

- Grade A represents very active disease requiring immunosuppressive drugs and/or a prednisone dose of &gt; 20 mg/day or equivalent;
- Grade B represents moderate disease activity requiring a lower dose of corticosteroids ( ≤ 20 mg prednisone/day), topical steroids, topical immunosuppressives, antimalarials, or NSAID;
- Grade C indicates mild stable disease;
- Grade D implies no disease activity but the system has previously been affected;
- Grade E indicates no current or previous disease activity.

The SLEDAI-2K disease activity index consists of a list of organ manifestations, each with a definition. A certified  investigator  or  designated  physician  will  complete  the  SLEDAI-2K assessment and decide whether  each  manifestation  is ' present ' or ' absent ' in  the  last  4  weeks.  The  assessment  also includes the collection of blood and urine for assessment of the laboratory categories of the SLEDAI-2K.

The SLEDAI-2K assessment consists of 24 lupus-related items in which signs, symptoms, and laboratory tests for each of 9 organ systems are given a weighted score. Items present in the last 28 days are scored and summed to create a total score. For example, items in the renal organ system are given a weight of 4 points each. The SLEDAI-2K score range is 0 to 105 points with 0 indicating inactive disease.

The  'Clinical'  SLEDAI-2K  score  is  the  SLEDAI-2K  assessment  score  without  the  inclusion  of  points attributable  to  any  urine  or  laboratory  results  including  immunologic  measures.  Its  use  may  permit earlier clinical decisions to be made (such as OCS reduction or treating increased disease activity) without waiting for immunologic measures (including anti-dsDNA antibodies and C3, C4, and CH50 complement levels).  However,  in  any  circumstance  where  the  'Clinical'  SLEDAI-2K  score  is  used,  sites  must subsequently update the SLEDAI-2K assessment when laboratory data become available.

<div style=\"page-break-after: always\"></div>

For any joint to count as an 'active joint', both tenderness and swelling present in that joint was a requirement.

The PGA represents  the  physician's  overall  assessment  of  average  SLE  disease  severity  on  a  visual analog scale (VAS) scale with 0 (no disease) to 3 (severe) disease activity over the last 4 weeks.

A BICLA responder was defined as a patient meeting all of the following criteria:

- Reduction of all baseline BILAG-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no BILAG2004 worsening in other organ systems, as defined by ≥ 1 new BILAG -2004 A or ≥ 2 new BILAG -2004 B.
- No worsening from baseline in SLEDAI-2K, where worsening is defined as an increase from baseline of &gt; 0 points in SLEDAI-2K.
- No worsening from baseline in patients' lupus disease activity, where worsening is defined by an increase ≥ 0.30 points on a 3 -point PGA VAS.

## Key secondary endpoints:

## BICLA response at Week 52 with maintained low (or reduced) use of OCS

The proportion of patients with BICLA response at Week 52 who also have maintained low (or reduced) use of OCS in the anifrolumab treatment group was compared to that in the placebo group. To be a responder, a patient was to be a BICLA responder and had maintained low (reduced) OCS use defined as follows:

- If baseline OCS ≥ 10 mg/day an OCS dose of ≤ 7.5 mg/day prednisone or equivalent must be achieved by Week 40 and an OCS dose ≤ 7.5 mg/day prednisone or equivalent must be maintained from Week 40 to Week 52.
- If baseline OCS &lt; 10 mg/day, OCS dose at Week 40 must be less than or equal to OCS dose at baseline, with no increase from Week 40 OCS dose between Week 40 and Week 52.

## Time to BICLA response sustained through Week 52.

Time to BICLA response sustained through Week 52 was defined as the date of first BICLA response in which all subsequent BICLA assessments result in a BICLA response sustained up to, and including, Week 52.

## Time to flare through Week 52

Time to flare was defined as the time from the first dose of study intervention during the DB treatment period to the first flare over the 52-week treatment period. A flare was defined as either 1 or more new BILAG-2004 A or 2 or more new BILAG -2004 B items compared to the previous visit.

## Other secondary endpoints:

## Proportion of patients who achieve an OCS dose ≤ 7.5 mg/day at Week 40, which is maintained through Week 52 in the subgroup of patients with baseline OCS ≥ 10 mg/day

Maintained OCS reduction was defined by meeting all of the following criteria:

- Achieve an OCS dose ≤ 7.5 mg/day prednisone or equivalent by Week 40
- Maintain an OCS dose ≤ 7.5 mg/day prednisone or equivalent from Week 40 to Week 52

## Annualised flare rate through Week 52

<div style=\"page-break-after: always\"></div>

The flare rate in the anifrolumab treatment group was compared with the flare rate in the placebo group. A flare was defined as either 1 or more new BILAG 2004 A or 2 or more new BILAG-2004 B items compared to the previous visit.

## Proportion of patients achieving an SRI(4) response at Week 52

The difference in response between anifrolumab and placebo in SRI(4) at Week 52 was analysed using the same method as for the primary analysis. To be an SRI(4) responder, the patient had to meet all of the following criteria:

- Reduction from baseline of ≥ 4 points in the SLEDAI-2K
- SLEDAI-2K will be derived as the sum of the scores for all items. A ≥ 4 points reduction is reached if the change from baseline is ≤ 4
- No new organ systems affected as defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B items compared to baseline using BILAG-2004
- No worsening from baseline in the patients' lupus disease activity, where worsening is defined by an increase ≥ 0.30 points on a 3-point PGA VAS

## · Sample size

The application is based on a pre-specified IA, performed once the first 220 randomised patients of the total planned 360 patients completed the 52-week DB treatment period or withdrew early from the study. The study was planned to continue regardless of the IA results and is ongoing, with a CDL planned after all 367 randomised patients complete the 52-week placebo-controlled DB treatment period or withdraw early from the study.

The sample size of approximately 360 patients for the final analyses was determined based on a fixed study design, powered to detect a clinically meaningful difference of at least 10% in the proportion of BICLA responders at Week 52 comparing anifrolumab to placebo (primary endpoint). For the primary endpoint, the α level for the IA was determined based on the Pocock spending function. Based on 220 patients eligible for the IA and 367 patients confirmed randomized at completion of recruitment, the information fraction is 0.60 (220/367), resulting in α \\_IA of 3.54% and α \\_Final Analysis of 2.57%.

## · Randomisation and Blinding (masking)

All  patients  were  centrally  assigned  to  randomized  study  intervention  using  an  Interactive  Response Technology/Randomisation  and  Trial  Supply  Management  (IRT/RTSM)  system.  Randomization  was stratified by SLEDAI2K score at screening (&lt; 10 vs ≥ 10 points), OCS use on Day 1 (&lt; 10 mg vs ≥ 10 mg prednisone or equivalent per day), and type I IFN gene signature test result (high vs low).

This  study  design  included  assessor,  investigator,  and  patient  blinding.  In  the  event  of  a  medical emergency where unblinding was considered necessary for the safety of the patient due to possible impact on-treatment decisions, the investigator could unblind an individual patient's study intervention allocation after consulting with the study medical monitor.

## · Statistical methods

The primary endpoint estimand was designed to answer a clinically relevant question, comparing the proportion of patients able to both complete the study treatment and achieve a clinically meaningful treatment response without further medication being required.

For patients who had intercurrent event (ICE) due to restricted medication (RM) use, premature end of treatment (PEOT), and/or death, the BICLA response after the ICE was set to non-response as per the

<div style=\"page-break-after: always\"></div>

composite  strategy.  For  patients  who  had  ICE  due  to  noncompliance  (NC),  response  after  NC  was imputed using the hypothetical strategy.

The same estimand strategy was implemented for BICLA response at Week 52 with maintained low (or reduced) use of OCS.

Time to BICLA response sustained through Week 52 was defined as the date of first BICLA response in which all subsequent BICLA assessments result in a BICLA response sustained up to, and including, Week 52. The definition of BICLA response was the same as for the primary endpoint. A composite handling strategy was used for intercurrent events of study intervention discontinuation, restricted medication use,  and  death,  resulting  in  non-response  from  the  time  of  the  event.  Missing  data  due  to  study withdrawal or lost to follow up was handled by censoring the patient. Patients who did not achieve BICLA response by Week 52 or whose response was not sustained up to Week 52 was censored at Week 52.

Time to flare was defined as the time from the first dose of study intervention during the DB treatment period to the first flare over the 52-week treatment period. A flare was defined as either 1 or more new BILAG-2004  A  or  2  or  more  new  BILAG -2004 B items compared to the previous  visit.  A  composite handling strategy was used for the intercurrent events of restricted medication use, study intervention discontinuation,  and  death,  resulting  in  a  flare  on  the  date  of  the  event.  Missing  data  due  to  study withdrawal or lost to follow up was handled by censoring the patient on the date of the last assessment. Patients who did not experience an intercurrent event or a flare by Week 52 were censored at Week 52; unless  the  Week  52  BILAG  assessment  was  not  performed,  then  the  date  of  last  available  BILAG assessment prior to Week 52 was used as the censoring date.

All efficacy analyses were conducted using the FAS. Patients who withdrew consent to participate in the study are included up to the date of their study termination. For the IA, the FAS consisted of the first 220 randomized patients who completed the Week 52 DB treatment period or withdrew early from the study.

The  summary  measure  for  the  primary  endpoint  was  the  difference  in  the  proportion  of  subjects achieving BICLA response at Week 52 using the FAS, comparing the anifrolumab to the placebo groups. Multiple imputation method was used for missing value.

The null hypothesis was that the proportion of subjects achieving BICLA response on anifrolumab is equal to that on placebo. The alternative hypothesis is that the proportion of subjects achieving BICLA response on anifrolumab is not equal to that on placebo, i.e.,

H0: difference in proportion achieving BICLA response (anifrolumab vs placebo) = 0

Ha: difference in proportion achieving BICLA response (anifrolumab vs placebo) ≠ 0.

The primary endpoint, BICLA response at Week 52, was analysed using a stratified CMH method.

The application was based on a pre-specified IA of TULIP SC, performed once the first 220 randomised patients of the total planned 360 patients completed the 52-week DB treatment period or withdrew early from the study. The study was planned to continue regardless of the IA results and was ongoing during the procedure, with a CDL planned after all 367 randomized patients complete the 52-week placebocontrolled DB treatment period or withdraw early from the study.

For  the  IA,  only  the  primary  endpoint,  BICLA  response  at  Week  52,  was  hypothesis  tested  (i.e., multiplicity protected).

The key secondary endpoints were not hypothesis tested for the IA in the multiple testing procedure, but point estimates, CIs, and nominal p-values are provided.

<div style=\"page-break-after: always\"></div>

## Results

## · Participant flow

First patient was enrolled on 8-June-2021 and last patient was enrolled on 18-July-2024. The analyses are based on a clinical data lock date of 13-September-2024 and data cut-off date of 23-July-2024 for the IA.

Overall, 695 patients were screened and of the 220 patients included in the FAS for the IA, 78.6% completed the DB treatment and 21.8% withdrew from study without entering OLE (Table 9 ).

Table 9: Study disposition (Full Analysis Set)

|                                                                     | Anifrolumab 120mg n (%)   | Placebo n (%)   | Total n (%)   |
|---------------------------------------------------------------------|---------------------------|-----------------|---------------|
| Subjects randomized                                                 | 109                       | 111             | 220           |
| Subjects randomized, not treated                                    | 0                         | 0               | 0             |
| Subjects started double-blind treatment [a]                         | 109                       | 111             | 220           |
| Subjects completed or discontinued double-blind treatment           | 109 (100)                 | 111 (100)       | 220 (100)     |
| Subjects completed double-blind treatment                           | 86 (78.9)                 | 87 (78.4)       | 173 (78.6)    |
| Subjects discontinued double-blind treatment                        | 23 (21.1)                 | 24 (21.6)       | 47 (21.4)     |
| SUBJECT DECISION                                                    | 9 (8.3)                   | 7 (6.3)         | 16 (7.3)      |
| ADVERSEEVENT                                                        | 9 (8.3)                   | 3 (2.7)         | 12 (5.5)      |
| LACKOFTHERAPEUTIC RESPONSE                                          | 1 (0.9)                   | 4 (3.6)         | 5 (2.3)       |
| DEVELOPMENTOFSTUDYSPECIFIC DISCONTINUATIONCRITERIA                  | 1 (0.9)                   | 1 (0.9)         | 2 (0.9)       |
| SUBJECTLOSTTOFOLLOW-UP                                              | 0                         | 1 (0.9)         | 1 (0.5)       |
| PREGNANCY                                                           | 0                         | 1 (0.9)         | 1 (0.5)       |
| OTHER                                                               | 3 (2.8)                   | 7 (6.3)         | 10 (4.5)      |
| extension                                                           | 9 (8.3)                   | 3 (2.7)         | 12 (5.5)      |
| Subjects completed study without entering open-label extension      | 44 (40.4)                 | 45 (40.5)       | 89 (40.5)     |
| Subjects withdrawn from study without entering open-label extension | 22 (20.2)                 | 26 (23.4)       | 48 (21.8)     |
| DEVELOPMENTOFSTUDY-SPECIFICWITHDRAWAL CRITERIA                      | 1 (0.9)                   | 2 (1.8)         | 3 (1.4)       |
| OTHER                                                               | 2 (1.8)                   | 3 (2.7)         | 5 (2.3)       |
| ADVERSEEVENT                                                        | 3 (2.8)                   | 2 (1.8)         | 5 (2.3)       |
| LOST TO FOLLOW-UP                                                   | 1 (0.9)                   | 2 (1.8)         | 3 (1.4)       |
| WITHDRAWAL BY SUBJECT                                               | 11 (10.1)                 | 11 (9.9)        | 22 (10.0)     |
| PHYSICIAN DECISION                                                  | 4 (3.7)                   | 6 (5.4)         | 10 (4.5)      |
| Subjects enter open-label extension treatment [b]                   | 34 (100)                  | 37 (100)        | 71 (100)      |
| Subjects ongoing open-label extension treatment                     | 33 (97.1)                 | 37 (100)        | 70 (98.6)     |
| Subjects completed or discontinued open-label extension treatment   | 1 (2.9)                   | 0               | 1 (1.4)       |
| Subjects completed open-label extension treatment                   | 0                         | 0               | 0             |
| Subjects discontinued open-label extension treatment                | 1 (2.9)                   | 0               | 1 (1.4)       |
| OTHER                                                               | 1 (2.9)                   | 0               | 1 (1.4)       |
| Subjects ongoing study follow-up                                    | 1 (2.9)                   | 0               | 1 (1.4)       |
| Subjects completed study                                            | 0                         | 0               | 0             |
| Subjects withdrawn from study                                       | 0                         | 0               | 0             |

<div style=\"page-break-after: always\"></div>

Screened subjects are those who signed mtonned consent.Discontinued treatment subjects are those who prematurely and permanently discontinued study intervention.Completed study subjects are those completed and exit study accordingstudyprotocol.

Percentagesare based on the number of subjectswho stanted double-blind treatment.

b Percentages arebased on the number of subjects who started open-label extension treatment.

The most commonly reported important protocol deviation was randomisation (incorrect randomisation or stratification) in the anifrolumab group and study intervention administration in the placebo group (Table 10 ).

Table 10: Important protocol deviations (Full analysis set)

|                                                                                                | Anifrolumab 120mg N=109 n (%)   | Placebo N=111 n (%)   | Total N=220 n (%)   |
|------------------------------------------------------------------------------------------------|---------------------------------|-----------------------|---------------------|
| Subjectswithat leastoneimportant protocol deviation                                            | 6 (5.5)                         | 1 (0.9)               | 7 (3.2)             |
| Randomization                                                                                  | 3 (2.8)                         | 0                     | 3 (1.4)             |
| StudyInterventionAdministration                                                                | 2 (1.8)                         | 1 (0.9)               | 3 (1.4)             |
| Subject Discontinuation                                                                        | 1 (0.9)                         | 0                     | 1 (0.5)             |
| Subjects with at least one important protocol deviation related toglobal/country/areasituation | 0                               | 0                     | 0                   |

|                                                                                                | Anifrolumab 120mg N= 109 n (%)   | Placebo N=111 n (%)   | Total N= 220 n (%)   |
|------------------------------------------------------------------------------------------------|----------------------------------|-----------------------|----------------------|
| Subjects with at least one important protocol deviation                                        | 6 (5.5)                          | 1 (0.9)               | 7 (3.2)              |
| Randomization                                                                                  | 3 (2.8)                          | 0                     | 3 (1.4)              |
| Study Intervention Administration                                                              | 2 (1.8)                          | 1 (0.9)               | 3 (1.4)              |
| Subject Discontinuation                                                                        | 1 (0.9)                          | 0                     | 1 (0.5)              |
| Subjects with at least one important protocol deviation related oglobal/country/area situation | 0                                | 0                     | 0                    |

In terms of first ICE of RM/PEOT/Death at or before week 52, RM use was reported in 11 (10.1%) and 13 (11.7%) patients and PEOT in 17 (15.6%) and 16 (14.4%) of patients in anifrolumab and placebo groups, respectively. No deaths occurred.

<div style=\"page-break-after: always\"></div>

Table 11: Intercurrent event of restricted medication use during double-blind treatment period (Full analysis set)

| ATc Classification Generie Drug Nane   | Anifrolumab 120mg N=109   | Placebo N=111 n（6）   | Total N=220   |
|----------------------------------------|---------------------------|----------------------|---------------|
| SENITORINOONINY                        | 1(0.9）                    | 3(2.7)               | 4（1.0)        |
| ZNIOOOHOTHSAKOEGAR                     | 1(0.9）                    |                      | 4（1.0)        |
| DIPHENYEHETHANEDERIVATIVES             | 1（0.9）                    |                      | 1（0.5)        |
| ZNIZAXOHGAR                            | 1(0.9)                    |                      | 1（0.5)        |
|                                        | 9（9.3)                    | 12 （10.0)            | 21(9.5)       |
| DEFLAZACORT                            | 0                         | 2 (1.0)              | 2（0.9)        |
| HYDROCORTISONE                         | 2 （1.8]                   | 2 （1.0]              | 4（1.8)        |
| MEPREDNISONE                           | 0                         | 1 (6'0)              | 1（0.5)        |
| KETHYLPREDNISOLONE                     | 1(0.9)                    | 1 (5*0）              | 2(0.9)        |
|                                        | 1(0.9)                    | 0                    | 1（0.5)        |
| ZIVNISOOSKNTOOS3NOTOSINGTNdTAHL3H      | 1(0.9)                    |                      | 1（0.5)        |
| PREDNTSOLONE                           | 1(0.9)                    | 0                    | 1(0.5)        |
| PREDNISONE                             | 5(4.6)                    | 6(5.4)               | 11(5.0)       |
| OTHER BLOOD PRODUCTS                   | 0                         | 1(0.9)               | 1（0.5)        |
| RED BLOOD CELES                        | 0                         | 1(0.9)               | 1（0.5)        |
| OTHER IMNUNOSUPFRESSANTS               | 1(0.9)                    | 0                    | 1（0.5)        |
| METHOTREXATE                           | 1(0.9)                    | 0                    | 1（0.5)        |

Conconitantmedicationsthatvererevievedanddeterninedtoaffecteither theinterpretation orthe exiatenceof themeasurements associated vith the clinical question of interest.

Xedicationsinitiated vithin 2sdays ofthe last double-blindtreatmentis considered.

Asubject may have more than one medication that meets the criteria of first intercurrent event of restricted medication, in which case,the subject is counted in multiple medications in the table.

ATcclassificationAnatomical TherapeuticChemical classificationyIPInvestigationalproduct;nnunberofsubjectspercategory: HMumber of subjects per treatment group:WHoDrug Global World Health Organization Global Drug Dictionary.

Table issorted in alphabetical order for ATc claseification and Generie Drug Hant.

## · Conduct of the study

Two amendments were made after the patient recruitment began that included substantial changes to the protocol impacting the study conduct and initial planned analyses.

Amendment 2 (14 July 2022): Changes included e.g. additions of Patient Global Impression of Change (PGIC) and Patient Global Impression of Severity (PGIS) as new patient reported outcome instruments, updated inclusion criterion  9  for  screening  SLEDAI-2K  (with  the  rationale  to  clarify  that  to  count  as 'active' a joint must be both tender and swollen, and to strengthen requirement for rash), deletion of exclusion criterion 9 concerning subjects with concurrent diagnosis of fibromyalgia to remove redundancy with inclusion criterion 12, addition of the section on capturing major acute cardiovascular events (MACE) and  adjudication  by  Cardiovascular  Event  Adjudication  Committee  (CV-EAC)  and  updated  list  of prohibited medications.

Amendment 3 (14 June 2023): The study design was updated and the possibility for all eligible patients completing the DB treatment period to continue in an OLE period was added. Additionally, the screening period was extended from 30 days to 35 days. Overall, the update included several substantial changes that also affected the DB period. For example, the following modifications impacting the eligibility criteria and/or use of allowed or prohibited concomitant medications were made (with MAH's rationale):

- -Tacrolimus and cyclosporine were added to the list of standard therapy regimen allowed before study entry (to reflect the standard clinical use of tacrolimus and cyclosporine as SoC).
- -Clarification that combinations of mycophenolate mofetil or mycophenolic acid or mycophenolate sodium azathioprine, methotrexate, or tacrolimus are not permitted, and that such combination would be a reason for study intervention termination (combination of 2 immunosuppressants is not allowed for safety reasons).
- -Wording  regarding  additional  corticosteroid  usage  during  the  Double-Blind  Period  added (clarification of allowable additional corticosteroid use).

<div style=\"page-break-after: always\"></div>

The changes to the planned analyses are summarised in Table 12 .

Table 12: Changes to the planned analyses

| Key details of change                                                                                                                                                                                                             | Reason for change                                                                                              | SAP amendment?                         |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|----------------------------------------|
| Changesmadebeforeunblindingofstudydata                                                                                                                                                                                            | Changesmadebeforeunblindingofstudydata                                                                         | Changesmadebeforeunblindingofstudydata |
| In the primary endpoint, the ICE of withdrawal from study was updated to categorize non-death related events categorized as missing data while death remained as ICE. Missing data to be handled via multiple imputation methods. | To align with Health Authorities guidance and expectations                                                     | Yes                                    |
| In the primary endpoint, ICE of NC was added for reasons related to global/country situation, including handling strategy for all relevant endpoints and analyses.                                                                | To address the impact of pandemic and war related NC.                                                          | Yes                                    |
| Multiple testing procedure was updated with details for the IA,removal of BICLA response assessment at Week 16, and reordered key secondary endpoints for sequential testing.                                                     | To align with CSP version 4.0, including that BICLA response at Week 16 no longer reflects an early response   | Yes                                    |
| Forkey secondary endpoints,updates specified composite strategy to handle certain ICEs and described methods to use for missing data.                                                                                             | To align main analyses with the composite strategy for handling of ICEs and to meet Health Authority guidance. | Yes                                    |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Key details of change                                                                                                                                                                                                                                                                                                                                                   | Reasonfor change                                                                                                         | SAP amendment?                        |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|---------------------------------------|
| Certain other secondary endpoints were recategorized as exploratory analyses.                                                                                                                                                                                                                                                                                           | To align with CSP version 4.0                                                                                            | Yes                                   |
| Analyses for the open label extension period were added, and exploratory endpoints not included in the CSP moved to a separate exploratory analysis plan.                                                                                                                                                                                                               | To alignwith CSPversion 4.0 and to simplify andfocus theSAPtoanalyses that will be written into the CSR                  | Yes                                   |
| For the primary endpoint, the multiple imputationregressionmodel wasmodified toincludeonlytheimmediateprevious visit's evaluation as a covariate rather than all previous visits? evaluations.                                                                                                                                                                          | To simplify the multiple imputation model                                                                                | Yes                                   |
| For the primary endpoint, method for tipping point analysis was updated to vary underlying assumed response probability for patients with NC ICE or missing assessment at Week 52.                                                                                                                                                                                      | To meet guidance from the United States Food andDrugAdministration                                                       | Yes                                   |
| An additional sensitivity analysis was addedfor the time to thefirst sustained BICLA response (secondary endpoint). The sensitivity analysis assesses the impact of dropping the requirement for at least 3 consecutive visits for BICLA responders.                                                                                                                    | To align withinitial CSP-specified analysis that did not include the requirement of 3 consecutive visits                 | Yes                                   |
| Analysesfor DORIS and LLDAS endpoints were added as exploratory endpoints to be performed at the final analysis.                                                                                                                                                                                                                                                        | TocharacterizeSLE-relatedremission endpoints at the final DB analysis (these endpoints have not been assessed at the IA) | Yes                                   |
| Clarifications were added regarding: the IA sample size for PK, PD, and immunogenicity analyses; the inclusion of by-visit evaluation on the same day as the open-label treatment first dose date into the by-visit summary, and the change to require 20 patients instead of 25 patients with available datainthe combined treatment groups for the subgroup analyses. | To clarify and update data presentation in final outputs                                                                 | Yes                                   |
| Changesmadeafterunblindingofstudydata                                                                                                                                                                                                                                                                                                                                   | Changesmadeafterunblindingofstudydata                                                                                    | Changesmadeafterunblindingofstudydata |
| No changes                                                                                                                                                                                                                                                                                                                                                              | Not applicable                                                                                                           | 10N applicable                        |

## · Baseline data

The demographics at baseline are shown in Table 13 .

<div style=\"page-break-after: always\"></div>

Table 13: Demographics (Full Analysis Set)

<!-- image -->

| Demographiccharacteristic              | Statistic   | Anifrolumab 120mg N=109   | Placebo N=111   | Total N=220   |
|----------------------------------------|-------------|---------------------------|-----------------|---------------|
| Age (years)                            | n           | 109                       | 111             | 220           |
|                                        | Mean        | 43.0                      | 42.3            | 42.7          |
|                                        | SD          | 12.43                     | 11.39           | 11.89         |
|                                        | Median      | 44.0                      | 43.0            | 43.0          |
|                                        | Min         | 21                        | 19              | 19            |
|                                        | Max         | 70                        | 68              | 70            |
| Age group (years)                      |             |                           |                 |               |
| >= 18 to < 65                          | n (%)       | 102 (93.6)                | 110 (99.1)      | 212 (96.4)    |
| >=65                                   | (%) u       | 7 (6.4)                   | 1 (0.9)         | 8 (3.6)       |
| Sex                                    |             |                           |                 |               |
| Female                                 | n (%)       | 94 (86.2)                 | 102 (91.9)      | 196 (89.1)    |
| Male                                   | n (%)       | 15 (13.8)                 | 9 (8.1)         | 24 (10.9)     |
| Race                                   |             |                           |                 |               |
| White                                  | (%) u       | 81 (74.3)                 | 91 (82.0)       | 172 (78.2)    |
| Black or African American              | n (%)       | 2 (1.8)                   | 6 (5.4)         | 8 (3.6)       |
| Asian                                  | (%) u       | 10 (9.2)                  | 6 (5.4)         | 16 (7.3)      |
| NativeHawaiian or OtherPacificIslander | (%) u       | 0                         | 0               | 0             |
| American Indian or Alaska Native       | n (%)       | 8 (7.3)                   | 7 (6.3)         | 15 (6.8)      |

<!-- image -->

| Other                    | n (%)   | 8 (7.3)   | 1 (0.9)   | 9 (4.1)    |
|--------------------------|---------|-----------|-----------|------------|
| Not Reported             | n (%)   | 0         | 0         | 0          |
| Ethnicity                |         |           |           |            |
| Hispanie or Latino       | n (%)   | 47 (43.1) | 53 (47.7) | 100 (45.5) |
| Not Hispanie or Latino   | n (%)   | 62 (56.9) | 58 (52.3) | 120 (54.5) |
| BMI (kg/m2)              | I       | 109       | 111       | 220        |
|                          | Mean    | 27.82     | 27.27     | 27.54      |
|                          | SD      | 6.430     | 6.600     | 6.507      |
|                          | Median  | 26.50     | 25.81     | 26.34      |
|                          | Min     | 17.9      | 16.6      | 16.6       |
|                          | Max     | 47.1      | 48.8      | 48.8       |
| BMI group (kg/m2)        |         |           |           |            |
| =28                      | n (%)   | 65 (59.6) | 67 (60.4) | 132 (60.0) |
| > 28                     | n (%)   | 44 (40.4) | 44 (39.6) | 88 (40.0)  |
| Region                   |         |           |           |            |
| United States of America | n (%)   | 11 (10.1) | 11 (9.9)  | 22 (10.0)  |
| Europe                   | n (%)   | 45 (41.3) | 47 (42.3) | 92 (41.8)  |
| Asia                     | n (%)   | 8 (7.3)   | 6 (5.4)   | 14 (6.4)   |
| Latin Ameriea            | n (%)   | 45 (41.3) | 47 (42.3) | 92 (41.8)  |
| Rest of World            | n (%)   | 0         | 0         | 0          |

<div style=\"page-break-after: always\"></div>

The SLE disease characteristics at baseline are shown in Table 14 .

The  most  commonly  affected  organ  systems  (BILAG  A  or  B  at  baseline)  were  the  musculoskeletal (94.6%)  and  mucocutaneous  (92.3%)  systems;  2.3%  renal  and  1.9%  cardiorespiratory  domain involvement.  At  baseline,  95.5%  were  seropositive  for  ANA  antibodies  and  40.5%  for  anti  dsDNA antibodies; 33.2% of patients had low C3, and 24.1% low C4.

Table 14: SLE Disease Characteristics (Full Analysis Set)

| Demographiccharacteristic                                 | Statistic   | Anifrolumab 120mg N=109   | Placebo N=111   | Total N=220   |
|-----------------------------------------------------------|-------------|---------------------------|-----------------|---------------|
| Time from initial SLE diagnosis to randomization (months) | n           | 109                       | 111             | 220           |
|                                                           | Mean        | 121.980                   | 108.202         | 115.028       |
|                                                           | SD          | 113.011                   | 92.184          | 103.026       |
|                                                           | Median      | 88.082                    | 80.230          | 83.844        |
|                                                           | Min         | 0.986                     | 0.854           | 0.854         |
|                                                           | Max         | 461.339                   | 466.431         | 466.431       |
| SLEDAI-2K score at screening                              |             |                           |                 |               |
| <10 points                                                | (%)         | 36 (33.0)                 | 36 (32.4)       | 72 (32.7)     |
| >= 10 points                                              | n (%)       | 73 (67.0)                 | 75 (67.6)       | 148 (67.3)    |
|                                                           | n           | 109                       | 111             | 220           |
|                                                           | Mean        | 11.2                      | 10.4            | 10.8          |
|                                                           | SD          | 3.73                      | 2.61            | 3.24          |
|                                                           | Median      | 10.0                      | 10.0            | 10.0          |
|                                                           | Min         | 6                         | 6               | 6             |
|                                                           | Max         | 22                        | 18              | 22            |
| SLEDAI-2K score at baseline                               |             |                           |                 |               |
| < 10 points                                               | n (%)       | 33 (30.3)                 | 39 (35.1)       | 72 (32.7)     |
| >= 10 points                                              | n (%)       | 76 (69.7)                 | 72 (64.9)       | 148 (67.3)    |
|                                                           | n           | 109                       | 111             | 220           |
|                                                           | Mean        | 11.3                      | 10.5            | 10.9          |
|                                                           | SD          | 3.83                      | 2.88            | 3.40          |
|                                                           | Median      | 10.0                      | 10.0            | 10.0          |
|                                                           | Min         | 6                         | 6               | 6             |
|                                                           | Max         | 26                        | 18              | 26            |
| Clinical SLEDAI-2K score at baseline                      | n           | 109                       | 111             | 220           |
|                                                           | Mean        | 8.9                       | 8.4             | 8.6           |
|                                                           | SD          | 2.66                      | 2.14            | 2.42          |
|                                                           | Median      | 8.0                       | 8.0             | 8.0           |
|                                                           | Min         | 4                         | 6               | 4             |
|                                                           | Max         | 18                        | 18              | 18            |
| Overall BILAG at screening                                |             |                           |                 |               |
| At least one A                                            | n (%)       | 50 (45.9)                 | 45 (40.5)       | 95 (43.2)     |

<div style=\"page-break-after: always\"></div>

| No A and at least 2 Bs              | (%) u   | 57 (52.3)   | 65 (58.6)   | 122 (55.5)   |
|-------------------------------------|---------|-------------|-------------|--------------|
| No A and< 2 Bs                      | (%) U   | 2 (1.8)     | 0           | 2 (0.9)      |
| Not Available                       | n (%)   | 0           | 1 (0.9)     | 1 (0.5)      |
| Overall BILAG at baseline           |         |             |             |              |
| At least one A                      | (%) u   | 51 (46.8)   | 47 (42.3)   | 98 (44.5)    |
| No A and at least 2 Bs              | n (%)   | 52 (47.7)   | 59 (53.2)   | 111 (50.5)   |
| No A and< 2 Bs                      | n (%)   | 6 (5.5)     | 5 (4.5)     | 11 (5.0)     |
| Not Available                       | n (%)   | 0           | 0           | 0            |
| BILAG-2004 global score at baseline | n       | 109         | 111         | 220          |
|                                     | Mean    | 18.5        | 18.1        | 18.3         |
|                                     | SD      | 4.01        | 3.61        | 3.81         |
|                                     | Median  | 17.0        | 17.0        | 17.0         |
|                                     | Min     | 4           | 9           | 4            |
|                                     | Max     | 32          | 28          | 32           |
| PGA score at baseline               | n       | 109         | 111         | 220          |
|                                     | Mean    | 1.92        | 1.88        | 1.90         |
|                                     | SD      | 0.411       | 0.389       | 0.400        |
|                                     | Median  | 2.00        | 1.90        | 2.00         |
|                                     | Min     | 1.0         | 1.0         | 1.0          |
|                                     | Max     | 2.8         | 2.8         | 2.8          |
| CLASI activity score at baseline    |         |             |             |              |
| <10                                 | n (%)   | 72 (66.1)   | 80 (72.1)   | 152 (69.1)   |
| >=10                                | (%)     | 37 (33.9)   | 31 (27.9)   | 68 (30.9)    |
| 0                                   | (%) UI  | 1 (0.9)     | 0           | 1 (0.5)      |
| >0                                  | n (%)   | 108 (99.1)  | 111 (100)   | 219 (99.5)   |
|                                     | n       | 109         | 111         | 220          |
|                                     | Mean    | 8.7         | 7.8         | 8.2          |
|                                     | SD      | 6.79        | 5.62        | 6.23         |
|                                     | Median  | 7.0         | 6.0         | 6.0          |
|                                     | Min     | 0           | 1           | 0            |
|                                     | Max     | 36          | 25          | 36           |
| SDI global score at baseline        |         |             |             |              |
| 0                                   | n (%)   | 71 (65.1)   | 82 (73.9)   | 153 (69.5)   |

<div style=\"page-break-after: always\"></div>

| >= 1                    | n (%)     | 38 (34.9)   | 29 (26.1)   | 67 (30.5)   |
|-------------------------|-----------|-------------|-------------|-------------|
|                         |           | 109         | 111         | 220         |
|                         | Mean      | 0.5         | 0.4         | 0.4         |
|                         | SD        | 0.81        | 0.76        | 0.79        |
|                         | Median    | 0.0         | 0.0         | 0.0         |
|                         | Min       | 0           | 0           | 0           |
|                         | Max       | 3           | 5           | 5           |
| Joint count at baseline |           |             |             |             |
| Swollen joints          | > 0 n (%) | 108 (99.1)  | 109 (98.2)  | 217 (98.6)  |
|                         | Mean      | 7.5         | 7.3         | 7.4         |
|                         | SD        | 4.26        | 4.30        | 4.27        |
|                         | Median    | 7.0         | 6.0         | 6.0         |
|                         | Min       | 0           | 0           | 0           |
|                         | Max       |             | 24          | 28          |
| Tender joints           | (%)0<     | 107 (98.2)  | 110 (99.1)  | 217 (98.6)  |
|                         | Mean      | 11.5        | 10.7        | 11.1        |
|                         | SD        | 6.38        | 5.56        | 5.98        |
|                         | Median    | 12.0        | 10.0        | 10.0        |
|                         | Min       | 0           | 0           | 0           |
|                         | Max       | 87          | 28          | 28          |
| Active joints           | (%)0<     | 105 (96.3)  | 109 (98.2)  | 214 (97.3)  |
|                         | Mean      | 7.1         | 6.8         | 7.0         |
|                         | SD        | 4.35        | 4.09        | 4.21        |
|                         | Median    | 6.0         | 6.0         | 6.0         |
|                         | Min       | 0           | 0           | 0           |
|                         | Max       | 82          | 24          | 28          |

The clinical SLEDAI-2K score is the SLEDAI-2K score excluding items attributable to any urine or laboratory results including immunologic measures, which includes: vasculitis,arthritis,myositis,rash,alopecia,mucosal uleers. pleurisy. and pericarditis.

Active joints are defined for the joints where both swollen and tender are in the same joint.

Only subjects with baseline positive anti-dsDNA and abnormal complement level, respectively, are included in the summarv statistics for the respective variables.

Medical  and  surgical  history  was  generally  similar  between  patients  in  the  anifrolumab  and  placebo groups.  The  most  commonly  reported  risk  factors,  excluding  common  characteristics  of  SLE,  were hypertension (25.7% and 27.9%), obesity (16.5% and 19.8%), hypothyroidism (14.7% and 10.8%), and COVID-19 (13.8% and 11.7%, respectively).

CV risk factors were generally similar between the anifrolumab and placebo groups. The most common risk  factors  were  hypertension  (25.0%  and  25.9%),  cigarette  smoking  (14.8%  and  12.9%),  and hyperlipidemia (10.8% and 7.1%, respectively). Surgical history was reported by 28.4% and 36.0% of patients in the anifrolumab and placebo groups, respectively.

The most frequently used prior medications in the anifrolumab and placebo groups were glucocorticoids (85.3% and 84.7%), aminoquinolines (78.0% and 88.3%), and other immunosuppressants (45.0% and 40.5%). The most frequently used prior SLE-related treatments were methotrexate (22.0% and 23.4%), azathioprine  (22.9%  and  18.0%),  and  hydroxychloroquine  (13.8%  and  18.0%,  respectively).  Prior belimumab use was reported in 9.2% and 9.9%, and prior rituximab use in 0.9% and 1.8% of patients in the anifrolumab and placebo groups, respectively.

At baseline, 82.3% of patients included in the FAS were on OCS, i.e. 85.3% and 79.3% of patients in the  anifrolumab  and  placebo  groups,  respectively.  55.9%  of  patients  were  on  immunosuppressants

<div style=\"page-break-after: always\"></div>

(61.5%  and  50.5%)  and  80.5%  were  on  antimalarials  (78.0%  and  82.9%).  Commonly  used immunosuppressant included azathioprine (23.9% and 18.0%), methotrexate (19.3% and 21.6%), and mycophenolate (18.3 and 11.7%, respectively). NSAIDs were used in 12.8% and 23.4%, and other SLE medications by 30.3% and 30.6% of patients in the anifrolumab and placebo groups, respectively (Table Table 15 ).

Table 15: SLE-related treatment at baseline (Full analysis set)

<!-- image -->

| Medication Categories                               | Statistic   | Anifrolumab 120mg N=109   | Placebo N=111   | Total N=220   |
|-----------------------------------------------------|-------------|---------------------------|-----------------|---------------|
| Any SLE-related medication                          | n (%)       | 109 (100)                 | 107 (96.4)      | 216 (98.2)    |
| Ocs                                                 |             |                           |                 |               |
| Yes                                                 | n (%)       | 93 (85.3)                 | 88 (79.3)       | 181 (82.3)    |
| No                                                  | n (%)       | 16 (14.7)                 | 23 (20.7)       | 39 (17.7)     |
| OCS dose (mg/day)                                   |             |                           |                 |               |
| < 10 mg/day                                         | n (%)       | 52 (47.7)                 | 65 (58.6)       | 117 (53.2)    |
| > =10 mg/day                                        | n (%)       | 57 (52.3)                 | 46 (41.4)       | 103 (46.8)    |
|                                                     | 1n          | 109                       | 111             | 220           |
|                                                     | Mean        | 8.638                     | 7.450           | 8.039         |
|                                                     | SD          | 5.972                     | 6.401           | 6.207         |
|                                                     | Median      | 10.000                    | 5.000           | 7.500         |
|                                                     | Min         | 0.000                     | 0.000           | 0.000         |
|                                                     | Max         | 25.000                    | 30.000          | 30.000        |
| OCS dose (mg/day) excluding patients not taking OCS |             |                           |                 |               |
| < 10 mg/day                                         | n (%)       | 36 (33.0)                 | 42 (37.8)       | 78 (35.5)     |
| > = 10 mg/day                                       | n (%)       | 57 (52.3)                 | 46 (41.4)       | 103 (46.8)    |
|                                                     | n           | 93                        | 88              | 181           |
|                                                     | Mean        | 10.124                    | 9.398           | 9.771         |
|                                                     | SD          | 5.164                     | 5.770           | 5.464         |
|                                                     | Median      | 10.000                    | 10.000          | 10.000        |
|                                                     | Min         | 1.250                     | 2.000           | 1.250         |
|                                                     | Max         | 25.000                    | 30.000          | 30.000        |
| OCS only                                            |             |                           |                 |               |
| Yes                                                 | n (%)       | 3 (2.8)                   | 1 (0.9)         | 4 (1.8)       |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Medication Categories                                         | Statistic   | Anifrolumab 120mg N=109   | Placebo N=111   | Total N=220   |
|---------------------------------------------------------------|-------------|---------------------------|-----------------|---------------|
| No                                                            | n (%)       | 106 (97.2)                | 110 (99.1)      | 216 (98.2)    |
| OCS dose (mg/day)                                             | n           | 3                         | 1               | 4             |
|                                                               | Mean        | 9.17                      | 10.00           | 9.38          |
|                                                               | SD          | 1.443                     |                 | 1.250         |
|                                                               | Median      | 10.00                     | 10.00           | 10.00         |
|                                                               | Min         | 7.5                       | 10.0            | 7.5           |
|                                                               | Max         | 10.0                      | 10.0            | 10.0          |
| OCS in combination with immunosuppressants                    |             |                           |                 |               |
| Yes                                                           | n (%)       | 57 (52.3)                 | 49 (44.1)       | 106 (48.2)    |
| No                                                            | n (%)       | 52 (47.7)                 | 62 (55.9)       | 114 (51.8)    |
| OCS dose (mg/day)                                             | n           | 57                        | 49              | 106           |
|                                                               | Mean        | 10.627                    | 10.469          | 10.554        |
|                                                               | SD          | 5.277                     | 6.498           | 5.844         |
|                                                               | Median      | 10.000                    | 10.000          | 10.000        |
|                                                               | Min         | 5.000                     | 2.500           | 2.500         |
|                                                               | Max         | 25.000                    | 30.000          | 30.000        |
| OCSin combination with anti-malarials                         |             |                           |                 |               |
| Yes                                                           | n (%)       | 71 (65.1)                 | 77 (69.4)       | 148 (67.3)    |
| No                                                            | n (%)       | 38 (34.9)                 | 34 (30.6)       | 72 (32.7)     |
| OCS dose (mg/day)                                             |             | 71                        | 77              | 148           |
|                                                               | Mean        | 10.204                    | 9.312           | 9.740         |
|                                                               | SD          | 5.473                     | 5.826           | 5.658         |
|                                                               | Median      | 10.000                    | 10.000          | 10.000        |
|                                                               | Min         | 1.250                     | 2.000           | 1.250         |
|                                                               | Max         | 25.000                    | 30.000          | 30.000        |
| OCS in combination with anti-malarials and immunosuppressants |             |                           |                 |               |
| Yes                                                           | n (%)       | 38 (34.9)                 | 39 (35.1)       | 77 (35.0)     |
| No                                                            | n (%)       | 71 (65.1)                 | 72 (64.9)       | 143 (65.0)    |
| OCS dose (mg/day)                                             | n           | 38                        | 39              | 77            |
|                                                               | Mean        | 10.954                    | 10.590          | 10.769        |
|                                                               | SD          | 5.691                     | 6.711           | 6.190         |
|                                                               | Median      | 10.000                    | 10.000          | 10.000        |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| MedicationCategories                                            | Statistic   | Anifrolumab 120mg N=109   | Placebo N=111   | Total N=220   |
|-----------------------------------------------------------------|-------------|---------------------------|-----------------|---------------|
|                                                                 | Min         | 5.000                     | 2.500           | 2.500         |
|                                                                 | Max         | 25.000                    | 30.000          | 30.000        |
| Anti-malarials                                                  | n (%)       | 85 (78.0)                 | 92 (82.9)       | 177 (80.5)    |
| Anti-malarials only                                             | n (%)       | 6 (5.5)                   | 9 (8.1)         | 15 (6.8)      |
| Anti-malarials in combination with OCSand/or immunosuppressants | n (%)       | 79 (72.5)                 | 83 (74.8)       | 162 (73.6)    |
| Immunosuppressants                                              | n (%)       | 67 (61.5)                 | 56 (50.5)       | 123 (55.9)    |
| Azathioprine (mg/day)                                           | n (%)       | 26 (23.9)                 | 20 (18.0)       | 46 (20.9)     |
|                                                                 | Mean        | 95.2                      | 96.3            | 95.7          |
|                                                                 | SD          | 36.76                     | 35.61           | 35.86         |
|                                                                 | Median      | 100.0                     | 100.0           | 100.0         |
|                                                                 | Min         | 50                        | 50              | 50            |
|                                                                 | Max         | 150                       | 150             | 150           |
| Methotrexate (mg/week)                                          | n (%)       | 21 (19.3)                 | 24 (21.6)       | 45 (20.5)     |
|                                                                 | Mean        | 15.952                    | 14.387          | 15.118        |
|                                                                 | SD          | 5.091                     | 4.817           | 4.953         |
|                                                                 | Median      | 15.000                    | 15.000          | 15.000        |
|                                                                 | Min         | 7.500                     | 2.800           | 2.800         |
|                                                                 | Max         | 25.000                    | 25.000          | 25.000        |
| Mycophenolate (g/day)[a]                                        | n (%)       | 20 (18.3)                 | 13 (11.7)       | 33 (15.0)     |
|                                                                 | Mean        | 1.519                     | 1.224           | 1.403         |
|                                                                 | SD          | 0.526                     | 0.573           | 0.555         |
|                                                                 | Median      | 1.720                     | 1.000           | 1.440         |
|                                                                 | Min         | 0.50                      | 0.25            | 0.25          |
|                                                                 | Max         | 2.00                      | 2.00            | 2.00          |
| Cyclosporine (mg/kg/day)                                        | n (%)       | 0                         | 0               | 0             |
|                                                                 | Mean        |                           |                 |               |
|                                                                 | SD          |                           |                 |               |
|                                                                 | Median      |                           |                 |               |
|                                                                 | Min         |                           |                 |               |
|                                                                 | Max         |                           |                 |               |
| Tacrolimus (mg/kg/day)                                          | n (%)       | 0                         | 0               | 0             |
|                                                                 | Mean        |                           |                 |               |

<div style=\"page-break-after: always\"></div>

| Medication Categories         | Statistic   | Anifrolumab 120mg N= 109   | Placebo N=111   | Total N=220   |
|-------------------------------|-------------|----------------------------|-----------------|---------------|
|                               | SD          |                            |                 |               |
|                               | Median      |                            |                 |               |
|                               | Min         |                            |                 |               |
|                               | Max         |                            |                 |               |
| Mizoribine (mg/day)           | n (%)       | 0                          | 0               | 0             |
|                               | Mean        |                            |                 |               |
|                               | SD          |                            |                 |               |
|                               | Median      |                            |                 |               |
|                               | Min         |                            |                 |               |
|                               | Max         |                            |                 |               |
| More than 1 immunosuppressant | n (%)       | 1 (0.9)                    | 1 (0.9)         | 2 (0.9)       |
| NSAIDs                        | n (%)       | 14 (12.8)                  | 26 (23.4)       | 40 (18.2)     |
| Other SLE medications         | n (%)       | 33 (30.3)                  | 34 (30.6)       | 67 (30.5)     |

Medication selection is based on collected medications in the Prior and Concomitant medication pages. Medieations are coded according to WHODrug Global World Health Organization Global Drug Dictionary. SLE-related medieations at baseline are defined as all medications with therapy reason of\"disease under study\" or \"disease under study, clinical failure of study\" with an intake at the date of first dose of investigational product.

Immunosuppressant: azathioprine, mycophenolate mofetil/mycophenolie acid, methotrexate, cyclosporine, tacrolimus,ormizonibine.

[a] Mycophenolate or mycophenolic acid.

During the DB treatment period, the most commonly used concomitant medications were glucocorticoids in 88.1% and 88.3% of patients, aminoquinolines in 78.0% and 88.3% of patients, and other immunosuppressants in 41.4% and 45.9% of patients in anifrolumab and placebo groups, respectively.

## · Numbers analysed

Altogether 220 patients were included in the FAS for the IA, 109 patients in the anifrolumab group and 111 patients in the placebo group.

## · Outcomes and estimation

## Primary endpoint

The primary endpoint BICLA response rate at week 52 was 59.4% for anifrolumab and 43.9% for placebo, resulting in a 15.5% treatment difference (95% CI 2.3, 28.6).

The efficacy results for the primary and key secondary endpoints are shown in Table 16 .

<div style=\"page-break-after: always\"></div>

Table 16: Overview of key efficacy results (FAS)

|                                                                    |                                     |                           |    |          |              | Comparison with Placebo   | Comparison with Placebo   | Comparison with Placebo   | Comparison with Placebo   |
|--------------------------------------------------------------------|-------------------------------------|---------------------------|----|----------|--------------|---------------------------|---------------------------|---------------------------|---------------------------|
| Endpoint                                                           | Type of estimate Type of comparison | Group                     | n  | Estimate | 95% CI       | Estimate                  | 95% CI                    | p-value                   | Reject H0                 |
| Primary                                                            |                                     |                           |    |          |              |                           |                           |                           |                           |
| BICLA response at Week 52                                          | Response rate Rate difference       | Anifrolumab 120mg N = 109 | 65 | 59.4     | (50.1, 68.7) | 15.5                      | (2.3, 28.6)               | 0.0211                    | Yes                       |
|                                                                    |                                     | Placebo N = 111           | 49 | 43.9     | (34.6, 53.3) |                           |                           |                           |                           |
| Key Secondary                                                      |                                     |                           |    |          |              |                           |                           |                           |                           |
| BICLA response at Week 52 with Maintained Low (or reduced) OCS use | Response rate Rate difference       | Anifrolumab 120mg N = 109 | 65 | 59.4     | (50.1, 68.7) | 19.9                      | (6.9, 32.9)               | 0.0027                    | NA                        |
|                                                                    |                                     | Placebo N = 111           | 44 | 39.5     | (30.4, 48.7) |                           |                           |                           |                           |
| Time to BICLA response sustained through Week 52                   | Percentage of response Hazard ratio | Anifrolumab 120mg N = 109 | 43 | 39.8     | (31.3, 49.7) | 2.038                     | (1.248, 3.408)            | 0.0052                    | NA                        |
|                                                                    |                                     | Placebo N = 111           | 24 | 22.8     | (15.9, 32.1) |                           |                           |                           |                           |
| Time to First Flare through Week 52                                | Percentage of flare Hazard ratio    | Anifrolumab 120mg N = 109 | 42 | 39.3     | (30.7, 49.2) | 0.757                     | (0.499, 1.141)            | 0.1841                    | NA                        |
|                                                                    |                                     | Placebo N = 111           | 50 | 46.6     | (37.6, 56.5) |                           |                           |                           |                           |

Only subjects with non-missing covariates/stratification factors are included in the analysis. At the interim analysis, only the primary endpoint will be tested at 0.0354 level. The 0.0354 is determined based on the information fraction at the time of the interim analysis using Pocock spending function. All other p-values are nominal. The responder/nonresponder rates (percentages), are performed using stratified CMH adjusting for the stratification factors. Missing data are imputed using multiple imputation as specified in the SAP, and all results are combined to obtain a single estimated treatment effect as per the Rubins rule. For Time to BICLA sustained response and time to Flare through Week 52, Kaplan-Meier estimate with its 95% CI is presented for each treatment group. Hazard ratios, and 95% CIs for Hazard ratios are estimated using a Cox regression model with treatment groups and the stratification factors. Stratification factors levels are: type I IFN gene signature test result = high and SLEDAI &lt; 10 points, IFN = high and SLEDAI &gt; = 10 points, and IFN = low.

<div style=\"page-break-after: always\"></div>

At Week 52, a larger proportion of patients with BICLA response in the anifrolumab 120 mg SC group displayed BILAG improvement compared with patients in the placebo group, while similar proportions of patients in the anifrolumab and placebo groups had no worsening of SLEDAI-2K and no worsening of PGA (Table 17 ).

Table 17: BICLA Response Rate at Week 52 by BICLA Components (FAS)

| BICLA Response at Week 52             | Anifrolumab 120 mg (N = 109)   | Placebo (N = 111)   |
|---------------------------------------|--------------------------------|---------------------|
| Number (%) responders *               | 65 (59.4)                      | 49 (43.9)           |
| Comparison with placebo               |                                |                     |
| Difference in response rate           | 15.5                           |                     |
| g5% CI of difference in response rate | (2.3,28.6)                     |                     |
| P-value b                             | 0.0211                         |                     |
| Components of BICLA response          |                                |                     |
| BILAG improvement, n (%)              | 65 (59.5)                      | 49 (44.1)           |
| No worsening of SLEDAI-2K,n (%)       | 81 (74.3)                      | 80 (71.0)           |
| No worsening of PGA, n (%)            | 81 (74.4)                      | 82 (73.7)           |

The  BICLA  response  rates  by  visit  is  shown  in  Figure 11 .  The  results  demonstrated  a  nominal significance  for  treatment  differences  at  all  timepoints  from  Week 24  and  onwards,  except  for Week 44.

Figure 11: BICLA Response Rate by Visit (Primary Analysis): RM, PEOT and Deaths Result in NR, NC is Handled with MI (MAR) - Line Plot (FAS)

<!-- image -->

The analyses are performed using stratified CMH adjusting for the stratification factors. Missing data are imputed using multiple imputation as specified in the SAP, and all results are combined to obtain a single estimated treatment effect as per the Rubins rule.

and SLEDAI&gt;=10 points, and IFN=low.

BICLA response is defined as reduction of all baseline BILAG-2004 A and B scores and no worsening in other organ systems, no worsening from baseline in SLEDAI-2K, and no increase =0.30 points on a 3-point PGA VAS from baseline.

<div style=\"page-break-after: always\"></div>

The results of a sensitivity analysis of the primary endpoint, excluding patients with no BILAG A or B  or  baseline  PGA  VAS  score  &gt;  2.7,  were  consistent  with  the  primary  analysis  with  nominal significance for treatment differences at all timepoints from Week 24 and onwards, except for Weeks 40 and 44. At week 52, the BICLA response rate was 58.6% for anifrolumab and 43.9% for placebo, resulting in a treatment difference of 14.6% (95% CI 1.3, 27.9).

The results of supplementary analyses of the primary endpoint were consistent with and supported the findings of the main analysis.

## Key secondary endpoints

A greater proportion of patients treated with anifrolumab achieved a BICLA response at Week 52 while achieving or maintaining low OCS use, compared with placebo (Table 17 ).  Treatment with anifrolumab also reduced the time to the first BICLA response and numerically delayed the time to the first flare (Table 17 and Figure 12 and Figure 13 ).

Figure 12: Time to BICLA Response Sustained Through Week 52 (Primary Analysis): RM, PEOT and Death Result in NR and NC is Censored - Kaplan-Meier Plot (FAS)

<!-- image -->

BICLA response is defined as reduction of all baseline BILAG-2004 A and B scores and no worsening in other organ systems, no worsening from baseline in SLEDAI-2K, and no increase &gt;= 0.30 points on a 3 point PGA VAS from baseline. Subjects had first intercurrent event of RM/PEOT/Death are regarded as no observed event. BICLA British Isles Lupus Assessment Group-based Composite Lupus Assessment; SLEDAI-2K Systemic Lupus Erythematosus Disease Activity Index 2000; PGA: Physician's Global Assessment VAS: Visual Analogue Scale; n Number of subjects in analysis; N Number of subjects per treatment group.

NR Non-responder; RM Restricted Medication use; PEOT Premature End of Treatment; NC Non compliance for reasons related to civil crisis, natural disaster, or public health crisis.

<div style=\"page-break-after: always\"></div>

Figure 13: Time to First Flare (Primary Analysis): RM, PEOT, Deaths are Flare and NC is Censored - Kaplan-Meier Plot (FAS)

<!-- image -->

Flare is defined as either 1 or more new BILAG-2004 A or 2 or more new BILAG-2004 B items compared to the previous visit.

If an ICE of RM/PEOT/Death occurred, it is considered as a flare in the event that ICE is not in the same visit window of the previous observed flare.

n Number of subjects in analysis; N Number of subjects per treatment group; PEOT Premature End of Treatment; RM Restricted Medication use; NC Non compliance for reasons related to civil crisis, natural disaster, or public health crisis.

## Other secondary endpoints

A higher proportion of patients with baseline OCS ≥ 10 mg/day receiving anifrolumab achieved an OCS dose of ≤ 7.5 mg/day by Week 40, which was maintained through Week 52, compared with patients receiving placebo (74.2% vs 48.6%; difference 25.6% [95% CI 7.6, 43.5]; nominal p = 0.0053).

There was a slight numerical reduction of the annual flare rate for the anifrolumab group compared with  the  placebo  group  (0.80  rate  ratio  anifrolumab:placebo  [95%  CI  0.52,  1.23];  nominal  p  = 0.3018).

A numerically higher proportion of patients treated with anifrolumab achieved an SRI(4) response at Week 52 compared with patients receiving placebo (67.8% vs 59.4%; difference 8.4% [95% CI 4.5, 21.1]; nominal p = 0.2012).

## · Ancillary analyses

## Subgroup analysis

The  BICLA  response  rates  across  the  pre-defined  subgroups,  including  ADA-positive  and  ADAnegative subgroups, are shown in Figure 14 .

<div style=\"page-break-after: always\"></div>

Figure 14: BICLA Response Rate at Week 52 (Subgroup Analysis): RM, PEOT and Deaths Result in NR, NC is Handled with MI (MAR) - forest plot (FAS)

<!-- image -->

The analyses are performed using stratified CMH adjusting for the stratification factors. Missing data are imputed using multiple imputation as specified in the SAP, and all results are combined to obtain a single estimated treatment effect as per the Rubins rule.

Stratification factors used for each subgroup may vary depending on the number of participants within each stratum for the subgroup of interest. Factors used in the stratified CMH for each subgroup can be found in the corresponding subgroup summary table

A positive rate difference favours Anifrolumab.

BICLA response is defined as reduction of all baseline BILAG-2004 A and B scores and no worsening in other organ systems, no worsening from baseline in SLEDAI-2K, and no increase &gt;=0.30 points on a 3 point PGA VAS from baseline.

BICLA British Isles Lupus Assessment Group-based Composite Lupus Assessment; SLEDAI-2K Systemic Lupus Erythematosus Disease

Activity Index 2000; PGA: Physician's Global Assessment; VAS: Visual Analogue Scale; OCS Oral corticosteroids; IFN Interferon.

n Number of subjects in analysis; N Number of subjects per treatment group.

CMH Cochran-Mantel-Haenszel; CI Confidence interval; NR Non-responder; RM Restricted Medication use;

PEOT Premature End of Treatment; NC Non compliance for reasons related to civil crisis, natural disaster, or public health crisis; MAR Missing at Random; MI Multiple Imputation.

<div style=\"page-break-after: always\"></div>

## · Summary of main efficacy results

The following table summarises the efficacy results from the main study supporting the present application. This summary should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 18: Summary of efficacy for study D3465C00001 (TULIP SC)

| Title                     | A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier          | D3465C00001 EudraCT/EU CT Number: 2020-004529-22/2022-502396-28 NCT Number: NCT04877691                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | D3465C00001 EudraCT/EU CT Number: 2020-004529-22/2022-502396-28 NCT Number: NCT04877691                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | D3465C00001 EudraCT/EU CT Number: 2020-004529-22/2022-502396-28 NCT Number: NCT04877691                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Design                    | Phase III, multicenter, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of an SC treatment regimen of anifrolumab versus placebo in adult patients with moderate to severe SLE despite receiving standard therapy. The primary objective of the study was to compare efficacy of anifrolumab with placebo on overall disease activity in patients with SLE. The efficacy assessments in this application are based on an IA of the first 220 randomized of 360 planned patients in TULIP SC who completed the 52-week DB treatment period or withdrew early from the study. Randomization was stratified using SLEDAI-2K score at screening (< 10 points vs ≥ 10 points), Week 0 (Day 1) OCS dose (< 10 mg/day vs ≥ 10 mg/day prednisone or equivalent), and results of the type I interferon gene signature test at screening (high vs low). | Phase III, multicenter, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of an SC treatment regimen of anifrolumab versus placebo in adult patients with moderate to severe SLE despite receiving standard therapy. The primary objective of the study was to compare efficacy of anifrolumab with placebo on overall disease activity in patients with SLE. The efficacy assessments in this application are based on an IA of the first 220 randomized of 360 planned patients in TULIP SC who completed the 52-week DB treatment period or withdrew early from the study. Randomization was stratified using SLEDAI-2K score at screening (< 10 points vs ≥ 10 points), Week 0 (Day 1) OCS dose (< 10 mg/day vs ≥ 10 mg/day prednisone or equivalent), and results of the type I interferon gene signature test at screening (high vs low). | Phase III, multicenter, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of an SC treatment regimen of anifrolumab versus placebo in adult patients with moderate to severe SLE despite receiving standard therapy. The primary objective of the study was to compare efficacy of anifrolumab with placebo on overall disease activity in patients with SLE. The efficacy assessments in this application are based on an IA of the first 220 randomized of 360 planned patients in TULIP SC who completed the 52-week DB treatment period or withdrew early from the study. Randomization was stratified using SLEDAI-2K score at screening (< 10 points vs ≥ 10 points), Week 0 (Day 1) OCS dose (< 10 mg/day vs ≥ 10 mg/day prednisone or equivalent), and results of the type I interferon gene signature test at screening (high vs low).  |
| Hypothesis                | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Treatments groups         | Anifrolumab 120 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Anifrolumab 120 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Anifrolumab 120 mg administered SC QW for 52 weeks N = 109 included in IA for efficacy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Treatments groups         | Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Placebo administered SC QW for 52 weeks N = 111 included in the IA for efficacy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Endpoints and definitions | Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | BICLA response at Week 52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | BICLA response at Week 52 is a composite binary endpoint whereby responders are defined by meeting all of the following criteria: • Improvement from baseline in disease activity as measured by BILAG-2004 (adjudicated). Improvement is defined as a reduction of all baseline BILAG-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no BILAG-2004 worsening in other organ systems, where w orsening is defined as ≥ 1 new BILAG-2004 A or ≥ 2 new BILAG 2004 B. • No worsening from baseline in SLEDAI-2K, where worsening is as defined as an increase from baseline of > 0 points in SLEDAI-2K total score. Increase from baseline corresponds to the change from baseline. SLEDAI-2K is derived as the sum of the scores for all items. • No worsening from baseline in subjects' lupus disease activity, where worsening is defined by an increase ≥ 0.30 points on a 3-point PGA VAS. |

<div style=\"page-break-after: always\"></div>

|                 |                                                                                                                         | For the IA, only the primary endpoint, BICLA response at Week 52, was hypothesis tested (ie,                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-----------------|-------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Key Secondary   | Proportion of patients who are BICLA responders at Week 52 and have maintained low (or reduced) OCS use through Week 52 | multiplicity protected). Maintained low (or reduced) OCS, assessed in conjunction with BICLA response, is defined as: • If baseline OCS ≥ 10 mg/day, an OCS dose of ≤ 7.5 mg/day prednisone or equivalent must be achieved by Week 40 and an OCS dose ≤ 7.5 mg/day prednisone or equivalent must be maintained from Week 40 to Week 52. • If baseline OCS < 10 mg/day, OCS dose at Week 40 must be less than or equal to OCS dose at baseline, with no increase from Week 40 OCS dose between Week 40 and Week 52. |
| Key Secondary   | Time to first BICLA response sustained through Week 52                                                                  | Defined for patients who are BICLA responders, and who responded for a minimum 3 consecutive visits including Week 52 (ie, at least responded since Week 44). Not hypothesis tested for the IA in the MTP, but point                                                                                                                                                                                                                                                                                               |
| Key Secondary   | Time to first flare through Week 52                                                                                     | estimates, CIs, and nominal p-values are provided. Flares were defined as either one or more new BILAG-2004 A or 2 or more new BILAG 2004 B items compared to the previous visit. Not hypothesis tested for the IA in the MTP, but point estimates, CIs, and nominal p-values are provided.                                                                                                                                                                                                                        |
| Other Secondary | OCS response                                                                                                            | Proportion of patients with baseline OCS ≥ 10 mg/day who have maintained OCS reduction through Week 52 defined by meeting all of the following criteria: • Achieve an OCS dose of ≤ 7.5 mg/day prednisone or equivalent by Week 40. • Maintain an OCS dose ≤ 7.5 mg/day prednisone or equivalent from Week 40 to Week 52.                                                                                                                                                                                          |
| Other Secondary | Annualized flare                                                                                                        | Annualized flare rate through Week 52 with flare defined as either one or more new BILAG-2004 A or 2 or more new BILAG-2004 B items compared to the previous visit.                                                                                                                                                                                                                                                                                                                                                |
| Other Secondary | SRI(4) response                                                                                                         | Proportion of patients achieving SRI(4) response at Week 52, defined by meeting all of the following criteria: • Reduction from baseline of ≥ 4 points in the SLEDAI-2K. • No new organ systems affected as defined by one or more BILAG-2004 A or 2 or more BILAG- 2004 B items compared to baseline using BILAG-2004. • No worsening from baseline in the patients'                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | defined by an increase ≥ 0.30 points on a 3- point PGA VAS.                                                                                                                                                                                                                                                                                                                                                                                                                                     | defined by an increase ≥ 0.30 points on a 3- point PGA VAS.                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Clinical Data Lock                              | 13 September 2024                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 13 September 2024                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 13 September 2024                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 13 September 2024                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Results and Analysis                            | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Analysis description                            | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Analysis population and time point description  | Full Analysis Set: All randomized patients who received at least one dose of IP and were analyzed according to their randomized treatment irrespective of whether or not they have received treatment as randomized or prematurely discontinued. For the IA, the FAS consisted of the first 220 randomized patients who completed Week 52 or withdrew early from the study. Week 52 For efficacy analyses in the DB phase of this study, ICEs accounted for in the estimands included: • RM use | Full Analysis Set: All randomized patients who received at least one dose of IP and were analyzed according to their randomized treatment irrespective of whether or not they have received treatment as randomized or prematurely discontinued. For the IA, the FAS consisted of the first 220 randomized patients who completed Week 52 or withdrew early from the study. Week 52 For efficacy analyses in the DB phase of this study, ICEs accounted for in the estimands included: • RM use | Full Analysis Set: All randomized patients who received at least one dose of IP and were analyzed according to their randomized treatment irrespective of whether or not they have received treatment as randomized or prematurely discontinued. For the IA, the FAS consisted of the first 220 randomized patients who completed Week 52 or withdrew early from the study. Week 52 For efficacy analyses in the DB phase of this study, ICEs accounted for in the estimands included: • RM use | Full Analysis Set: All randomized patients who received at least one dose of IP and were analyzed according to their randomized treatment irrespective of whether or not they have received treatment as randomized or prematurely discontinued. For the IA, the FAS consisted of the first 220 randomized patients who completed Week 52 or withdrew early from the study. Week 52 For efficacy analyses in the DB phase of this study, ICEs accounted for in the estimands included: • RM use |
| Descriptive statistics and estimate variability |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                                                 | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Anifrolumab 120 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Anifrolumab 120 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                                                 | Number of patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 109                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 109                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 111                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|                                                 | Primary endpoint: BICLA response at Week 52                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 59.4%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 59.4%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 43.9%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|                                                 | Response rate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                                                 | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | (50.1, 68.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (50.1, 68.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (34.6, 53.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|                                                 | Key Secondary endpoint: Proportion of patients who are BICLA responders at Week 52 and have maintained low (or reduced) OCS use through Week 52 Response rate                                                                                                                                                                                                                                                                                                                                   | 59.4%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 59.4%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 39.5%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|                                                 | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (50.1, 68.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (50.1, 68.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (30.4, 48.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|                                                 | Key secondary: Time to first BICLA response sustained through Week 52                                                                                                                                                                                                                                                                                                                                                                                                                           | 39.8%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 39.8%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 22.8%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|                                                 | Percentage of response                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                                                 | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | (31.3, 49.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (31.3, 49.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (15.9, 32.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|                                                 | Key secondary: Time to first flare through Week 52 Percentage of flare                                                                                                                                                                                                                                                                                                                                                                                                                          | 39.3%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 39.3%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 46.6%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|                                                 | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | (30.7, 49.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (30.7, 49.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (37.6, 56.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                                | Other secondary: OCS response Response rate                                                                                    | 74.2%                      | 48.6%                         |
|--------------------------------|--------------------------------------------------------------------------------------------------------------------------------|----------------------------|-------------------------------|
|                                | 95% CI                                                                                                                         | (62.4, 85.9)               | (35.0, 62.2)                  |
|                                | Other secondary: Annualized flare rate Rate                                                                                    | 0.59                       | 0.75                          |
|                                | 95% CI                                                                                                                         | (0.42, 0.83)               | (0.55, 1.00)                  |
|                                | Other secondary: SRI(4) response Response rate                                                                                 | 67.8%                      | 59.4%                         |
|                                | 95% CI                                                                                                                         | (58.9, 76.7)               | (50.2, 68.7)                  |
| Effect estimate per comparison | Primary endpoint: BICLA response at Week 52                                                                                    | Comparison groups          | Anifrolumab 120 mg vs Placebo |
|                                | Primary endpoint: BICLA response at Week 52                                                                                    | Rate difference            | 15.5%                         |
|                                | Primary endpoint: BICLA response at Week 52                                                                                    | 95% CI                     | (2.3, 28.6)                   |
|                                | Primary endpoint: BICLA response at Week 52                                                                                    | P-value                    | 0.0211                        |
|                                | Primary endpoint: BICLA response at Week 52                                                                                    | (stratified CMH method)    |                               |
|                                | Key secondary: Proportion of subjects who are BICLA responders at Week 52 and have maintained low (or reduced) OCS use through | Comparison groups          | Anifrolumab 120 mg vs Placebo |
|                                | Week 52                                                                                                                        | Rate difference            | 19.9%                         |
|                                | Week 52                                                                                                                        | 95% CI                     | (6.9, 32.9)                   |
|                                | Week 52                                                                                                                        | Nominal P-value            | 0.0027                        |
|                                | Week 52                                                                                                                        | (stratified CMH method)    |                               |
|                                | Key secondary: Time to first BICLA response sustained through Week 52                                                          | Comparison groups          | Anifrolumab 120 mg vs Placebo |
|                                | Key secondary: Time to first BICLA response sustained through Week 52                                                          | Hazard ratio               | 2.038                         |
|                                | Key secondary: Time to first BICLA response sustained through Week 52                                                          | Nominal P-value            | 0.0052                        |
|                                | Key secondary: Time to first BICLA response sustained through Week 52                                                          | (Cox proportional hazards) |                               |
|                                | Key secondary: Time to first flare through Week 52                                                                             | Comparison groups          | Anifrolumab 120 mg vs Placebo |
|                                |                                                                                                                                | Hazard ratio               | 0.757                         |
|                                |                                                                                                                                | 95% CI                     | (0.499, 1.141)                |
|                                |                                                                                                                                | Nominal P-value            | 0.1841                        |
|                                |                                                                                                                                | (Cox proportional hazards) |                               |
|                                | Other secondary: OCS response                                                                                                  | Comparison groups          | Anifrolumab 120 mg vs Placebo |
|                                | Other secondary: OCS response                                                                                                  | Rate difference            | 25.6%                         |
|                                | Other secondary: OCS response                                                                                                  | 95% CI                     | (7.6, 43.5)                   |
|                                | Other secondary: OCS response                                                                                                  | Nominal P-value            | 0.0053                        |
|                                | Other secondary: Annualized flare rate                                                                                         | Comparison groups          | Anifrolumab 120 mg vs Placebo |
|                                | Other secondary: Annualized flare rate                                                                                         | Rate ratio                 | 0.80                          |
|                                | Other secondary: Annualized flare rate                                                                                         | 95% CI                     | (0.52, 1.23)                  |
|                                | Other secondary: Annualized flare rate                                                                                         | Nominal P-value            | 0.3018                        |

<div style=\"page-break-after: always\"></div>

|       |                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (negative binomial regression model)                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|       | Other secondary: SRI(4) response                                                                                                                                                                                                                                                                                                                                                                                                                   | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                  | Anifrolumab 120 mg vs Placebo                                                                                                                                                                                                                                                                                                                                                                                                                      |
|       |                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Rate difference                                                                                                                                                                                                                                                                                                                                                                                                                                    | 8.4                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|       |                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                             | (-4.5, 21.2)                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|       |                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Nominal P-value                                                                                                                                                                                                                                                                                                                                                                                                                                    | 0.2012                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|       |                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (stratified CMH method)                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Notes | Disposition: The proportions of patients who discontinued DB treatment were similar between groups (21.1% and 21.6% in the anifrolumab and placebo groups, respectively). The proportions of patients who withdrew from study without entering OLE were similar between the groups (20.2% and 23.4% in the anifrolumab and placebo groups, respectively). The most common reasons for discontinuation of IP were AE and subject decision. The most | Disposition: The proportions of patients who discontinued DB treatment were similar between groups (21.1% and 21.6% in the anifrolumab and placebo groups, respectively). The proportions of patients who withdrew from study without entering OLE were similar between the groups (20.2% and 23.4% in the anifrolumab and placebo groups, respectively). The most common reasons for discontinuation of IP were AE and subject decision. The most | Disposition: The proportions of patients who discontinued DB treatment were similar between groups (21.1% and 21.6% in the anifrolumab and placebo groups, respectively). The proportions of patients who withdrew from study without entering OLE were similar between the groups (20.2% and 23.4% in the anifrolumab and placebo groups, respectively). The most common reasons for discontinuation of IP were AE and subject decision. The most |
|       | common reasons for withdrawal from the study were withdrawal by subject and physician decision.                                                                                                                                                                                                                                                                                                                                                    | common reasons for withdrawal from the study were withdrawal by subject and physician decision.                                                                                                                                                                                                                                                                                                                                                    | common reasons for withdrawal from the study were withdrawal by subject and physician decision.                                                                                                                                                                                                                                                                                                                                                    |
|       | BICLA components for the primary endpoint of BICLA response: A larger proportion of patients with BICLA response in the anifrolumab 120 mg SC group displayed BILAG improvement (59.5%) compared with patients in the placebo group (44.1%), while consistent proportions of patients in the anifrolumab and placebo groups had no worsening of SLEDAI-2K (74.3% and 71.6%, respectively) and no worsening of PGA (74.4% and 73.7%, respectively). | BICLA components for the primary endpoint of BICLA response: A larger proportion of patients with BICLA response in the anifrolumab 120 mg SC group displayed BILAG improvement (59.5%) compared with patients in the placebo group (44.1%), while consistent proportions of patients in the anifrolumab and placebo groups had no worsening of SLEDAI-2K (74.3% and 71.6%, respectively) and no worsening of PGA (74.4% and 73.7%, respectively). | BICLA components for the primary endpoint of BICLA response: A larger proportion of patients with BICLA response in the anifrolumab 120 mg SC group displayed BILAG improvement (59.5%) compared with patients in the placebo group (44.1%), while consistent proportions of patients in the anifrolumab and placebo groups had no worsening of SLEDAI-2K (74.3% and 71.6%, respectively) and no worsening of PGA (74.4% and 73.7%, respectively). |
|       | While there were no differences between the treatment groups with regard to no worsening of SLEDAI-2K or PGA, improvement in both measures was seen with anifrolumab compared with placebo.                                                                                                                                                                                                                                                        | While there were no differences between the treatment groups with regard to no worsening of SLEDAI-2K or PGA, improvement in both measures was seen with anifrolumab compared with placebo.                                                                                                                                                                                                                                                        | While there were no differences between the treatment groups with regard to no worsening of SLEDAI-2K or PGA, improvement in both measures was seen with anifrolumab compared with placebo.                                                                                                                                                                                                                                                        |
|       | • LS Mean difference for SLEDAI-2K was -1.52; 95% CI, -2.55 to -0.49; p = 0.0042. • LS Mean difference for PGA was -0.19; 95% CI, -0.35 to -0.03; p = 0.0204.                                                                                                                                                                                                                                                                                      | • LS Mean difference for SLEDAI-2K was -1.52; 95% CI, -2.55 to -0.49; p = 0.0042. • LS Mean difference for PGA was -0.19; 95% CI, -0.35 to -0.03; p = 0.0204.                                                                                                                                                                                                                                                                                      | • LS Mean difference for SLEDAI-2K was -1.52; 95% CI, -2.55 to -0.49; p = 0.0042. • LS Mean difference for PGA was -0.19; 95% CI, -0.35 to -0.03; p = 0.0204.                                                                                                                                                                                                                                                                                      |
|       | Disposition of ICEs: The proportions of patients with first ICEs of RM (10.1% and 11.7%) and PEOT use (15.6% and 14.4%) were consistent between the anifrolumab and placebo groups.                                                                                                                                                                                                                                                                | Disposition of ICEs: The proportions of patients with first ICEs of RM (10.1% and 11.7%) and PEOT use (15.6% and 14.4%) were consistent between the anifrolumab and placebo groups.                                                                                                                                                                                                                                                                | Disposition of ICEs: The proportions of patients with first ICEs of RM (10.1% and 11.7%) and PEOT use (15.6% and 14.4%) were consistent between the anifrolumab and placebo groups.                                                                                                                                                                                                                                                                |
|       | Time course of BICLA response: A separation in BICLA response rate favoring anifrolumab                                                                                                                                                                                                                                                                                                                                                            | Time course of BICLA response: A separation in BICLA response rate favoring anifrolumab                                                                                                                                                                                                                                                                                                                                                            | Time course of BICLA response: A separation in BICLA response rate favoring anifrolumab                                                                                                                                                                                                                                                                                                                                                            |
|       | over placebo was apparent from Week 12 and was maintained throughout the DB treatment period with nominal significance for treatment differences at all timepoints from Week 24 and onwards, except for Week 44.                                                                                                                                                                                                                                   | over placebo was apparent from Week 12 and was maintained throughout the DB treatment period with nominal significance for treatment differences at all timepoints from Week 24 and onwards, except for Week 44.                                                                                                                                                                                                                                   | over placebo was apparent from Week 12 and was maintained throughout the DB treatment period with nominal significance for treatment differences at all timepoints from Week 24 and onwards, except for Week 44.                                                                                                                                                                                                                                   |

AE, Adverse event; BICLA, British Isles Lupus Assessment Group-based Composite Lupus Assessment; BILAG, LBritish Isles Lupus Assessment Group; CI, Confidence interval; CMH, Cochran-Mantel-Haenszel; DB, Doubleblind; LFAS, Full analysis set; IA, Interim analysis; ICE, Intercurrent event; IP, Investigational product; LS, Least squares; LMTP, Multiple testing procedure; NC, Non-compliance for reasons related to civil crisis, natural disaster, or public health crisis; OCS, Oral corticosteroid steroid; OLE, Open-label extension; PEOT, Premature End of Treatment; PGA,

Physician's Global Assessment; QW, Once weekly; RM, Restricted Medication use; SC, Subcutaneous; SLE,

Systemic lupus erythematosus; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000; SRI(4),

Systemic Lupus Erythematosus Responder Index of ≥ 4; VAS, Visual analog scale.

<div style=\"page-break-after: always\"></div>

## 2.6.5.3. Clinical studies in special populations

|                                        | Age 65-74 (Older subjects number /total number)   | Age 75-84 (Older subjects number /total number)   | Age 85+ (Older subjects number /total number)   |
|----------------------------------------|---------------------------------------------------|---------------------------------------------------|-------------------------------------------------|
| TULIP SC Full Analysis Set (N = 220)   | 8/220                                             | -                                                 | -                                               |
| TULIP SC Safety Analysis Set (N = 346) | 10/346                                            | -                                                 | -                                               |

## 2.6.5.4. In vitro biomarker test for patient selection for efficacy

N/A

## 2.6.5.5. Analysis performed across studies (pooled analyses and meta-analysis)

## Comparison of the primary and key secondary endpoints in TULIP SC vs. IV Studies 04 and 05

To support the overall efficacy assessment of SC anifrolumab, the efficacy results observed with anifrolumab 120 mg SC QW was compared with that of anifrolumab 300 mg IV Q4W for the primary endpoint of BICLA response at Week 52 (a pre-specified endpoint in studies 04 and 05) and a posthoc analysis of the 3 key secondary endpoints in TULIP SC for the IV studies (Table 19 ).

<div style=\"page-break-after: always\"></div>

Table 19: Summary of Efficacy Results in TULIP SC and IV studies 04 and 05

| Endpoint                                                                                        | Type of estimate   | Study       | Treatmentdifference Vs placebo (95%CI)   | p-value   |
|-------------------------------------------------------------------------------------------------|--------------------|-------------|------------------------------------------|-----------|
| BICLA response at Week 52                                                                       | Rate difference    | TULIP SC    | 15.5% (2.3,28.6)                         | 0.0211    |
|                                                                                                 |                    | IV study 04 | 16.3% (6.3, 26.3)                        | 0.001     |
|                                                                                                 |                    | IV study 05 | 17.0% (7.2,26.8)                         | <0.001    |
| Proportion of patients who achieved a BICLA response while achieving or maintaining low ocs use | Rate difference    | TULIP SC    | 19.9% (6.9, 32.9)                        | 0.0027    |
|                                                                                                 |                    | IV study 04 | 15.0% (5.0, 25.0)                        | 0.0032    |
|                                                                                                 |                    | IV study 05 | 19.0% (9.1,28.9)                         | 0.0002    |
| Time to BICLA response sustained through Week 52                                                | Hazard ratio       | TULIP SC    | 2.038 (1.248,3.408)                      | 0.0052    |
|                                                                                                 |                    | IV study 04 | 1.714 (1.070, 2.788)                     | 0.0267    |
|                                                                                                 |                    | IV study 05 | 2.015(1.281,3.236)                       | 0.0029    |
| Time to First Flare throughWeek52                                                               | Hazard ratio       | TULIP SC    | 0.757 (0.499, 1.141)                     | 0.1841    |
|                                                                                                 |                    | IV study 04 | 0.554 (0.413, 0.739)                     | <0.0001   |
|                                                                                                 |                    | IV study 05 | 0.721(0.543,0.953)                       | 0.0222    |

BICLA British Isles Lupus Assessment Group-based Composite Lupus Assessment; CI confidence interval; IV intravenous: OcS oral corticosteroids: SC subcutaneous.

## 2.6.5.6. Supportive study(ies)

N/A

## 2.6.6. Discussion on clinical efficacy

## Design and conduct of clinical studies

The anifrolumab SC clinical programme included one pivotal global, multicenter, randomised, DB, placebo-controlled, Phase III study (TULIP SC). Given the approval of the IV anifrolumab, a single phase III study was considered sufficient for the assessment of efficacy of SC anifrolumab in the same target population and same indication, i.e. as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite standard therapy.

The efficacy assessments of this line extension application were based on an IA of the first 220 patients in TULIP SC study who completed the 52-week DB treatment period or withdrew early from the study.

No dose-response studies were conducted for SC anifrolumab. Based on the PK/PD data of the Phase II SC study D3461C00008, as well as data from the anifrolumab IV studies, a dose of 120 mg QW

<div style=\"page-break-after: always\"></div>

was selected for the TULIP SC study, as it was expected to provide at least similar efficacy to 300 mg IV Q4W used in the anifrolumab pivotal IV studies 04 and 05.

The eligibility criteria in TULIP SC study with the minimum SLEDAI-2K and BILAG criteria outlined a SLE population with active disease of at least moderate severity despite of standard of care. The criteria defining the SLE patients were essentially the same to the eligibility criteria used in the key studies that formed the basis for the approval of the IV anifrolumab.

The same stratification factors as in the pivotal 04 and 05 studies supporting the initial approval for the IV formulation were used, i.e. SLEDAI-2K score at screening (&lt; 10 vs ≥ 10 points), OCS use on Day 1 (&lt; 10 vs ≥ 10 mg prednisone or equivalent per day), and type I IFN gene signature test result (high vs low).

The key instruments used for the assessment of disease activity by the investigator were standard, including BILAG-2004, SLEDAI-2K and PGA.

Altogether,  the  target  population  and  the  used  efficacy  assessments  in  TULIP  SC  study  were essentially the same as in the pivotal IV anifrolumab studies, supporting no change to the proposed indication  approved  for  the  IV  formulation:  ' Saphnelo is  indicated  as  an  add-on  therapy  for  the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite standard therapy .' This was endorsed by the CHMP.

The primary endpoint BICLA response is a validated composite index to assess SLE disease activity and  acceptable  from  the  regulatory  point  of  view  as  it  is  in  line  with  the  Guideline  on  clinical investigation of medicinal products for the treatment of systemic lupus erythematosus and lupus nephritis (EMA/CHMP/51230/2013 corr 1). BICLA was also the primary endpoint in study 04, another pivotal  study  that  contributed  to  the  approval  of  the  IV  anifrolumab  (for  detailed  discussion  on endpoint selection, see section '2.5.6. Discussion on clinical efficacy' in EPAR of Saphnelo). Although SRI(4) was proposed as the primary endpoint during the initial EMA SA (EMEA/H/SA/2903/3/2018/III), the BICLA response was selected as the primary endpoint before the study commenced. Overall, BICLA response was considered appropriate primary endpoint for the TULIP SC study.

For the primary estimand, FAS population was used meaning that all patients who were randomised and received at least one dose were included. In principle, this is not acceptable, and all randomised patients  should  have  been  used.  However,  as  in  practice,  there  is  no  difference  in  these  two populations,  this  did  not  impact  the  results.  A  composite  strategy  was  used  for  the  intercurrent events due to discontinuation (or death) and use of restricted medication, and these patients were counted as non-responders, whereas hypothetical strategy was applied for the intercurrent events due to non-compliance as a result of factors external to the study. The estimand was considered adequate and the clinical questions of interest relevant. The study was conducted during the COVID19 pandemic and the war in Ukraine commenced during the study and there were sites in Ukraine. Therefore, it may have been that these external events have a major impact on the reliability of the results. This risk, however, did not materialise.

BICLA response at week 52 with maintained low (or reduced) use of OCS, time to BICLA response sustained  through  week  52  and  time  to  flare  through  week  52  were  selected  as  key  secondary endpoints. It is notable that these endpoints differed from the proposed key secondary endpoints at the time of the EMA SA (EMEA/H/SA/2903/3/2018/III). Further, none of the key secondary endpoints

<div style=\"page-break-after: always\"></div>

in  the  pivotal  anifrolumab  IV  studies  (i.e.  maintained  OCS  tapering,  CLASI  response,  joints  and annualized flare rate) were included as key secondary endpoints in the TULIP SC study.

The estimand as defined for time to sustained BICLA response and the clinical question it is designed to answer is difficult to comprehend. In the analysis, all patients are included and patients who did not receive a BICLA response are censored at the last BICLA assessment during the double-blind treatment period if they had no ICEs prior to that. This means that these patients are still expected to have an equal chance to respond which is unlikely true. Furthermore, in the analysis data up to week 52 is included, though, per definition, no new responders can occur for the last 3 assessment time points (because sustained response needs to be at least over 3 weeks). It is very likely that with the analysis defined as it is a difference in time to sustained response is observed even when this actually only reflects the difference between the arms at week 52 as per the primary endpoint. A sustained response in the placebo arm in any case is a phenomena difficult to comprehend. The MAH was invited to comment and discuss which question the analysis is intended to answer and propose a more meaningful way to analyse the data. The Applicant provided additional analyses, which confirm that a higher number of sustained responses were achieved in the anifrolumab group. However, the results as pre-defined in the SAP and presented in the CSR with HRs, CIs and p-values (and corrected results as presented in the errata document) are not considered methodologically reliable. The issue is not pursued further because it does not impact results in the SmPC.

While time to flare is a recognised efficacy variable in the EMA guideline, the guideline states that an effect on the prevention of flares (decreased frequency/severity) should be measured either as a primary endpoint or as a key secondary endpoint. On the other hand, the other two endpoints are connected to the BICLA response and do not describe the treatment effect in the whole study population. As stated in the EMA guideline, supportive evidence derived from secondary endpoints is of particular interest to fully characterize the treatment effect, given the heterogeneity of SLE manifestations (see discussion on the IA below). With these considerations, the MAH was requested to justify the choice and clinical relevance of the key secondary endpoints and the chosen IA strategy. On request, the MAH provided some further justification for the clinical relevance of the endpoints. However, no discussion on the differences between choice of endpoints between the SC and IV indications was provided.

In terms of OCS tapering, the used target of ≤ 7.5 mg/day in the (key) secondary endpoints can be considered acceptable, although e.g. the most recent EULAR guideline (2024) recommends more stringent target of ≤ 5 mg/day.

The statistical methods outlined for the primary and secondary endpoints are overall standard and similar to those used in the IV studies.

An interim analysis with only 60% of the patients (i.e. 220/367 patients) was introduced late into the study. Enrolment continued after the 220 patients had been enrolled and the study was ongoing at the time of the assessment with further data to be collected. The MAH specified the interim analysis only for the primary endpoint and the secondary endpoints will be formally tested only when data on all  367  patients  is  available.  This  plan  is  not  consistent  with the  regulatory  strategy  as  the  MAH submitted the dossier based on the interim analysis. Ideally, confirmatory results for all clinically relevant and important endpoints should have been available at the time of submission. Furthermore, the IA has been introduced late into the study as discussed below. These points are discussed under key Secondary Endpoint of Time to BICLA Response Sustained Through Week 52 above.

A comparison of the shared primary endpoint BICLA response at week 52 between TULIP SC and pivotal  anifrolumab  IV  studies  and  post-hoc  analysis  of  the  key  secondary  endpoints  across  the studies (not originally included in the IV program) was also performed. While this comparison is helpful, it is considered only as supportive evidence in the current application.

<div style=\"page-break-after: always\"></div>

## Efficacy data and additional analyses

## Changes in the planned conduct of the study

After  the  patient  recruitment  began,  substantial  changes  were  made  to  the  study  protocol  with Amendment 2 and particularly  Amendment 3 that  added  the  52-week  OLE  period  to  the  study. Despite many of the substantial changes also concerned the DB period, including modifications to the eligibility criteria and allowed concomitant medications, the CHMP considered that a  major impact on patient management and, as a consequence, safety and efficacy results was unlikely.

The analysis plan was changed in a profound manner. First, an efficacy interim analysis was added in an amendment and the timing and efficacy boundary of the interim analysis were again changed in  a  later  amendment  both  occurring  after  first  patient  was  enrolled.  Furthermore,  the  list  of secondary endpoints to  be  tested  in  a  confirmatory  manner  (referred  to  as  key  secondary)  was changed  multiple  times.  The  current  interim  analysis  strategy  was  such  that  the  interim  was conducted only for the primary endpoint and secondary endpoints were to be tested only when week 52 data was available for all patients.

Importantly, there were no concerns at this stage that the changes would be data driven based on results of this double-blind study. From that point of view the study integrity was not considered compromised. Nevertheless, the CHMP reminded that such several, late, fundamental changes are not considered good practice.

## Participant flow and numbers analysed

Out of the 220 randomised patients, 109 received anifrolumab and 111 placebo. Similar proportions of patients discontinued the treatment in anifrolumab and placebo groups (21.1% and 21.6%), most common  reasons  being  subject  decision  (8.3%  and  6.3%)  and  AEs  (8.3%  and  2.7%).  Similar proportions also withdrew from the study without entering the OLE period (20.2% and 23.4% in the anifrolumab and placebo groups, respectively). Further, similar numbers completed the study without entering the OLE period (40.4% and 40.5% in the anifrolumab and placebo groups, respectively). In fact, only a small proportion of patients entered the OLE period (34/109 and 37/111). In a placebocontrolled study, it would have been a reasonable expectation that patients are interested to enter the OLE. The MAH clarified that the small number of patients entering the OLE period was due to the late protocol amendment to include the OLE period to the study. The number of important protocol violations were reported in 6 (5.5%) patients in the anifrolumab group and in 1 (0.9%) patient in the placebo group. The most commonly reported important protocol deviations were randomisation (incorrect randomisation or stratification) for 3 (2.8%) patients in the anifrolumab group and study intervention  administration  for  2  (1.8%)  and  1  (0.9%)  patients  in  the  anifrolumab  and  placebo groups, respectively.

Overall, similar proportions of patients in the anifrolumab group and placebo groups had premature end of treatment and use of restricted medication, i.e. ICEs that were handled as per the composite strategy (patients were considered as non-responders in the primary analysis of efficacy). Thus, no bias was evident in this regard.

## Baseline and demographics

The demographic characteristics between the treatment groups were well balanced, mean age was 42.7 and 89.1% were female.

The following SLE disease characteristics at baseline indicated slightly higher disease activity in the anifrolumab group vs. placebo group: proportion of patients with SLEDAI2K score ≥10 (69.7% vs. 64.9%), mean clinical SLEDAI-2K (8.9 vs. 8.4), proportion of patients with at least one BILAG A

<div style=\"page-break-after: always\"></div>

(46.8% vs. 42.3%), mean BILAG-global score (18.5 vs. 18.1) and mean PGA score (1.92 vs. 1.88, in the anifrolumab vs. placebo groups, respectively).

The medical and surgical history was generally well balanced between the group. However, the use of OCS and immunosuppressants at baseline was higher in the anifrolumab group vs. placebo group (85.3% vs. 79.3% and 61.5% vs. 50.5%, respectively). Upon CHMP's request, the MAH further clarified that despite the imbalance in the disease severity (i.e. SLEDAI2K score &lt; 10 points vs. ≥ 10 points) and in the use of SLE-related treatments (i.e. OCS dose &lt;10 mg/day vs ≥10 mg/day and use vs. no use of immunosuppressants) between anifrolumab and placebo, the point estimates in all of these subgroups favoured anifrolumab over placebo in terms of BICLA response rate at week 52. Therefore,  these  imbalances  were  not  thought  to  impact  the  overall  interpretation  of  the  study results. This was agreed by the CHMP.

## Primary and secondary efficacy outcomes

Another concern was issued to clarify the primary analysis results because there was a discrepancy in the numbers and it was not evident how the number and type of ICEs was constructed and matched between tables, for example Study Disposition and Restricted Medication use. The MAH clarified that for both the primary endpoint of BICLA response as well as its components, the percentages presented are adjusted rates, calculated using stratified CMH and adjusting for stratification factors and used multiple imputation for some ICEs as defined in the SAP. Therefore, this issue was resolved, and a corresponding footnote was added to the SmPC. Regarding the question related to the ICEs, the MAH submitted an errata document, which included updated numbers for all efficacy results. On request, the MAH further clarified the numbers and confirmed that the results in the errata document are correct and supersede the results of the CSR. In conclusion, (IA as described in the errata document), the response rate of BICLA response at week 52 was 59.4% for anifrolumab and 43.9% for placebo, resulting in a 15.5% treatment difference (95% CI 2.3, 28.6). Therefore, the primary endpoint was met. The results of the sensitivity and supplementary analyses were consistent with those of the primary analysis.

The key secondary endpoints were all numerically in favour of anifrolumab, including BICLA response at week 52 with maintained low (or reduced) use of OCS, time to BICLA response sustained through week 52, and time to flare through week 52. The selection of the key secondary endpoints was different from the IV studies (see discussion above) and other than time to first flare do not measure clearly different manifestations of SLE compared to the primary endpoint. It was considered a major weakness  that  these  endpoints  were  not  hypothesis  tested  for  the  IA  in  the  multiple  testing procedure, which was planned only at the time of the final analysis.

There were only 42 and 50 events in the time to flare analysis, for anifrolumab and placebo respectively. Subjects treated with restricted medication, those with premature end of treatment, and those who died were regarded as flare in the time to first flare analysis. The MAH clarified, that 18.3% and 25.2% of patients in anifrolumab and placebo group, respectively, had clinical BILAG flares. The proportions of patients with first events due to an ICE of RM, PEOT (due to other reason), death were similar between the treatment arms, while fewer patients in the anifrolumab arm had a first ICE of PEOT (due to lack of efficacy), which is consistent with the overall efficacy results observed with SC anifrolumab vs. placebo.

As discussed in the methods section, the time to BICLA response sustained through week 52 does not appear to answer to any well-defined and clear question and is therefore of negligible value.

Nevertheless, the efficacy data as a whole, including the other secondary endpoints (i.e. reduced OCS dose to ≤ 7.5 mg/day in those with baseline OCS ≥ 10 mg/day, annual flare rate and SRI(4) response), suggest a modest, but clinically relevant efficacy for SC anifrolumab that is broadly similar to the efficacy seen with the approved IV anifrolumab (see also the post-hoc analysis of the TULIP

<div style=\"page-break-after: always\"></div>

SC study vs. IV studies). The MAH has committed to submit the final CSR corresponding to the week 52 results for all patients, once available, and expected on 1Q2026.

## Subgroup analysis

In the predefined subgroup analyses, point estimates showing favourable effect for anifrolumab over placebo was observed in all subgroups, except for geographical region United States of America and Asian race, which is likely random variability and related to the small number of patients in these subgroups.

Regarding the effect of immunogenicity on efficacy, the point estimates favouring anifrolumab over placebo was seen in both ADA negative and ADA positive subgroups. However, the number of ADA positive patients was too small to make any definite conclusions.

## Post-hoc analysis

To support the SC anifrolumab efficacy assessment, the MAH also conducted a comparison of TULIP SC study and IV anifrolumab phase 3 studies 04 and 05 using the shared primary endpoint, i.e. BICLA response at week 52 and the key secondary endpoint of the TULIP SC study. Although the SLE disease characteristics of the study population in the studies were similar, the caveats in the nonrandomized,  post-hoc  comparison  across  studies  are  recognised.  Although  there  were  apparent differences in the absolute BICLA response rates at week 52 between SC TULIP and IV anifrolumab studies, the estimated treatment effect between the studies was similar, i.e. 15.5% (95% CI 2.3, 28.6) in TULIP SC study, 16.3% (95% CI 6.3, 26.3) in the IV study 04 and 17.0% (95% CI 7.2, 26.8) in the IV study 05. Also, the key secondary endpoints selected for the TULIP SC study showed similar  results  to  those  in  the  IV  anifrolumab  studies,  supporting  broadly  comparable  efficacy between SC anifrolumab and IV anifrolumab.

## 2.6.7. Conclusions on the clinical efficacy

The efficacy data of TULIP SC study suggested a modest, but clinically relevant efficacy for SC anifrolumab that is broadly similar to the efficacy seen with the approved IV anifrolumab. Therefore, the clinical efficacy data supports the approval of the SC formulations as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite standard therapy.

## 2.6.8. Clinical safety

The safety data for the proposed new route of administration for Saphnelo (anifrolumab) 120 mg SC QW in the treatment of moderate to severe SLE, derive mainly from the single, pivotal, phase 3, randomized, double-blind (DB), multinational, multicenter, parallel-group, placebo-controlled study (TULIP SC; D3465C00001). Within this procedure, the MAH has provided safety results from an interim analysis (IA) of this pivotal study (N=346/367).

The analysis of safety data was based on the 52-week double-blind treatment period, including all available data up to the data cut off for the IA (23 July 2024), irrespective of whether they are ongoing in the study, have completed the 52-week double-blind treatment period, or have withdrawn from the study early (Safety Analysis Set, N = 346). All safety analyses for the 52-week double-blind treatment period were performed using the Safety Analysis Set, which included all patients who received at least one dose of the IMP.

To confirm that the safety of anifrolumab 120 mg SC QW was consistent with the established profile for anifrolumab 300 mg IV Q4W for up to 52 weeks of double-blind treatment, pooled safety data

<div style=\"page-break-after: always\"></div>

from 2 Phase III studies D3461C00004 and D3461C00005, and one Phase II study CD-IA-MEDI-5461013 (hereafter referred to as studies 04, 05, and 1013, respectively) are presented side-by-side with the TULIP SC data.

The SC Safety Analysis Set includes patients with a wider range of exposure times than those included in the IA FAS (the analysis set for assessment of efficacy; N = 220), as not all patients had completed the DB treatment period or withdrawn from the study early. Thus, a subset of AE analyses was also conducted for the population of 220 patients only (referred to as the SC 220 Safety Analysis Set). This was to confirm conclusions drawn from the comparison of SC and IV EAIR in a population where most patients had completed the 52 weeks DB treatment period.

Some data were also submitted for the open-label extension part of the study.

## Demographic and baseline disease-related characteristics (Safety Analysis Set)

Demographic  and  baseline  disease-related  characteristics  (Table 20 )  were  generally  balanced between the anifrolumab 120 mg SC QW and placebo groups in TULIP SC. Patients in the study were representative of the intended target population for treatment with anifrolumab SC.

Baseline demographics and characteristics in TULIP SC were generally consistent with those of the patients  included  in  IV  studies  04  and  05.  Differences  were  observed  for  race,  ethnicity,  and geographic region. A greater proportion of patients in TULIP SC were enrolled in Latin America and in Europe; a greater proportion of patients in the IV studies were enrolled in North America.

Table 20: Disease specific baseline characteristics (SC vs IV Safety analysis set)

|                              |           | SC                         |                 |               | IV                         |                 |               |
|------------------------------|-----------|----------------------------|-----------------|---------------|----------------------------|-----------------|---------------|
|                              | Statistic | Anifrolumab 120 mg N = 176 | Placebo N = 170 | Total N = 346 | Anifrolumab 300 mg N = 459 | Placebo N = 466 | Total N = 925 |
| SLEDAI-2K score at screening | N*        | 110                        | 110             | 220           | 459                        | 466             | 925           |
| < 10                         | n (%)     | 37 (33.6)                  | 35 (31.8)       | 72 (32.7)     | 148 (32.2)                 | 146 (31.3)      | 294 (31.8)    |
| > = 10                       | n (%)     | 73 (66.4)                  | 75 (68.2)       | 148 (67.3)    | 311 (67.8)                 | 320 (68.7)      | 631 (68.2)    |
|                              | n         | 110                        | 110             | 220           | 459                        | 466             | 925           |
|                              | Mean      | 11.2                       | 10.4            | 10.8          | 11.3                       | 11.2            | 11.2          |
|                              | SD        | 3.72                       | 2.62            | 3.24          | 3.82                       | 3.81            | 3.81          |
|                              | Median    | 10.0                       | 10.0            | 10.0          | 10.0                       | 10.0            | 10.0          |
|                              | Min       | 6                          | 6               | 6             | 6                          | 6               | 6             |
|                              | Max       | 22                         | 18              | 22            | 26                         | 37              | 37            |
| OCS dose (mg/day)            |           |                            |                 |               |                            |                 |               |
| < 10                         | n (%)     | 88 (50.0)                  | 96 (56.5)       | 184 (53.2)    | 198 (43.1)                 | 203 (43.6)      | 401 (43.4)    |
| > = 10                       | n (%)     | 88 (50.0)                  | 74 (43.5)       | 162 (46.8)    | 250 (54.5)                 | 251 (53.9)      | 501 (54.2)    |
|                              | n         | 176                        | 170             | 346           | 448                        | 454             | 902           |

<div style=\"page-break-after: always\"></div>

|                                                     |           | SC                         |                 |               | IV                         |                 |               |
|-----------------------------------------------------|-----------|----------------------------|-----------------|---------------|----------------------------|-----------------|---------------|
|                                                     | Statistic | Anifrolumab 120 mg N = 176 | Placebo N = 170 | Total N = 346 | Anifrolumab 300 mg N = 459 | Placebo N = 466 | Total N = 925 |
|                                                     | Mean      | 8.5                        | 7.5             | 8.0           | 10.0                       | 10.2            | 10.1          |
|                                                     | SD        | 6.24                       | 6.18            | 6.22          | 9.81                       | 8.51            | 9.18          |
|                                                     | Median    | 10.0                       | 7.2             | 7.5           | 10.0                       | 10.0            | 10.0          |
|                                                     | Min       | 0                          | 0               | 0             | 0                          | 0               | 0             |
|                                                     | Max       | 33                         | 30              | 33            | 99                         | 50              | 99            |
| OCS dose (mg/day) excluding patients not taking OCS |           |                            |                 |               |                            |                 |               |
| < 10                                                | n (%)     | 61 (34.7)                  | 60 (35.3)       | 121 (35.0)    | 127 (27.7)                 | 141 (30.3)      | 268 (29.0)    |
| > = 10                                              | n (%)     | 88 (50.0)                  | 74 (43.5)       | 162 (46.8)    | 250 (54.5)                 | 251 (53.9)      | 501 (54.2)    |
|                                                     | n         | 149                        | 134             | 283           | 377                        | 392             | 769           |
|                                                     | Mean      | 10.1                       | 9.6             | 9.8           | 11.9                       | 11.8            | 11.9          |
|                                                     | SD        | 5.51                       | 5.38            | 5.44          | 9.58                       | 8.06            | 8.83          |
|                                                     | Median    | 10.0                       | 10.0            | 10.0          | 10.0                       | 10.0            | 10.0          |
|                                                     | Min       | 1                          | 2               | 1             | 1                          | 1               | 1             |
|                                                     | Max       | 33                         | 30              | 33            | 99                         | 50              | 99            |
| Immunosuppressants                                  | n (%)     | 104 (59.1)                 | 84 (49.4)       | 188 (54.3)    | 232 (50.5)                 | 229 (49.1)      | 461 (49.8)    |
| Azathioprine (mg/day)                               | n (%)     | 36 (20.5)                  | 30 (17.6)       | 66 (19.1)     | 96 (20.9)                  | 85 (18.2)       | 181 (19.6)    |
|                                                     | Mean      | 96.5                       | 98.3            | 97.3          | 94.8                       | 104.9           | 99.5          |
|                                                     | SD        | 35.93                      | 30.75           | 33.43         | 49.33                      | 105.91          | 80.90         |
|                                                     | Median    | 100.0                      | 100.0           | 100.0         | 100.0                      | 100.0           | 100.0         |
|                                                     | Min       | 50                         | 50              | 50            | 25                         | 14              | 14            |
|                                                     | Max       | 150                        | 150             | 150           | 200                        | 1000            | 1000          |
| Methotrexate (mg/week)                              | n (%)     | 41 (23.3)                  | 33 (19.4)       | 74 (21.4)     | 79 (17.2)                  | 93 (20.0)       | 172 (18.6)    |
|                                                     | Mean      | 16.0                       | 15.6            | 15.8          | 14.2                       | 15.3            | 14.8          |
|                                                     | SD        | 5.04                       | 8.14            | 6.56          | 5.62                       | 10.64           | 8.70          |
|                                                     | Median    | 15.0                       | 15.0            | 15.0          | 15.0                       | 15.0            | 15.0          |
|                                                     | Min       | 6                          | 3               | 3             | 1                          | 3               | 1             |
|                                                     | Max       | 25                         | 53              | 53            | 25                         | 105             | 105           |

<div style=\"page-break-after: always\"></div>

|                                            |           | SC                         |                 |               | IV                         |                 |               |
|--------------------------------------------|-----------|----------------------------|-----------------|---------------|----------------------------|-----------------|---------------|
|                                            | Statistic | Anifrolumab 120 mg N = 176 | Placebo N = 170 | Total N = 346 | Anifrolumab 300 mg N = 459 | Placebo N = 466 | Total N = 925 |
| Mycophenolate (g/day)[a]                   | n (%)     | 27 (15.3)                  | 22 (12.9)       | 49 (14.2)     | 66 (14.4)                  | 58 (12.4)       | 124 (13.4)    |
|                                            | Mean      | 1.5                        | 1.4             | 1.5           | 1.4                        | 1.4             | 1.4           |
|                                            | SD        | 0.50                       | 0.57            | 0.54          | 0.68                       | 0.57            | 0.63          |
|                                            | Median    | 1.5                        | 1.3             | 1.4           | 1.2                        | 1.4             | 1.4           |
|                                            | Min       | 1                          | 0               | 0             | 0                          | 0               | 0             |
|                                            | Max       | 2                          | 2               | 2             | 4                          | 2               | 4             |
| Cyclosporine (mg/kg/day)                   | n (%)     | 0                          | 0               | 0             | 0                          | 0               | 0             |
| Tacrolimus (mg/kg/day)                     | n (%)     | 0                          | 0               | 0             | 0                          | 0               | 0             |
| Mizoribine (mg/day)                        | n (%)     | 0                          | 0               | 0             | 4 (0.9)                    | 3 (0.6)         | 7 (0.8)       |
|                                            | Mean      |                            |                 |               | 112.5                      | 150.0           | 128.6         |
|                                            | SD        |                            |                 |               | 47.87                      | 0.00            | 39.34         |
|                                            | Median    |                            |                 |               | 125.0                      | 150.0           | 150.0         |
|                                            | Min       |                            |                 |               | 50                         | 150             | 50            |
|                                            | Max       |                            |                 |               | 150                        | 150             | 150           |
| More than 1 immunosuppressant              | n (%)     | 1 (0.6)                    | 1 (0.6)         | 2 (0.6)       | 13 (2.8)                   | 10 (2.1)        | 23 (2.5)      |
| OCS in combination with immunosuppressants |           |                            |                 |               |                            |                 |               |
| Yes                                        | n (%)     | 90 (51.1)                  | 70 (41.2)       | 160 (46.2)    | 193 (42.0)                 | 203 (43.6)      | 396 (42.8)    |
| No                                         | n (%)     | 86 (48.9)                  | 100 (58.8)      | 186 (53.8)    | 259 (56.4)                 | 254 (54.5)      | 513 (55.5)    |
| OCS dose (mg/day)                          | n         | 90                         | 70              | 160           | 193                        | 203             | 396           |
| OCS dose (mg/day)                          | Mean      | 10.5                       | 10.5            | 10.5          | 12.6                       | 11.7            | 12.1          |
|                                            | SD        | 5.96                       | 5.96            | 5.94          | 9.78                       | 8.62            | 9.20          |
|                                            | Median    | 10.0                       | 10.0            | 10.0          | 10.0                       | 10.0            | 10.0          |
|                                            | Min       | 3                          | 3               | 3             | 1                          | 1               | 1             |
|                                            | Max       | 33                         | 30              | 33            | 90                         | 50              | 90            |

n:Number of subjects in analysis for a continuous variable and number of subjects per category for a categorical variable; N Number of subjects per treatment group; N* Number of subjects with available SLEDAI-2K value (used as the denominator for percentage calculation.

<div style=\"page-break-after: always\"></div>

For SC study, only first 220 randomized subjects have SLEDAI-2K data extracted for analyses). Baseline is defined as the last measurement prior to first double-blind dose administration.

The baseline demographic characteristic were balanced between the treatment groups also for the SC  Safety  Analysis  Set  (N=346)  subpopulation.  The  median  age  was  44.0  vs.  42.0  years  the anifrolumab vs placebo treatment groups respectively. No differences were seen in weight, height, or BMI. In the subgroups numbers were also similar between treatment groups with numbers higher for the female, white race, the Not Hispanic or Latino group and the geographic region of Europe. These demographic data were similar to that of the IV safety set. Slight differences were observed for race, ethnicity, and geographic region.

## 2.6.8.1. Patient exposure

Table 21: Disposition (TULIP SC Safety analysis set)

|                                                                    | TULIP SC Safety Analysis Set   | TULIP SC Safety Analysis Set   | TULIP SC Safety Analysis Set   |
|--------------------------------------------------------------------|--------------------------------|--------------------------------|--------------------------------|
|                                                                    | Anifrolumab 120mg n (%)        | Placebo n (%)                  | Total n (%)                    |
| Subjects started treatment                                         | 176 (100)                      | 170 (100)                      | 346 (100)                      |
| Subjects completed double-blind treatment                          | 88 (50.0)                      | 86 (50.6)                      | 174 (50.3)                     |
| Subjects discontinued double-blind treatment                       | 30 (17.0)                      | 36 (21.2)                      | 66 (19.1)                      |
| Adverse event                                                      | 12 (6.8)                       | 5 (2.9)                        | 17 (4.9)                       |
| Withdrawal by subject                                              | 12 (6.8)                       | 13 (7.6)                       | 25 (7.2)                       |
| Lost to follow-up                                                  | 0                              | 2 (1.2)                        | 2 (0.6)                        |
| Severe non-compliance to protocol                                  | 0                              | 0                              | 0                              |
| Lack of efficacy                                                   | 1 (0.6)                        | 4 (2.4)                        | 5 (1.4)                        |
| Condition under investigation worsened                             | 0                              | 0                              | 0                              |
| Development of study specific discontinuation criteria             | 1 (0.6)                        | 1 (0.6)                        | 2 (0.6)                        |
| Other                                                              | 4 (2.3)                        | 11 (6.5)                       | 15 (4.3)                       |
| Subjects ongoing on double-blind treatment at data cut-off date    | 58 (33.0)                      | 48 (28.2)                      | 106 (30.6)                     |
| Subjects withdrawn from study during double-blind treatment period | 27 (15.3)                      | 35 (20.6)                      | 62 (17.9)                      |
| Adverse event                                                      | 3 (1.7)                        | 2 (1.2)                        | 5 (1.4)                        |
| Death                                                              | 1 (0.6)                        | 0                              | 1 (0.3)                        |
| Withdrawal by subject                                              | 15 (8.5)                       | 16 (9.4)                       | 31 (9.0)                       |
| Lost to follow-up                                                  | 1 (0.6)                        | 3 (1.8)                        | 4 (1.2)                        |
| Development of study specific withdrawal criteria                  | 1 (0.6)                        | 2 (1.2)                        | 3 (0.9)                        |
| Lack of efficacy                                                   | 0                              | 0                              | 0                              |
| Condition under investigation worsened                             | 0                              | 0                              | 0                              |
| Severe non-compliance to protocol                                  | 0                              | 0                              | 0                              |
| Physician Decision                                                 | 4 (2.3)                        | 8 (4.7)                        | 12 (3.5)                       |
| Other                                                              | 2 (1.1)                        | 4 (2.4)                        | 6 (1.7)                        |

Percentages are based on the number of subjects started treatment. Data cut-off date is 2024-07-23. NA: Not applicable.

In TULIP SC, anifrolumab 120 mg or placebo was administered SC using the APFS. The study is being conducted at 145 sites in 16 countries. As of the DCO, a total of 346 patients were randomized and

<div style=\"page-break-after: always\"></div>

received at least one dose of IP and were included in the Safety Analysis Set: 176 patients received anifrolumab 120 mg SC QW and 170 patients received placebo during the DB period. The total PY of treatment  exposure  to  anifrolumab  120 mg  SC  was  128.6 PY  and  was  similar  between  the anifrolumab and placebo groups (Table 22 ). A total of 88 patients were treated with anifrolumab SC and completed the 52-week DB treatment period. In the SC+IV Pool, the total PY of treatment exposure was 548.0 PY in the anifrolumab group. Table 22 shows the duration of exposure.

Table 22: Duration of Exposure - During Double-Blind Treatment (Safety Analysis Set)

|                       | Statistic   |   Anifrolumab 120mg N = 176 |   Placebo N = 170 |   Total N = 346 |
|-----------------------|-------------|-----------------------------|-------------------|-----------------|
| Total PYs of exposure |             |                      128.56 |            124.69 |          253.25 |
| Duration (days)       | N           |                      176    |            170    |          346    |
|                       | Mean        |                      266.8  |            267.9  |          267.3  |
|                       | SD          |                      136.84 |            132.36 |          134.46 |
|                       | Median      |                      359    |            362    |          362    |
|                       | Min         |                        1    |              1    |            1    |
|                       | Max         |                      448    |            462    |          462    |

Exposure duration is calculated as: (Last dosing date + 28 days) - first dosing date + 1. The total PY of exposure is the sum of duration of exposure (days) of all patients in the respective treatment group divided by 365.25 (days/year).

## 2.6.8.2. Adverse events

The incidence of any AE during the double-blind treatment period was 74.4% in the anifrolumab 120 mg SC group and 71.2% in the placebo  group  (Table 23 ).  Most  AEs  were  mild  to  moderate  in intensity.

The proportions of patients with SAEs were low and balanced between the anifrolumab and placebo groups with no PT predominating during the 52-week double-blind treatment period (Table 23 ). The proportions of patients with AEs leading to IP discontinuation were low (5.1% in the anifrolumab group and 2.9% in the placebo group) with no PT predominating.

<div style=\"page-break-after: always\"></div>

Table 23: Overall summary of adverse events - during double-blind treatment (SC vs IV Safety analysis set)

|                                            | SC                              | SC                              | SC             | SC              | IV                           | IV                           | IV                | IV                |
|--------------------------------------------|---------------------------------|---------------------------------|----------------|-----------------|------------------------------|------------------------------|-------------------|-------------------|
|                                            | Anifrolumab 120 mg (N = 176) (N | Anifrolumab 120 mg (N = 176) (N | Placebo = 170) | Placebo = 170)  | Anifrolumab 300 mg (N = 459) | Anifrolumab 300 mg (N = 459) | Placebo (N = 466) | Placebo (N = 466) |
|                                            | n(%)                            | EAIR per 100 PY                 | n(%)           | EAIR per 100 PY | n(%)                         | EAIR per 100 PY              | n(%)              | EAIR per 100 PY   |
| Any AE                                     | 131 (74.4)                      | 277.8                           | 121 (71.2)     | 244.9           | 399 (86.9)                   | 291.8                        | 370 (79.4)        | 225.4             |
| Any SAE                                    | 19 (10.8)                       | 15.5                            | 15 (8.8)       | 12.4            | 54 (11.8)                    | 13.6                         | 78 (16.7)         | 20.8              |
| Any SAE with outcome death                 | 1 (0.6)                         | 0.8                             | 0              | 0               | 2 (0.4)                      | 0.5                          | 0                 | 0                 |
| Any AE leading to discontinuation of IP    | 9 (5.1)                         | 7.1                             | 5 (2.9)        | 4.0             | 19 (4.1)                     | 4.6                          | 24 (5.2)          | 6.0               |
| Any AESI                                   | 41 (23.3)                       | 38.3                            | 37 (21.8)      | 36.7            | 52 (11.3)                    | 13.1                         | 39 (8.4)          | 10.1              |
| non-opportunistic serious infections       | 11 (6.3)                        | 8.8                             | 6 (3.5)        | 4.9             | 22 (4.8)                     | 5.4                          | 26 (5.6)          | 6.6               |
| opportunistic infections                   | 0                               | 0                               | 0              | 0               | 1 (0.2)                      | 0.2                          | 1 (0.2)           | 0.3               |
| MACE                                       | 2 (1.1)                         | 1.6                             | 1 (0.6)        | 0.8             | 1 (0.2)                      | 0.2                          | 3 (0.6)           | 0.8               |
| malignancy                                 | 0                               | 0                               | 0              | 0               | 3 (0.7)                      | 0.7                          | 3 (0.6)           | 0.7               |
| herpes zoster                              | 7 (4.0)                         | 5.6                             | 2 (1.2)        | 1.6             | 28 (6.1)                     | 6.9                          | 6 (1.3)           | 1.5               |
| tuberculosis including latent tuberculosis | 1 (0.6)                         | 0.8                             | 1 (0.6)        | 0.8             | 4 (0.9)                      | 0.9                          | 1 (0.2)           | 0.2               |
| injection site reaction                    | 27 (15.3)                       | 23.7                            | 29 (17.1)      | 28.0            | -                            | -                            | -                 | -                 |

EAIR (per 100-patient year) is defined as the sum of subjects with the event/[sum across subjects' time at risk for the event /(365.25)]*100, where time at risk is time to first event for subjects who experienced the event during the analysis period and time during the analysis period for subjects who do not experience the event. Confidence interval of the difference is constructed based on Miettinen and Nurminen method. Possibly related is defined as reasonable possibility that the AE was caused by investigational product, as assessed by investigator. Double-blind treatment period starts on the date of first study intervention and ends on 28 days following the date of last dose of double-blind study intervention for subjects who do not go into OLE or date of first dose of open-label treatment-1 for subjects who go into OLE. Subjects with multiple occurrences in the same category are counted once per category regardless of the number of occurrences.

## Adverse drug reactions

The following PTs and medical concepts were identified as ADRs of anifrolumab based on the IV clinical studies (i.e., considered to have a reasonable possibility of having a causal association with anifrolumab  treatment):  upper  respiratory  tract  infection  (grouped  terms),  bronchitis  (grouped terms),  herpes  zoster,  respiratory  tract  infection  (grouped  terms),  hypersensitivity,  anaphylactic

<div style=\"page-break-after: always\"></div>

reaction, and infusion related reaction. Arthralgia has been included as an ADR in the SmPC section 4.8. with unknown frequency based on post-marketing information.

The most commonly reported adverse reactions during anifrolumab treatment were upper respiratory tract infection (31%), bronchitis (10%), infusionrelated reaction (9.4%) and herpes zoster (6.0%). The most common serious adverse reaction was herpes zoster (0.4%).

Data  for  the  SC+IV  Pool  were  evaluated  to  assess  potential  ADRs,  irrespective  of  route  of administration, during 52 weeks of treatment with anifrolumab. Frequencies of ADRs are summarized for the SC 220+IV Pool Safety Analysis Set (i.e., patients who completed the 52-week double blind treatment  period  or  were  prematurely  discontinued  in  TULIP  SC  plus  the  IV  Pool)  to  ensure comparable durations of  exposure in  TULIP  SC  and  the  IV  Pool;  different  exposure  times  would confound the safety profile, as some events occur more frequently early on during treatment (Table 24 ).

There were no events of anaphylaxis reported in the SC+IV Pool (the one anaphylactic event reported with anifrolumab was reported at the 150 mg dose and therefore is not included in the SC+IV Pool and SC220+IV Pool).

Table 24: Adverse Drug Reactions by System Organ Class and Preferred Term - during double-blind treatment (SC 220 + IV Safety analysis set)

|                                                         | Anifrolumab 120 mg SC and 300 mg IV N = 569   | Anifrolumab 120 mg SC and 300 mg IV N = 569   | Placebo N = 576   | Placebo N = 576   |
|---------------------------------------------------------|-----------------------------------------------|-----------------------------------------------|-------------------|-------------------|
| System Organ Class Preferred Term (MedDRA version 27.0) | n (%)                                         | Classification                                | n (%)             | Classification    |
| Infections and infestations                             |                                               |                                               |                   |                   |
| Upper respiratory tract infection [b]                   | 176 (30.9)                                    | Very common                                   | 117 (20.3)        | Very common       |
| Bronchitis [c]                                          | 58 (10.2)                                     | Very common                                   | 30 (5.2)          | Common            |
| Herpes zoster [a]                                       | 34 (6.0)                                      | Common                                        | 8 (1.4)           | Common            |
| Respiratory tract infection [d]                         | 17 (3.0)                                      | Common                                        | 8 (1.4)           | Common            |
| Immune system disorders                                 |                                               |                                               |                   |                   |
| Hypersensitivity                                        | 14 (2.5)                                      | Common                                        | 3 (0.5)           | Uncommon          |
| Anaphylactic reaction                                   | 0                                             | Not known                                     | 0                 | Not known         |

Frequencies of occurrence of adverse reactions are defined as: very common ( &gt; = 10%), common ( &gt; = 1% to &lt; 10%); uncommon ( &gt; = 0.1% to &lt; 1%); rare ( &gt; = 0.01% to &lt; 0.1%); very rare ( &lt; 0.01%); not known (cannot be estimated from available data). [a] grouped term that includes: PT Herpes zoster; [b] Grouped term that includes: PT Nasopharyngitis, PT Pharyngitis, PT Upper respiratory tract infection; [c] Grouped term that includes: PT Bronchitis, PT Bronchitis viral, PT Tracheobronchitis; [d] Grouped term that includes: PT Respiratory tract infection, PT Respiratory tract infection viral. n, Number of subjects per category; N Number of subjects per treatment group. The preferred term of 'Respiratory tract infection bacterial' was also included as an ADR for anifrolumab, but no cases were found in the SC 220 + IV Safety Analysis Set.

## 2.6.8.3. Serious adverse events, deaths and other significant events

## AEs of special interest

In TULIP SC, consistent with the known safety profile of anifrolumab 300 mg IV Q4W, patients in the anifrolumab 120 mg SC QW group had an increased incidence of herpes zoster compared with the

<div style=\"page-break-after: always\"></div>

placebo group during the 52-week DB treatment period (Table 25 ).  Most events were cutaneous localized, nonserious, mild or moderate in intensity, resolved with antiviral therapy, and did not lead to IP discontinuation. In the anifrolumab 120 mg SC QW group, 3 of the 7 events had an onset during the first 12 weeks of treatment. The incidence of herpes zoster infections with anifrolumab 120 mg SC QW treatment was similar to that seen with anifrolumab 300 mg IV Q4W treatment.

Table 25: Herpes zoster - during double-blind treatment (SC vs IV Safety analysis set)

|                                          |             |     |          |                 |                 | Placebo   | Placebo   | Placebo         | Placebo         |                                                  |
|------------------------------------------|-------------|-----|----------|-----------------|-----------------|-----------|-----------|-----------------|-----------------|--------------------------------------------------|
| AESI category                            | Anifrolumab | N   | n (%)    | Expos ure years | EAIR per 100 PY | N         | n (%)     | Expos ure years | EAIR per 100 PY | EAIR per 100 PY (Anifrolumab - Placebo) (95% CI) |
| Any AE                                   | 120 mg SC   | 176 | 7 (4.0)  | 124.5           | 5.6             | 170       | 2 (1.2)   | 124.4           | 1.6             | 4.0 (-0.9, 10.2)                                 |
|                                          | 300 mg IV   | 459 | 28 (6.1) | 406.9           | 6.9             | 466       | 6 (1.3)   | 399.5           | 1.5             | 5.4 (2.7, 8.6)                                   |
| Any SAE                                  | 120 mg SC   | 176 | 0        | 128.6           | 0               | 170       | 0         | 124.7           | 0               | 0.0 (-3.1, 3.0)                                  |
|                                          | 300 mg IV   | 459 | 2 (0.4)  | 418.5           | 0.5             | 466       | 0         | 403.0           | 0               | 0.5 (-0.5, 1.7)                                  |
| Any SAE with outcome death               | 120 mg SC   | 176 | 0        | 128.6           | 0               | 170       | 0         | 124.7           | 0               | 0.0 (-3.1, 3.0)                                  |
|                                          | 300 mg IV   | 459 | 0        | 419.4           | 0               | 466       | 0         | 403.0           | 0               | 0.0 (-1.0, 0.9)                                  |
| Any AE leading to discontinuation of IP  | 120 mg SC   | 176 | 1 (0.6)  | 128.5           | 0.8             | 170       | 0         | 124.7           | 0               | 0.8 (-2.3, 4.4)                                  |
|                                          | 300 mg IV   | 459 | 2 (0.4)  | 419.3           | 0.5             | 466       | 0         | 403.0           | 0               | 0.5 (-0.4, 1.8)                                  |
| Any cutaneous (localized) herpes zoster  | 120 mg SC   | 176 | 6 (3.4)  | 124.6           | 4.8             | 170       | 2 (1.2)   | 124.4           | 1.6             | 3.2 (-1.6, 9.1)                                  |
|                                          | 300 mg IV   | 459 | 18 (3.9) | 409.9           | 4.4             | 466       | 5 (1.1)   | 400.2           | 1.2             | 3.2 (0.9, 5.9)                                   |
| Any cutaneous disseminated herpes zoster | 120 mg SC   | 176 | 0        | 128.6           | 0               | 170       | 0         | 124.7           | 0               | 0.0 (-3.1, 3.0)                                  |
|                                          | 300 mg IV   | 459 | 2 (0.4)  | 418.0           | 0.5             | 466       | 0         | 403.0           | 0               | 0.5 (-0.5, 1.7)                                  |
| Any visceral disseminated herpes zoster  | 120 mg SC   | 176 | 1 (0.6)  | 128.5           | 0.8             | 170       | 0         | 124.7           | 0               | 0.8 (-2.3, 4.4)                                  |
|                                          | 300 mg IV   | 459 | 0        | 419.4           | 0               | 466       | 0         | 403.0           | 0               | 0.0 (-1.0, 0.9)                                  |

EAIR is defined as the sum of subjects with the event/[sum across subjects' time at risk for the event /(365.25)] * 100, where time at risk is time to first event for subjects who experienced the event during the analysis period and time during the analysis period for subjects who do not experience the event. In the event that multiple studies are combined, the Miettinen and Nurminen weighted average EAIRs are presented for each treatment group. 95% CIs are calculated via the Miettinen and Nurminen method, stratified by study where applicable.

During double-blind treatment: Includes adverse events with an onset date on or after the date of first dose of IP up to and including 28 days following the date of last double-blind IP dose.

Subjects with multiple occurrences are counted once per AE category regardless of the number of occurrences. n Number of subjects per category; N Number of subjects per treatment group.

MedDRA version 27.0.

<div style=\"page-break-after: always\"></div>

## Tuberculosis (Including Latent Tuberculosis)

In TULIP SC, a total of 2 events of tuberculosis (including latent tuberculosis) were reported in the 52week DB treatment period. There was one event of latent tuberculosis (assessed as not possibly related to IP and not an SAE) based on positive QuantiFERON test during screening in the anifrolumab 120 mg SC QW group. There was one event of extrapulmonary tuberculosis (assessed as possibly related to IP, categorized as an SAE, and led to IP discontinuation) in the placebo treatment group. No events of active tuberculosis were reported for the IV Pool.

## MACE

In TULIP SC, 7 events reported for 7 patients during the 52-week DB treatment period plus follow-up were submitted to the CV-EAC; of these, a total of 3 patients had CV-EAC-confirmed MACE events: 2 in the anifrolumab 120 mg SC QW group (Myocardial infarction [non-fatal] and Stroke [non-fatal]) and 1 in the placebo group (Myocardial infarction [non-fatal]).

The incidence of CV-EAC-confirmed MACE during the 52-week DB treatment period plus follow-up period with anifrolumab 120 mg SC QW treatment was low and similar to that seen during the DB treatment period in TULIP SC and with anifrolumab 300 mg IV Q4W treatment.

## Malignancy

In TULIP SC, no malignancies were reported during the 52-week DB treatment period. Incidences of malignancies with anifrolumab 300 mg IV Q4W were low.

## Injection Site Reactions

In  TULIP  SC,  the  proportions  of  patients  with  AESIs  of  injection  site  reactions  were  similar  in  the anifrolumab 120 mg SC QW group (27 patients [15.3%]) and the placebo group (29 patients [17.1%]). All injection site reaction AESIs were nonserious, mild/moderate in intensity, and transient in nature. None resulted in discontinuation of IP. Most injection site reaction AEs were reported in the first 12 weeks of treatment in both treatment groups. According to the MAH, based on review of all available safety information, a reasonable possibility of a causal relationship between anifrolumab 120 mg administered SC QW and injection site reactions has not been established at this time.

## Other significant events

## Hypersensitivity and Anaphylaxis

Consistent with anifrolumab IV administration, there was a low rate of hypersensitivity reactions with anifrolumab 120 mg administered SC QW (2 patients) during the 52-week DB treatment period. There was 1 patient with a hypersensitivity  AE  that  led  to  discontinuation  of  IP  and  was  assessed  by  the investigator as possibly related to IP.

There were no events of anaphylactic reactions reported with anifrolumab 120 mg SC QW or 300 mg IV Q4W treatment. (One anaphylactic event was reported for anifrolumab 150 mg and therefore is not included in the IV Pool.)

## Suicidal Ideation and Attempts

There  was  no  evidence  of  an  increased  risk  in  suicidal  ideation  or  behaviour  in  patients  receiving anifrolumab compared with placebo, as assessed by the C-SSRS. There was no apparent increase in AEs of depression based on an evaluation of PTs.

<div style=\"page-break-after: always\"></div>

## Serious Adverse Events

In TULIP SC, there were no clinically meaningful differences in the frequency and event rate of SAEs (including  events with the outcome of death) between the anifrolumab 120 mg SC QW and placebo groups during the 52-week DB treatment period (Table 26 ). The SAEs of pneumonia (5 events in the anifrolumab  120 mg  SC  QW  group  and  1 event  in  the  placebo  group),  extrapulmonary  tuberculosis (placebo group), tubo-ovarian abscess (placebo group), cellulitis (placebo group), osteomyelitis (placebo group), and renal abscess (placebo group) were assessed as possibly related to IP by the Investigator.

The  most  common  SOC  with  reported  SAEs  in  TULIP  SC  was  Infections  and  Infestations  for  both treatment groups during the 52-week DB treatment period (Table 26 ).  The  only  SAE  PTs  that  were reported in more than one patient were pneumonia and dengue fever in the anifrolumab 120 mg SC QW group.

Incidences of SAEs with anifrolumab 120 mg SC QW treatment were similar to those observed with anifrolumab 300 mg IV Q4W treatment. The most frequently reported PT in TULIP SC and in the IV Pool was pneumonia (Table 26 ).

<div style=\"page-break-after: always\"></div>

Table 26: Serious adverse events (at least 2 patients in any treatment group) - during double-blind treatment (SC vs IV Safety analysis set)

|                                      |             |               |                |                 | Placebo   | Placebo   | Placebo        | Placebo         |                                                  |
|--------------------------------------|-------------|---------------|----------------|-----------------|-----------|-----------|----------------|-----------------|--------------------------------------------------|
| Preferred Term (MedDRA version 27.0) | Anifrolumab | N n (%)       | Exposure years | EAIR per 100 PY | N         | n (%)     | Exposure years | EAIR per 100 PY | EAIR per 100 PY (Anifrolumab - Placebo) (95% CI) |
| Any SAE                              | 120 mg SC   | 176 19 (10.8) | 122.4          | 15.5            | 170       | 15 (8.8)  | 120.8          | 12.4            | 3.1 (-6.7, 13.1)                                 |
| Any SAE                              | 300 mg IV   | 459 54 (11.8) | 397.9          | 13.6            | 466       | 78 (16.7) | 376.0          | 20.8            | -7.1 (-13.2, -1.3)                               |
| Pneumonia                            | 120 mg SC   | 176 4 (2.3)   | 127.6          | 3.1             | 170       | 1 (0.6)   | 124.3          | 0.8             | 2.3 (-1.7, 7.3)                                  |
| Pneumonia                            | 300 mg IV   | 459 8 (1.7)   | 417.3          | 1.9             | 466       | 9 (1.9)   | 400.4          | 2.3             | -0.4 (-2.6, 1.7)                                 |
| Dengue fever                         | 120 mg SC   | 176 3 (1.7)   | 126.6          | 2.4             | 170       | 0         | 124.7          | 0               | 2.4 (-0.7, 7.0)                                  |
| Dengue fever                         | 300 mg IV   | 459 0         | 419.4          | 0               | 466       | 0         | 403.0          | 0               | 0.0 (-1.0, 0.9)                                  |
| Systemic lupus erythematosus         | 120 mg SC   | 176 1 (0.6)   | 127.9          | 0.8             | 170       | 1 (0.6)   | 124.6          | 0.8             | -0.0 (-3.8, 3.7)                                 |
| Systemic lupus erythematosus         | 300 mg IV   | 459 7 (1.5)   | 416.4          | 1.7             | 466       | 14 (3.0)  | 399.4          | 3.5             | -1.9 (-4.4, 0.4)                                 |
| Anaemia                              | 120 mg SC   | 176 0         | 128.6          | 0               | 170       | 0         | 124.7          | 0               | 0.0 (-3.1, 3.0)                                  |
| Anaemia                              | 300 mg IV   | 459 0         | 419.4          | 0               | 466       | 2 (0.4)   | 402.2          | 0.5             | -0.5 (-1.8, 0.4)                                 |
| Angioedema                           | 120 mg SC   | 176 0         | 128.6          | 0               | 170       | 0         | 124.7          | 0               | 0.0 (-3.1, 3.0)                                  |
| Angioedema                           | 300 mg IV   | 459 2 (0.4)   | 418.6          | 0.5             | 466       | 0         | 403.0          | 0               | 0.5 (-0.5, 1.8)                                  |
| Appendicitis                         | 120 mg SC   | 176 0         | 128.6          | 0               | 170       | 0         | 124.7          | 0               | 0.0 (-3.1, 3.0)                                  |
| Appendicitis                         | 300 mg IV   | 459 3 (0.7)   | 418.7          | 0.7             | 466       | 0         | 403.0          | 0               | 0.7 (-0.2, 2.1)                                  |
| Asthma                               | 120 mg SC   | 176 0         | 128.6          | 0               | 170       | 0         | 124.7          | 0               | 0.0 (-3.1, 3.0)                                  |
| Asthma                               | 300 mg IV   | 459 2 (0.4)   | 418.7          | 0.5             | 466       | 1 (0.2)   | 403.0          | 0.3             | 0.2 (-0.9, 1.5)                                  |
| Atrial fibrillation                  | 120 mg SC   | 176 0         | 128.6          | 0               | 170       | 0         | 124.7          | 0               | 0.0 (-3.1, 3.0)                                  |

<div style=\"page-break-after: always\"></div>

|                                      |             |             |                |                 | Placebo   | Placebo   | Placebo        | Placebo         |                                                  |
|--------------------------------------|-------------|-------------|----------------|-----------------|-----------|-----------|----------------|-----------------|--------------------------------------------------|
| Preferred Term (MedDRA version 27.0) | Anifrolumab | N n (%)     | Exposure years | EAIR per 100 PY | N         | n (%)     | Exposure years | EAIR per 100 PY | EAIR per 100 PY (Anifrolumab - Placebo) (95% CI) |
|                                      | 300 mg IV   | 459 0       | 419.4          | 0               | 466       | 2 (0.4)   | 402.2          | 0.5             | -0.5 (-1.8, 0.4)                                 |
| Chest pain                           | 120 mg SC   | 176 0       | 128.6          | 0               | 170       | 0         | 124.7          | 0               | 0.0 (-3.1, 3.0)                                  |
|                                      | 300 mg IV   | 459 2 (0.4) | 418.8          | 0.5             | 466       | 1 (0.2)   | 403.0          | 0.3             | 0.2 (-0.9, 1.5)                                  |
| Gastroenteritis                      | 120 mg SC   | 176 0       | 128.6          | 0               | 170       | 0         | 124.7          | 0               | 0.0 (-3.1, 3.0)                                  |
|                                      | 300 mg IV   | 459 2 (0.4) | 419.0          | 0.5             | 466       | 3 (0.6)   | 401.3          | 0.8             | -0.3 (-1.8, 1.1)                                 |
| Gastroenteritis viral                | 120 mg SC   | 176 0       | 128.6          | 0               | 170       | 0         | 124.7          | 0               | 0.0 (-3.1, 3.0)                                  |
|                                      | 300 mg IV   | 459 2 (0.4) | 418.4          | 0.5             | 466       | 0         | 403.0          | 0               | 0.5 (-0.5, 1.7)                                  |
| Herpes zoster                        | 120 mg SC   | 176 0       | 128.6          | 0               | 170       | 0         | 124.7          | 0               | 0.0 (-3.1, 3.0)                                  |
|                                      | 300 mg IV   | 459 2 (0.4) | 418.5          | 0.5             | 466       | 0         | 403.0          | 0               | 0.5 (-0.5, 1.7)                                  |
| Influenza                            | 120 mg SC   | 176 0       | 128.6          | 0               | 170       | 0         | 124.7          | 0               | 0.0 (-3.1, 3.0)                                  |
|                                      | 300 mg IV   | 459 2 (0.4) | 418.3          | 0.5             | 466       | 1 (0.2)   | 402.2          | 0.3             | 0.2 (-1.0, 1.5)                                  |
| Ischaemic stroke                     | 120 mg SC   | 176 0       | 128.6          | 0               | 170       | 0         | 124.7          | 0               | 0.0 (-3.1, 3.0)                                  |
|                                      | 300 mg IV   | 459 0       | 419.4          | 0               | 466       | 2 (0.4)   | 401.1          | 0.5             | -0.5 (-1.9, 0.4)                                 |
| Pyrexia                              | 120 mg SC   | 176 0       | 128.6          | 0               | 170       | 0         | 124.7          | 0               | 0.0 (-3.1, 3.0)                                  |
|                                      | 300 mg IV   | 459 0       | 419.4          | 0               | 466       | 2 (0.4)   | 402.1          | 0.5             | -0.5 (-1.8, 0.4)                                 |
| Radius fracture                      | 120 mg SC   | 176 0       | 128.6          | 0               | 170       | 0         | 124.7          | 0               | 0.0 (-3.1, 3.0)                                  |
|                                      | 300 mg IV   | 459 0       | 419.4          | 0               | 466       | 2 (0.4)   | 402.3          | 0.5             | -0.5 (-1.8, 0.4)                                 |
| Sepsis                               | 120 mg SC   | 176 0       | 128.6          | 0               | 170       | 0         | 124.7          | 0               | 0.0 (-3.1, 3.0)                                  |

<div style=\"page-break-after: always\"></div>

|                                      |             |     |         |                |                 | Placebo   | Placebo   | Placebo        | Placebo         |                                                  |
|--------------------------------------|-------------|-----|---------|----------------|-----------------|-----------|-----------|----------------|-----------------|--------------------------------------------------|
| Preferred Term (MedDRA version 27.0) | Anifrolumab | N   | n (%)   | Exposure years | EAIR per 100 PY | N         | n (%)     | Exposure years | EAIR per 100 PY | EAIR per 100 PY (Anifrolumab - Placebo) (95% CI) |
|                                      | 300 mg IV   | 459 | 0       | 419.4          | 0               | 466       | 2 (0.4)   | 401.5          | 0.5             | -0.5 (-1.8, 0.4)                                 |
| Urinary tract infection              | 120 mg SC   | 176 | 0       | 128.6          | 0               | 170       | 0         | 124.7          | 0               | 0.0 (-3.1, 3.0)                                  |
|                                      | 300 mg IV   | 459 | 2 (0.4) | 418.2          | 0.5             | 466       | 1 (0.2)   | 402.8          | 0.2             | 0.2 (-1.0, 1.5)                                  |
| Vasculitis                           | 120 mg SC   | 176 | 0       | 128.6          | 0               | 170       | 0         | 124.7          | 0               | 0.0 (-3.1, 3.0)                                  |
|                                      | 300 mg IV   | 459 | 0       | 419.4          | 0               | 466       | 2 (0.4)   | 403.0          | 0.5             | -0.5 (-1.8, 0.4)                                 |

EAIR is defined as the sum of subjects with the event/[sum across subjects' time at risk for the event /(365.25)] * 100, where time at risk is time to first event for subjects who experienced the event during the analysis period and time during the analysis period for subjects who do not experience the event. In the event that multiple studies are combined, the Miettinen and Nurminen weighted average EAIRs are presented for each treatment group. 95% CIs are calculated via the Miettinen and Nurminen method, stratified by study where applicable. During double-blind treatment: Includes adverse events with an onset date on or after the date of first dose of IP up to and including 28 days following the date of last double-blind IP dose.  Subjects with multiple occurrences of the same preferred term are counted once regardless of the number of occurrences. Table is sorted by decreasing frequency on preferred term level in Anifrolumab 120 mg treatment group

n Number of subjects per category; N Number of subjects per treatment group.

<div style=\"page-break-after: always\"></div>

In TULIP SC, SAEs by SOC and PT with anifrolumab 120 mg SC in the 52-week DB treatment period plus follow-up and in the OLE period through the IA DCO were generally consistent with those observed during the 52-week DB treatment period.

## Deaths

As of the DCO for TULIP SC, one death occurred in the anifrolumab 120 mg SC QW group due to the AE PT gastrointestinal infection. The event was assessed as not possibly related to IP by the Investigator and considered to be related to the patient's underlying conditions. A structured patient narrative was provided in the CSR.

## ADRs of special interest, serious ADRs and deaths causally related to the medicinal product

According to the MAH incidence of ADRs, with anifrolumab 120 mg administered SC QW was consistent with the established safety profile of anifrolumab 300 mg Q4W administered by IV infusion. Collated data namely on the subgroups on AESI, SAE and deaths were not presented.

The single event of death was assessed as not possibly related to the IMP.

## 2.6.8.4. Laboratory findings

Consistent with anifrolumab 300 mg IV Q4W, there were no clinically meaningful differences between treatments  in  clinical  laboratory  values  with  anifrolumab  120 mg  SC  QW  during  the  52-week  DB treatment period .

There was no clinically meaningful worsening in hematology, clinical chemistry, and urinalysis values during 52 weeks of treatment with anifrolumab 120 mg SC QW. Mean hematology values were generally similar between the anifrolumab 120 mg SC QW and placebo groups at baseline and at Week 52, with the  exception  of  mean  change  from  baseline  in  lymphocyte  levels  showing  improvement  in  the anifrolumab group. There were no other clinically meaningful differences noted between the treatment groups in categorical shifts and no other differences in the frequency or pattern of potentially clinically significant treatment-emergent changes from baseline in hematology variables at 52 weeks.

Mean clinical  chemistry  values  were  generally  similar  between  the  anifrolumab  120 mg  SC  QW  and placebo  groups  at  baseline  and  at  Week 52.  There  were  no  clinically  meaningful  differences  noted between the treatment groups in categorical shifts and no other differences in the frequency or pattern of  potentially  clinically  significant  treatment-emergent  changes  from  baseline  in  clinical  chemistry variables at 52 weeks.

There were no Hy's Law cases (AST or ALT ≥ 3 × ULN and total bilirubin ≥ 2 × ULN) reported during the 52-week treatment period.

No trends were observed between the anifrolumab 120 mg SC QW and placebo groups in the pattern and frequency of patients shifting from negative to positive values in urinalysis tests during the 52-week DB treatment period.

## 2.6.8.5. In vitro biomarker test for patient selection for safety

N/A

<div style=\"page-break-after: always\"></div>

## 2.6.8.6. Safety in special populations

For ages 65 and older, only the ≥ 65 age category is shown in Table 27 , since there were no patients randomized in TULIP SC or the IV studies who were older than 70 years of age (based on inclusion criteria adults 18 to 70 years of age in TULIP SC and the Phase 3 IV studies and 18 to 65 years in the Phase 2 IV study). Therefore, all 36 patients included in this category are 65 to 70 years of age.

Table 27: Overall summary of adverse events by age - during double-blind treatment (SC + IV safety analysis set)

|                                         | Anifrolumab 120 mg SC + 300 mg IV   | Anifrolumab 120 mg SC + 300 mg IV   | Placebo        | Placebo         |
|-----------------------------------------|-------------------------------------|-------------------------------------|----------------|-----------------|
| AE Category                             | < 65 (N = 611)                      | > = 65 (N = 24)                     | < 65 (N = 624) | > = 65 (N = 12) |
| Any AE                                  | 510 (83.5)                          | 20 (83.3)                           | 481 (77.1)     | 10 (83.3)       |
| Any SAE                                 | 69 (11.3)                           | 4 (16.7)                            | 90 (14.4)      | 3 (25.0)        |
| Any SAE with outcome death              | 2 (0.3)                             | 1 (4.2)                             | 0              | 0               |
| Any AE leading to discontinuation of IP | 26 (4.3)                            | 2 (8.3)                             | 29 (4.6)       | 0               |
| Any severe AE                           | 54 (8.8)                            | 1 (4.2)                             | 44 (7.1)       | 1 (8.3)         |
| Any related AE                          | 208 (34.0)                          | 7 (29.2)                            | 166 (26.6)     | 3 (25.0)        |
| Any AESI                                | 90 (14.7)                           | 3 (12.5)                            | 75 (12.0)      | 1 (8.3)         |
| Non-opportunistic serious infections    | 31 (5.1)                            | 2 (8.3)                             | 32 (5.1)       | 0               |
| Opportunistic infections                | 1 (0.2)                             | 0                                   | 1 (0.2)        | 0               |
| MACE                                    | 3 (0.5)                             | 0                                   | 4 (0.6)        | 0               |
| Malignancy                              | 3 (0.5)                             | 0                                   | 3 (0.5)        | 0               |
| Herpes zoster                           | 35 (5.7)                            | 0                                   | 8 (1.3)        | 0               |
| Tuberculosis including latent TB        | 5 (0.8)                             | 0                                   | 2 (0.3)        | 0               |
| Injection site reaction                 | 26 (4.3)                            | 1 (4.2)                             | 28 (4.5)       | 1 (8.3)         |

Per the inclusion criteria, subjects aged 18 - 70 years old were enrolled in the study.  Therefore, age groups of  &lt; 65 and &gt; = 65 years are presented as no subjects older than 70 were enrolled. During double-blind treatment: The table includes adverse events with an onset date on or after the date of first dose of IP up to and including 28 days following the date of last double-blind IP dose. For subjects who go into open-label treatment, including events up until the date of first dose of open-label treatment-1. Subjects with multiple occurrences in the same category are counted once per category regardless of the number of occurrences. IP Investigational product; MACE Major acute cardiovascular events; n Number of subjects per category; N Number of subjects per treatment group. MedDRA version 27.0

As claimed by the MAH, there are no AE data available from TULIP SC for the indicated special populations of hepatically impaired, renally impaired or pregnant patients.  Both hepatically impaired and renally impaired patients were excluded from TULIP SC (and other anifrolumab studies) to protect potentially vulnerable patients and to avoid factors that may confound a complete understanding of the safety data.

Anifrolumab is eliminated by a target-mediated non-linear pathway through binding to IFNAR1 as well as a non-specific linear pathway in the reticuloendothelial system. Generally, clearance of monoclonal antibodies by the liver is considered to be a minor pathway. Therefore, there is no scientific rationale to suspect  that  the  safety  profile  of  patients  with  moderate  to  severe  hepatic  impairment  may  differ significantly to that characterized so far for the general target population.

Similarly, there is no scientific rationale, based on anifrolumab' s clearance mechanisms, to suspect the safety profile of anifrolumab in patients with severe renal impairment (due to lupus nephritis or any other cause) may differ from the general target population. Additionally, although patients with severe renal disease were not included in the SLE clinical program, patients with mild or moderate renal disease

<div style=\"page-break-after: always\"></div>

(n = 427) were enrolled in the completed Phase III IV studies. There were no differences in PK observed for patients with mild to moderate renal disease compared to patients with normal renal function.

For these reasons, neither hepatic nor renal impairment are considered missing information in the RMP.

For ethical reasons, as indicated by the MAH, pregnant patients have been excluded from anifrolumab studies,  including  TULIP SC.  A  small  number  of  patients  reported  pregnancies  in  the  anifrolumab program, but as patients were discontinued from IP once their pregnancy was known, there are no data of patients taking anifrolumab throughout the entirety of their pregnancy, and there are no data on the effect  of  anifrolumab  on  patients  who  are  breastfeeding  or  their  offspring.  Just  2  pregnancies  were reported in the double-blind period of TULIP SC, both in the placebo group. Pregnancy is considered missing information in the RMP and a post-authorization pregnancy study is being conducted.

## Intrinsic Factors

The  AE  and  SAE  profile  of  anifrolumab  120 mg  SC  QW  was  generally  consistent  across  pre-defined subgroups (sex, age, race, BMI, disease-related factors, and ADA status) based on analyses of AEs by category, common AEs, and SAEs, although there were small numbers of patients in some subgroups.

## Adverse Events by Anti-drug Antibody Status

Based on MAH, anifrolumab administered SC is poorly immunogenic in patients with moderate to severe SLE. There was no apparent effect of ADA-positive status on the overall incidence of AEs in TULIP SC, but due to very small numbers of ADA-positive patients, it was not possible to draw firm conclusions.

## Extrinsic Factors

The AE and SAE profile of anifrolumab 120 mg SC QW was generally consistent across the pre-defined geographic  region  subgroups  (Asia  Pacific,  Europe,  Latin  America,  US/Canada,  Rest  of  World)  and concomitant medication use at baseline (immunosuppressant use) based on analyses of AEs by category, common AEs, and SAEs.

## ADRs in special populations

According to the MAH incidences of ADRs, with anifrolumab 120 mg administered SC QW was consistent with the established safety profile of anifrolumab 300 mg Q4W administered by IV infusion. Collated data on the subgroups of special populations were not presented.

## 2.6.8.7. Immunological events

In the Device PK bridging study, ADA titer, ADA positivity, and nAb positivity at baseline, on Day 29 and Day 57 were assessed. Overall, the immunogenicity of anifrolumab SC was very low in both devices (AI or APFS) and there were no differences in relation to device used for administration, with total 3 (1.7%) participants ADA positive on Day 57 (1/90 [1.1%] AI device group; 2/90 [2.2%] APFS device group). Titers for the 3 ADA-positive participants were low, but all detected ADAs (3/180) showed neutralizing capabilities.

In the TULIP SC study, Pre dose sample for ADAs were planned to be collected at Week 0, 12, 24, 36, 52, 104. The data cut-off date for PK, PD, and immunogenicity assessments was 28 May 2024. At the time  of  data  cut-off  date,  only  the  data  from  first  220 patients  were  available  for  PK,  PD,  and immunogenicity assessments. All treatment-emergent-ADA-positive patients were positive during the double-blind treatment period. Among ADA-positive patients who received anifrolumab, no patients were

<div style=\"page-break-after: always\"></div>

classified as treatment-emergent nAb-positive in the study, suggesting that the detected ADAs lacked neutralizing properties in this study (Table 28 ).

Table 28: Summary of Anti-Drug Antibody Responses During Double-blind Treatment and Follow-up (Safety Analysis Set)

| ADA category                                                                              | Statistic      | Anifrolumab 120mg N = 176   | Placebo N = 170   |
|-------------------------------------------------------------------------------------------|----------------|-----------------------------|-------------------|
| ADA prevalence (ADA positive at baseline and/or post-baseline)                            | n/Nobs [a] (%) | 11/110 (10.0)               | 10/110 (9.1)      |
|                                                                                           | Median         | 80.0                        | 120.0             |
|                                                                                           | Min, max       | 39, 320                     | 39, 2560          |
| ADA incidence (TE-ADA positive)                                                           | n/Nobs [b] (%) | 6/107 (5.6)                 | 7/105 (6.7)       |
|                                                                                           | Median         | 160.0                       | 160.0             |
|                                                                                           | Min, max       | 39, 320                     | 39, 1280          |
| Treatment-induced ADA positive                                                            | n/Nobs [b] (%) | 6/107 (5.6)                 | 7/105 (6.7)       |
|                                                                                           | Median         | 160.0                       | 160.0             |
|                                                                                           | Min, max       | 39, 320                     | 39, 1280          |
| Treatment-boosted ADA positive                                                            | n/Nobs [b] (%) | 0/107                       | 0/105             |
|                                                                                           | Median         | -                           | -                 |
|                                                                                           | Min, max       | -, -                        | -, -              |
| Non-TE-ADA positive                                                                       | n/Nobs [b] (%) | 5/107 (4.7)                 | 3/105 (2.9)       |
|                                                                                           | Median         | 40.0                        | 39.0              |
|                                                                                           | Min, max       | 40, 80                      | 39, 2560          |
| Both baseline and post-baseline positive                                                  | n/Nobs [b] (%) | 2/107 (1.9)                 | 2/105 (1.9)       |
|                                                                                           | Median         | 60.0                        | 39.0              |
|                                                                                           | Min, max       | 40, 80                      | 39, 39            |
| Only baseline positive                                                                    | n/Nobs [c] (%) | 3/110 (2.7)                 | 1/109 (0.9)       |
|                                                                                           | Median         | 40.0                        | 2560.0            |
|                                                                                           | Min, max       | 40, 80                      | 2560, 2560        |
| ADA persistently positive                                                                 | n/Nobs [b] (%) | 3/107 (2.8)                 | 2/105 (1.9)       |
|                                                                                           | Median         | 80.0                        | 200.0             |
|                                                                                           | Min, max       | 39, 320                     | 80, 320           |
| ADA transiently positive                                                                  | n/Nobs [b] (%) | 3/107 (2.8)                 | 5/105 (4.8)       |
|                                                                                           | Median         | 160.0                       | 160.0             |
|                                                                                           | Min, max       | 160, 320                    | 39, 1280          |
| TE-ADA positive with maximum post-baseline titer > median of maximum post-baseline titers | n/Nobs [b] (%) | 2/107 (1.9)                 | 3/105 (2.9)       |
|                                                                                           | Median         | 320.0                       | 640.0             |
|                                                                                           | Min, max       | 320, 320                    | 320, 1280         |

<div style=\"page-break-after: always\"></div>

| ADA category                                                   | Statistic      | Anifrolumab 120mg N = 176   | Placebo N = 170   |
|----------------------------------------------------------------|----------------|-----------------------------|-------------------|
| nAb prevalence (nAb positive at baseline and/or post-baseline) | n/Nobs [a] (%) | 0/110                       | 0/110             |
|                                                                | Median         | -                           | -                 |
|                                                                | Min, max       | -, -                        | -, -              |
| nAb incidence (treatment-induced nAb positive)                 | n/Nobs [b] (%) | 0/107                       | 0/105             |
|                                                                | Median         | -                           | -                 |
|                                                                | Min, max       | -, -                        | -, -              |

a Nobs is the number of patients with an ADA result at baseline and/or post-baseline. b Nobs is the number of patients with an ADA result at baseline and at least one post-baseline assessment. c Nobs is the number of patients with an ADA result at baseline. For IA, only first 220 randomized subjects are considered with data cut-off of May 28 2024. Summary statistics are calculated based on the maximum post-baseline titer for each ADA-positive patient within each treatment group, with the exception of the following categories: only baseline positive (based on the baseline titer) and ADA and nAb prevalence (based on the maximum titer, baseline or post-baseline). Post-baseline assessments include assessments on or after date of first dose. Baseline is the last non-missing value prior to administration of the first dose of IP. Percentages are based on Nobs. Titers of borderline positive measurements reported as &lt; = 40 (limit of detection) are imputed as 39.

Median ADA titers in the anifrolumab group were similar to or lower than those in placebo (range of 40.0 to  320.0  anifrolumab;  39.0  to  2560.0  placebo)  and  close  to  the  MRD  of  40.  The  ADA  titer  did  not consistently increase over time, suggesting that maturation of ADA did not occur .

Due  to  the  low  level  of  immunogenicity  the  effect  of  ADA  on  PK,  efficacy  or  safety  could  not  be conclusively  assessed  (for  further  information  see  specific  sections  for  PK  on  clinical  pharmacology discussion 2.6.3., and discussion on clinical efficacy 2.6.7. and discussion on clinical safety 2.6.9.)

## 2.6.8.8. Safety related to drug-drug interactions and other interactions

No drug interaction studies were conducted.

## Immunisations/Immune response

In  a  previous  variation  application,  the  MAH  submitted  the  final  study  report  for  the  NAÏVE  study D3461C00023/ESR-20-21053. This study was concluded to fulfil the Post-Authorisation Safety Category 3 study, pending only a commitment to update the Saphnelo PI texts. This PI text update is now provided within this variation.

The  NAÏVE  study  was  a  phase  I,  non-randomised,  multi-centre,  open-label,  parallel  group  study  to evaluate the potential impact of anifrolumab administered intravenously (IV) on the effectiveness of immune responses to seasonal influenza vaccination in women or men of any race between the ages of 18 and 70 years with active moderate to severe manifestations of SLE.

## 2.6.8.9. Discontinuation due to adverse events

In  TULIP  SC,  during  the  52-week  DB  treatment  period,  proportions  of  patients  with  AEs  leading  to discontinuation of treatment were low in the anifrolumab 120 mg SC QW and placebo groups with no PT predominating (Table 29 ).  One  additional  AE  leading  to  IP  discontinuation  (PT:  lupus  nephritis)  was identified as missing in the anifrolumab group after the interim clinical data lock.

Incidences of AEs leading to discontinuation of anifrolumab 120 mg SC QW treatment were similar to those observed with anifrolumab 300 mg IV Q4W treatment (Table 29 ).

<div style=\"page-break-after: always\"></div>

Table 29: All adverse events leading to discontinuation of IP - during double-blind treatment (SC vs IV Safety analysis set)

|                                      |              |     |          |                 |                 | Placebo   | Placebo   | Placebo         | Placebo         |                                                  |
|--------------------------------------|--------------|-----|----------|-----------------|-----------------|-----------|-----------|-----------------|-----------------|--------------------------------------------------|
| Preferred Term (MedDRA version 27.0) | Anifrolu mab | N   | n (%)    | Exposur e years | EAIR per 100 PY | N         | n (%)     | Exposu re years | EAIR per 100 PY | EAIR per 100 PY (Anifrolumab - Placebo) (95% CI) |
| Any AE leading to IP discontinuation | 120 mg SC    | 176 | 9 (5.1)  | 127.4           | 7.1             | 170       | 5 (2.9)   | 124.2           | 4.0             | 3.0 (-3.2, 9.9)                                  |
|                                      | 300 mg IV    | 459 | 19 (4.1) | 418.1           | 4.6             | 466       | 24 (5.2)  | 401.3           | 6.0             | -1.4 (-4.8, 1.8)                                 |
| Acute myocardial infarction          | 120 mg SC    | 176 | 1 (0.6)  | 128.5           | 0.8             | 170       | 0         | 124.7           | 0               | 0.8 (-2.3, 4.4)                                  |
|                                      | 300 mg IV    | 459 | 0        | 419.4           | 0               | 466       | 0         | 403.0           | 0               | 0.0 (-1.0, 0.9)                                  |
| Cerebrovascular accident             | 120 mg SC    | 176 | 1 (0.6)  | 128.5           | 0.8             | 170       | 0         | 124.7           | 0               | 0.8 (-2.3, 4.4)                                  |
|                                      | 300 mg IV    | 459 | 0        | 419.4           | 0               | 466       | 0         | 403.0           | 0               | 0.0 (-1.0, 0.9)                                  |
| Gastric ulcer                        | 120 mg SC    | 176 | 1 (0.6)  | 128.5           | 0.8             | 170       | 0         | 124.7           | 0               | 0.8 (-2.3, 4.4)                                  |
|                                      | 300 mg IV    | 459 | 0        | 419.4           | 0               | 466       | 0         | 403.0           | 0               | 0.0 (-1.0, 0.9)                                  |
| Gastrointestinal infection           | 120 mg SC    | 176 | 1 (0.6)  | 128.5           | 0.8             | 170       | 0         | 124.7           | 0               | 0.8 (-2.3, 4.4)                                  |
|                                      | 300 mg IV    | 459 | 0        | 419.4           | 0               | 466       | 0         | 403.0           | 0               | 0.0 (-1.0, 0.9)                                  |
| Herpes zoster                        | 120 mg SC    | 176 | 1 (0.6)  | 128.5           | 0.8             | 170       | 0         | 124.7           | 0               | 0.8 (-2.3, 4.4)                                  |
|                                      | 300 mg IV    | 459 | 2 (0.4)  | 419.3           | 0.5             | 466       | 0         | 403.0           | 0               | 0.5 (-0.4, 1.8)                                  |
| Hypersensitivity                     | 120 mg SC    | 176 | 1 (0.6)  | 128.5           | 0.8             | 170       | 0         | 124.7           | 0               | 0.8 (-2.3, 4.4)                                  |
|                                      | 300 mg IV    | 459 | 0        | 419.4           | 0               | 466       | 1 (0.2)   | 402.9           | 0.3             | -0.3 (-1.4, 0.7)                                 |
| Osteonecrosis                        | 120 mg SC    | 176 | 1 (0.6)  | 127.9           | 0.8             | 170       | 0         | 124.7           | 0               | 0.8 (-2.3, 4.4)                                  |
|                                      | 300 mg IV    | 459 | 0        | 419.4           | 0               | 466       | 0         | 403.0           | 0               | 0.0 (-1.0, 0.9)                                  |
| Pneumonia                            | 120 mg SC    | 176 | 1 (0.6)  | 128.5           | 0.8             | 170       | 0         | 124.7           | 0               | 0.8 (-2.3, 4.4)                                  |
|                                      | 300 mg IV    | 459 | 1 (0.2)  | 419.4           | 0.2             | 466       | 2 (0.4)   | 402.9           | 0.5             | -0.3 (-1.6, 0.9)                                 |
| Rheumatoid arthritis                 | 120 mg SC    | 176 | 1 (0.6)  | 128.5           | 0.8             | 170       | 0         | 124.7           | 0               | 0.8 (-2.3, 4.4)                                  |
|                                      | 300 mg IV    | 459 | 0        | 419.4           | 0               | 466       | 0         | 403.0           | 0               | 0.0 (-1.0, 0.9)                                  |
| Acute sinusitis                      | 120 mg SC    | 176 | 0        | 128.6           | 0               | 170       | 0         | 124.7           | 0               | 0.0 (-3.1, 3.0)                                  |
|                                      | 300 mg IV    | 459 | 1 (0.2)  | 419.4           | 0.2             | 466       | 0         | 403.0           | 0               | 0.2 (-0.7, 1.3)                                  |

<div style=\"page-break-after: always\"></div>

|                                      |              |     |         |                 |                 | Placebo   | Placebo   | Placebo         | Placebo         |                                                  |
|--------------------------------------|--------------|-----|---------|-----------------|-----------------|-----------|-----------|-----------------|-----------------|--------------------------------------------------|
| Preferred Term (MedDRA version 27.0) | Anifrolu mab | N   | n (%)   | Exposur e years | EAIR per 100 PY | N         | n (%)     | Exposu re years | EAIR per 100 PY | EAIR per 100 PY (Anifrolumab - Placebo) (95% CI) |
| Adnexa uteri cyst                    | 120 mg SC    | 176 | 0       | 128.6           | 0               | 170       | 0         | 124.7           | 0               | 0.0 (-3.1, 3.0)                                  |
|                                      | 300 mg IV    | 459 | 0       | 419.4           | 0               | 466       | 1 (0.2)   | 402.9           | 0.2             | -0.2 (-1.4, 0.7)                                 |
| Angioedema                           | 120 mg SC    | 176 | 0       | 128.6           | 0               | 170       | 0         | 124.7           | 0               | 0.0 (-3.1, 3.0)                                  |
|                                      | 300 mg IV    | 459 | 1 (0.2) | 419.3           | 0.2             | 466       | 0         | 403.0           | 0               | 0.2 (-0.7, 1.4)                                  |
| Atrial fibrillation                  | 120 mg SC    | 176 | 0       | 128.6           | 0               | 170       | 0         | 124.7           | 0               | 0.0 (-3.1, 3.0)                                  |
|                                      | 300 mg IV    | 459 | 0       | 419.4           | 0               | 466       | 1 (0.2)   | 403.0           | 0.3             | -0.3 (-1.4, 0.7)                                 |
| Bronchitis                           | 120 mg SC    | 176 | 0       | 128.6           | 0               | 170       | 0         | 124.7           | 0               | 0.0 (-3.1, 3.0)                                  |
|                                      | 300 mg IV    | 459 | 1 (0.2) | 419.4           | 0.2             | 466       | 0         | 403.0           | 0               | 0.2 (-0.7, 1.3)                                  |
| Cervical dysplasia                   | 120 mg SC    | 176 | 0       | 128.6           | 0               | 170       | 0         | 124.7           | 0               | 0.0 (-3.1, 3.0)                                  |
|                                      | 300 mg IV    | 459 | 1 (0.2) | 419.3           | 0.2             | 466       | 2 (0.4)   | 402.7           | 0.5             | -0.3 (-1.6, 0.9)                                 |
| Diverticulitis                       | 120 mg SC    | 176 | 0       | 128.6           | 0               | 170       | 0         | 124.7           | 0               | 0.0 (-3.1, 3.0)                                  |
|                                      | 300 mg IV    | 459 | 1 (0.2) | 419.3           | 0.2             | 466       | 0         | 403.0           | 0               | 0.2 (-0.7, 1.3)                                  |
| Ecchymosis                           | 120 mg SC    | 176 | 0       | 128.6           | 0               | 170       | 0         | 124.7           | 0               | 0.0 (-3.1, 3.0)                                  |
|                                      | 300 mg IV    | 459 | 1 (0.2) | 419.4           | 0.2             | 466       | 0         | 403.0           | 0               | 0.2 (-0.7, 1.3)                                  |
| Extrapulmonary tuberculosis          | 120 mg SC    | 176 | 0       | 128.6           | 0               | 170       | 1 (0.6)   | 124.6           | 0.8             | -0.8 (-4.5, 2.2)                                 |
|                                      | 300 mg IV    | 459 | 0       | 419.4           | 0               | 466       | 0         | 403.0           | 0               | 0.0 (-1.0, 0.9)                                  |
| Face oedema                          | 120 mg SC    | 176 | 0       | 128.6           | 0               | 170       | 0         | 124.7           | 0               | 0.0 (-3.1, 3.0)                                  |
|                                      | 300 mg IV    | 459 | 1 (0.2) | 419.2           | 0.2             | 466       | 0         | 403.0           | 0               | 0.2 (-0.7, 1.4)                                  |
| Follicular lymphoma                  | 120 mg SC    | 176 | 0       | 128.6           | 0               | 170       | 0         | 124.7           | 0               | 0.0 (-3.1, 3.0)                                  |
|                                      | 300 mg IV    | 459 | 1 (0.2) | 419.4           | 0.2             | 466       | 0         | 403.0           | 0               | 0.2 (-0.7, 1.4)                                  |
| Gastroenteritis                      | 120 mg SC    | 176 | 0       | 128.6           | 0               | 170       | 0         | 124.7           | 0               | 0.0 (-3.1, 3.0)                                  |
|                                      | 300 mg IV    | 459 | 0       | 419.4           | 0               | 466       | 1 (0.2)   | 402.8           | 0.3             | -0.3 (-1.4, 0.7)                                 |
| Headache                             | 120 mg SC    | 176 | 0       | 128.6           | 0               | 170       | 0         | 124.7           | 0               | 0.0 (-3.1, 3.0)                                  |
|                                      | 300 mg IV    | 459 | 1 (0.2) | 419.4           | 0.2             | 466       | 0         | 403.0           | 0               | 0.2 (-0.7, 1.4)                                  |

<div style=\"page-break-after: always\"></div>

|                                       |              |     |         |                 |                 | Placebo   | Placebo   | Placebo         | Placebo         |                                                  |
|---------------------------------------|--------------|-----|---------|-----------------|-----------------|-----------|-----------|-----------------|-----------------|--------------------------------------------------|
| Preferred Term (MedDRA version 27.0)  | Anifrolu mab | N   | n (%)   | Exposur e years | EAIR per 100 PY | N         | n (%)     | Exposu re years | EAIR per 100 PY | EAIR per 100 PY (Anifrolumab - Placebo) (95% CI) |
| Hypertensive emergency                | 120 mg SC    | 176 | 0       | 128.6           | 0               | 170       | 0         | 124.7           | 0               | 0.0 (-3.1, 3.0)                                  |
|                                       | 300 mg IV    | 459 | 0       | 419.4           | 0               | 466       | 1 (0.2)   | 403.0           | 0.3             | -0.3 (-1.4, 0.7)                                 |
| Influenza like illness                | 120 mg SC    | 176 | 0       | 128.6           | 0               | 170       | 0         | 124.7           | 0               | 0.0 (-3.1, 3.0)                                  |
|                                       | 300 mg IV    | 459 | 0       | 419.4           | 0               | 466       | 2 (0.4)   | 402.9           | 0.5             | -0.5 (-1.8, 0.4)                                 |
| Infusion related reaction             | 120 mg SC    | 176 | 0       | 128.6           | 0               | 170       | 0         | 124.7           | 0               | 0.0 (-3.1, 3.0)                                  |
|                                       | 300 mg IV    | 459 | 0       | 419.4           | 0               | 466       | 1 (0.2)   | 402.9           | 0.3             | -0.3 (-1.4, 0.7)                                 |
| Lupus nephritis                       | 120 mg SC    | 176 | 0       | 128.6           | 0               | 170       | 0         | 124.7           | 0               | 0.0 (-3.1, 3.0)                                  |
|                                       | 300 mg IV    | 459 | 0       | 419.4           | 0               | 466       | 1 (0.2)   | 402.9           | 0.2             | -0.2 (-1.4, 0.7)                                 |
| Lupus vasculitis                      | 120 mg SC    | 176 | 0       | 128.6           | 0               | 170       | 1 (0.6)   | 124.6           | 0.8             | -0.8 (-4.5, 2.2)                                 |
|                                       | 300 mg IV    | 459 | 0       | 419.4           | 0               | 466       | 0         | 403.0           | 0               | 0.0 (-1.0, 0.9)                                  |
| Migraine                              | 120 mg SC    | 176 | 0       | 128.6           | 0               | 170       | 0         | 124.7           | 0               | 0.0 (-3.1, 3.0)                                  |
|                                       | 300 mg IV    | 459 | 1 (0.2) | 419.4           | 0.2             | 466       | 0         | 403.0           | 0               | 0.2 (-0.7, 1.4)                                  |
| Myasthenia gravis                     | 120 mg SC    | 176 | 0       | 128.6           | 0               | 170       | 0         | 124.7           | 0               | 0.0 (-3.1, 3.0)                                  |
|                                       | 300 mg IV    | 459 | 1 (0.2) | 419.4           | 0.2             | 466       | 0         | 403.0           | 0               | 0.2 (-0.7, 1.4)                                  |
| Mycobacterium avium complex infection | 120 mg SC    | 176 | 0       | 128.6           | 0               | 170       | 0         | 124.7           | 0               | 0.0 (-3.1, 3.0)                                  |
|                                       | 300 mg IV    | 459 | 1 (0.2) | 419.3           | 0.2             | 466       | 0         | 403.0           | 0               | 0.2 (-0.7, 1.4)                                  |
| Myelitis transverse                   | 120 mg SC    | 176 | 0       | 128.6           | 0               | 170       | 0         | 124.7           | 0               | 0.0 (-3.1, 3.0)                                  |
|                                       | 300 mg IV    | 459 | 1 (0.2) | 419.3           | 0.2             | 466       | 0         | 403.0           | 0               | 0.2 (-0.7, 1.3)                                  |
| Myocardial ischaemia                  | 120 mg SC    | 176 | 0       | 128.6           | 0               | 170       | 0         | 124.7           | 0               | 0.0 (-3.1, 3.0)                                  |
|                                       | 300 mg IV    | 459 | 0       | 419.4           | 0               | 466       | 1 (0.2)   | 403.0           | 0.3             | -0.3 (-1.4, 0.7)                                 |
| Nephritis                             | 120 mg SC    | 176 | 0       | 128.6           | 0               | 170       | 0         | 124.7           | 0               | 0.0 (-3.1, 3.0)                                  |
|                                       | 300 mg IV    | 459 | 1 (0.2) | 419.2           | 0.2             | 466       | 0         | 403.0           | 0               | 0.2 (-0.7, 1.4)                                  |
| Optic neuritis                        | 120 mg SC    | 176 | 0       | 128.6           | 0               | 170       | 0         | 124.7           | 0               | 0.0 (-3.1, 3.0)                                  |
|                                       | 300 mg IV    | 459 | 0       | 419.4           | 0               | 466       | 1 (0.2)   | 402.7           | 0.3             | -0.3 (-1.4, 0.7)                                 |

<div style=\"page-break-after: always\"></div>

|                                      |              |     |         |                 |                 | Placebo   | Placebo   | Placebo         | Placebo         |                                                  |
|--------------------------------------|--------------|-----|---------|-----------------|-----------------|-----------|-----------|-----------------|-----------------|--------------------------------------------------|
| Preferred Term (MedDRA version 27.0) | Anifrolu mab | N   | n (%)   | Exposur e years | EAIR per 100 PY | N         | n (%)     | Exposu re years | EAIR per 100 PY | EAIR per 100 PY (Anifrolumab - Placebo) (95% CI) |
| Pulmonary alveolar haemorrhage       | 120 mg SC    | 176 | 0       | 128.6           | 0               | 170       | 0         | 124.7           | 0               | 0.0 (-3.1, 3.0)                                  |
|                                      | 300 mg IV    | 459 | 0       | 419.4           | 0               | 466       | 1 (0.2)   | 402.9           | 0.3             | -0.3 (-1.4, 0.7)                                 |
| Retinal disorder                     | 120 mg SC    | 176 | 0       | 128.6           | 0               | 170       | 0         | 124.7           | 0               | 0.0 (-3.1, 3.0)                                  |
|                                      | 300 mg IV    | 459 | 1 (0.2) | 419.2           | 0.2             | 466       | 0         | 403.0           | 0               | 0.2 (-0.7, 1.3)                                  |
| Skin wound                           | 120 mg SC    | 176 | 0       | 128.6           | 0               | 170       | 1 (0.6)   | 124.6           | 0.8             | -0.8 (-4.5, 2.2)                                 |
|                                      | 300 mg IV    | 459 | 0       | 419.4           | 0               | 466       | 0         | 403.0           | 0               | 0.0 (-1.0, 0.9)                                  |
| Syncope                              | 120 mg SC    | 176 | 0       | 128.6           | 0               | 170       | 0         | 124.7           | 0               | 0.0 (-3.1, 3.0)                                  |
|                                      | 300 mg IV    | 459 | 1 (0.2) | 419.3           | 0.2             | 466       | 0         | 403.0           | 0               | 0.2 (-0.7, 1.3)                                  |
| Systemic lupus erythematosus         | 120 mg SC    | 176 | 0       | 128.6           | 0               | 170       | 0         | 124.7           | 0               | 0.0 (-3.1, 3.0)                                  |
|                                      | 300 mg IV    | 459 | 0       | 419.4           | 0               | 466       | 6 (1.3)   | 402.6           | 1.5             | -1.5 (-3.3, -0.5)                                |
| Thrombocytopenia                     | 120 mg SC    | 176 | 0       | 128.6           | 0               | 170       | 1 (0.6)   | 124.5           | 0.8             | -0.8 (-4.5, 2.2)                                 |
|                                      | 300 mg IV    | 459 | 0       | 419.4           | 0               | 466       | 0         | 403.0           | 0               | 0.0 (-1.0, 0.9)                                  |
| Upper respiratory tract infection    | 120 mg SC    | 176 | 0       | 128.6           | 0               | 170       | 0         | 124.7           | 0               | 0.0 (-3.1, 3.0)                                  |
|                                      | 300 mg IV    | 459 | 1 (0.2) | 419.4           | 0.2             | 466       | 0         | 403.0           | 0               | 0.2 (-0.7, 1.4)                                  |
| Urticaria                            | 120 mg SC    | 176 | 0       | 128.6           | 0               | 170       | 1 (0.6)   | 124.6           | 0.8             | -0.8 (-4.5, 2.2)                                 |
|                                      | 300 mg IV    | 459 | 0       | 419.4           | 0               | 466       | 0         | 403.0           | 0               | 0.0 (-1.0, 0.9)                                  |
| Uterine cancer                       | 120 mg SC    | 176 | 0       | 128.6           | 0               | 170       | 0         | 124.7           | 0               | 0.0 (-3.1, 3.0)                                  |
|                                      | 300 mg IV    | 459 | 0       | 419.4           | 0               | 466       | 1 (0.2)   | 402.9           | 0.3             | -0.3 (-1.4, 0.7)                                 |
| Varicose vein                        | 120 mg SC    | 176 | 0       | 128.6           | 0               | 170       | 0         | 124.7           | 0               | 0.0 (-3.1, 3.0)                                  |
|                                      | 300 mg IV    | 459 | 0       | 419.4           | 0               | 466       | 1 (0.2)   | 403.0           | 0.3             | -0.3 (-1.4, 0.7)                                 |

EAIR is defined as the sum of subjects with the event/[sum across subjects' time at risk for the event /(365.25)] * 100, where time at risk is time to first event for subjects who experienced the event during the analysis period and time during the analysis period for subjects who do not experience the event. In the event that multiple studies are combined, the Miettinen and Nurminen weighted average EAIRs are presented for each treatment group. 95% CIs are calculated via the Miettinen and Nurminen method, stratified by study where applicable. During double-blind treatment: Includes adverse events with an onset date on or after the date of first dose of IP up to and including 28 days following the date of last double-blind IP dose. Subjects with multiple occurrences of the same preferred term are counted once regardless of the number of occurrences. Table is sorted by decreasing frequency on preferred term level in Anifrolumab 120 mg treatment group n Number of subjects per category; N Number of subjects per treatment group.

<div style=\"page-break-after: always\"></div>

## 2.6.8.10. Post marketing experience

Anifrolumab is approved for the treatment of moderate to severe SLE in over 65 countries. A summary of safety data from post-marketing sources is presented in the Periodic Benefit-Risk Evaluation Report/EU Periodic Safety Update Reports provided to regulatory agencies on a regular basis. The cumulative global post-marketing patient exposure to anifrolumab is estimated to be 16,124 PY, from 30 July 2021 to 30 June 2024.

The MAH has safety reporting procedures that are designed to meet regulatory requirements worldwide. Safety surveillance activities for anifrolumab are conducted on an ongoing basis and include an analysis of data in clinical studies, published literature, data in MAH's safety database, and data available from other sources.

## 2.6.8.1. Human Factors Engineering (HFE)

## Accessorised prefilled syringe (APSF)

Medical devises document summarises the Human Factors Engineering (HFE) process related to design and development of the APFS, which includes formative evaluations, user interface design iterations, summative evaluation, and integration with Risk Management (RM).

The  Notified  Body  Opinion  described  the  Assessment  of  the  General  Safety  and  Performance Requirements (GSPR) of clinical issues regarding the device. The evaluated documents included, among other documents: Hazard Assessment anifrolumab APFS, Summary of Human Factors Engineering for Notified Body Anifrolumab APFS, Instructions for Use for Anifrolumab Accessorised Pre-filled Syringe, Summary of Post Market Data and Literature for Similar Prefilled Syringes Anifrolumab Accessorised Prefilled  Syringe,  Risk  Management  Plan  for  Accessorised  Pre-Filled  Syringe  for  MEDl-546  and  Risk Management  Summary  Report  for  an  Accessorised  Pre-Filled  Syringe  for  anifrolumab  120mg/0.8ml (anifrolumab) 120 mg / 0.8 ml.

Three formative evaluations were performed.

A formative study was conducted to compare three SSI APFS variants, one equipped with a manual safety feature (BO UltraSafe Needle Guard Device) and two equipped with automatic NSD (BO UltraSafe Passive Needle Guard and BD UltraSafe Plus Needle Guard) by using simulated use assessment. The participants consisted of 12 HCPs and 6 adult SLE patients. Participants were asked to perform simulated injections with three devices without training.

APFS  Formative  Usability  Study  #1  was  conducted  to  demonstrate  safe  and  effective  use  of  the commercial design of anifrolumab APFS by adult SLE patients in a non-clinical (e.g., home) environment. The study was conducted to assess the usability of the APFS, including its secondary packaging and labeling.  Participants in the study included 9 adult SLE patients, 4 of which were injection naive and 5 which were injection experienced.

A second APFS Formative Usability Study #2 was conducted using simulated use and knowledge-based assessments to evaluate the IFU and packaging changes. Participants in the study included 35 patients with chronic diseases.

As  outcome  of  the  formative  studies  conducted  design  modifications  were  implemented  in  the  user interface, and IFU.

The  HF  validation  study  with  45  participants  including  adult  patients  and  caregivers  in  simulated conditions was conducted and use-related risks analysis (URRA) was performed.

<div style=\"page-break-after: always\"></div>

A review of known use problems with similar devices was conducted by reviewing complaint databases, product  recalls,  safety  reports  and  literature.  Known  issues  identified  were  mitigated  with  design modifications.

Potential clinical hazards and hazardous associated with the use of the anifrolumab APFS were identified by a cross-functional risk management team, including clinical and patient safety representatives, and documented.

The applicant claims that the results of summative evaluation show that the device user interface has been optimized and the residual user related risks have been mitigated as far as possible. The design of the device user interface supports users in safely, accurately, and effectively administering a dose.

Risk management activities including clinical risks, and usability were conducted with a positive outcome considering the device part risk benefit. In addition, the manufacturer conducted postmarked clinical activities with acceptable sources, no additional risks were identified by the manufacturer.

## Autoinjector (AI)

The  Notified  Body  Opinion  described  the  Assessment  of  the  General  Safety  and  Performance Requirements (GSPR) of clinical  issues  regarding  the  AI  device.  The  evaluated  documents  included, among other documents: Risk Management Summary Report, Summary of Human Factors Engineering for  Notified  Body,  Instructions  for  Use  (IFU),  Human-factors-anifrolumab-ai,  General-safety-andperformance-requirements-mdr-(eu)-2017-745-anifrolumab-ai, Risk-management-plan-ai, hazardassessment,  General  Safety  and  Performance  Requirements  (MDR  (EU)  Anifrolumab  Autoinjector containing  an  overview  of  the  applicable  and  non-applicable  General  Safety  and  Performance Requirements.

Summary of Post Market Data and Literature for Similar devices reviews Known Use Problems with Similar Devices, complaints data search (MAUDE and MedSun- covering a 3 years period), Published Regulatory Review Summaries: Use Errors Reported in Regulatory Review Summaries,  literature (range of  issues  with  autoinjectors  in  general),  DESIGN  MODIFICATIONS  IMPLEMENTED  IN  RESPONSE  TO KNOWN ISSUES incl. an overview of updates done within the instruction for use and reference to those literature data.

Two formative studies have been performed:

Study #1 evaluated two revisions of IFUs accompanying an Ypsomed YpsoMate AI by intended untrained user populations (3 HCP, 3 caregivers and 16 patients) in two different phases. Based on this result the instruction for use was improved.

Study #2 Formative Human Factors Study for Platform: to Demonstrate safe and effective use of the commercial  design  of  the  anifrolumab N=19  untrained  adult  participants.  Based  on  the  result  the instruction for use was updated.

The outcomes of the formative evaluations were incorporated into the Use-Related Risk Assessment (URRA) and used to inform the selection of the device and the design and content of the commercial labelling and packaging that were used for summative evaluation.

A total of 32 participants, including adult patients and caregivers were included in the Summative Study. Adult patients (ages 18 years and older) with moderate to severe SLE performing self-administration, caregivers  of  patients  with  SLE  performing  administration  to  patients  and  Healthcare  Professionals (HCPs)  were  considered.    Intended  that  patients  and  caregivers  will  use  theAI  in  a  non-clinical environment, most commonly at home.

<div style=\"page-break-after: always\"></div>

Anifrolumab  AI  development  and  risk  management  was  conducted  with  consideration  of  the  target patient population. Device use by lay users, including use by patients and caregivers, was evaluated in the  formative  and  summative  studies.  SLE,  RA  and  OA  patients  (6  injection  naïve  and  5  injection experienced) were recruited in these studies. RA/OA patients can be considered the worst case in terms of physical capabilities when compared to SLE patients due to the dexterity impairments associated with RA/OA.  The  results  of  the  HF  summative  study  fed  into  the  evaluation  of  errors  associated  with performing use steps in the use FMEA. Additionally, the device was designed with redundant feedback mechanisms, including visual and auditory indications of delivery progress during an injection to support users delivering a full dose, including those with audible impairments. During the HF summative study, the device was validated with the final device design, and results were incorporated into the use FMEA.

Residual Risk for Health Care Professionals (HCP) and Home Use was reviewed and the process risk assessment covering the complete activity of the treatment by the patient and the health care personal. As an outcome from the human engineering study no separate training is needed for using the auto injector.

## 2.6.9. Discussion on clinical safety

Within  this  extension  application,  the  MAH  is  proposing  a  new  route  of  administration,  Saphnelo (anifrolumab) 120 mg SC QW as an add on therapy for the treatment of adult patients with moderate to severe, active autoantibody positive systemic lupus erythematosus (SLE), despite standard therapy. The safety data derive mainly from the single, pivotal, phase 3 study, randomized, double-blind, multicenter, parallel-group, placebo-controlled TULIP SC study. This study was on-going during the procedure and final results are expected in the last quarter of the current year 2025. This variation was based on an interim analysis (IA) of a study sample of 346 SLE patients of the planned 367 (94%) safety population (for detailed discussion on the IA, see the efficacy section 2.6.5).

The MAH has provided a commitment of submitting the final full 52 week safety results of this study, a discussion and an update of the PI, once available (1Q2026).

## TULIP SC study (D3465C00001)

This pivotal Phase 3 study (fixed dose 120 mg weekly) targeted a similar average belimumab exposure as the 300 mg IV dose, which is marketed, and a SLE population consistent with the population studied in the phase 3 IV studies. Accordingly, the same potential and identified risks, as well as AEs of special interest (AESI) that apply to the IV product were also prospectively defined for the SC development programme, now complemented with those inherent to the new mode of administration, which included local and systemic injection related reactions. This approach was endorsed by the CHMP.

The  analysis  of  safety  data  was  based  on  the  52-week  double-blind  treatment  period,  including  all available data up to the data cut off for the IA (23 July 2024), irrespective of whether they are ongoing in the study, have completed the 52-week double-blind treatment period, or have withdrawn from the study early (Safety Analysis Set, N = 346). All safety analyses for the 52-week double blind treatment period were performed using the Safety Analysis Set, which included all patients who received at least one dose of the IMP. All patients (N = 367) were randomized prior to the IA clinical data-lock. Limited safety data from the open-label extension (OLE) period is also available.

To confirm that the safety of anifrolumab 120 mg SC QW was consistent with the established profile for anifrolumab 300 mg IV Q4W for up to 52 weeks of double-blind treatment, pooled safety data from 2 Phase  III  studies  D3461C00004  and  D3461C00005,  and  one  Phase  II  study  CD-IA-MEDI-546-1013 (hereafter referred to as studies 04, 05, and 1013, respectively) are presented side-by-side with the

<div style=\"page-break-after: always\"></div>

TULIP SC data. This approach of evaluating safety in the context of the previous IV studies was endorsed by the CHMP.

The SC Safety Analysis Set included patients with a wider range of exposure times than those included in the IA FAS, the analysis set for assessment of efficacy (N = 220), as not all patients had completed the double-blind treatment period or withdrawn from the study early. Thus, a subset of AE analyses were also conducted for the population of 220 patients only (referred to as the SC 220 Safety Analysis Set). This was to confirm conclusions drawn from the comparison of SC and IV EAIR (exposure adjusted AEs) in a population where most patients had completed the 52 week double-blind treatment period.

## Exposure

Anifrolumab 120 mg was administered by subcutaneous (SC) injection in a 1 mL APFS with 0.8 mL fill volume. The safety assessment was based on an IA of the 346 (94%) patients in TULIP SC study. The maximum planned duration of the double-blind treatment period was 52 weeks. The total PY of treatment exposure to anifrolumab 120 mg SC was 128.56 PY and was similar between the anifrolumab and placebo groups (median duration of exposure 359.0 and 362.0 days, respectively). Thus, drug exposure was similar across study groups in the pivotal clinical study, enabling meaningful comparisons. The overall extent of exposure at the approved or intended dosing regimen was considered adequate to assess the overall safety profile of SC administered anifrolumab 120 mg QW, considering the previously established safety  profile  for  anifrolumab  administered  IV  Q4W.  The  MAH  provided  a  commitment  within  this procedure to submit the final CSR of the pivotal study TULIP SC once available (1Q2026) including an update of the SC anifrolumab SmPC.

## Baseline information

The baseline demographic characteristic were in general well balanced between the treatment groups also for the IA Safety Analysis Set (N=346) subpopulation. An imbalance in the disease related baseline data was observed. Considering only slight differences in the SLE disease severity between the study groups, and a clear imbalance in the use of SLE-related treatments was seen, with higher use in the anifrolumab treatment group. Further analyses (summaries of AEs by category for the TULIP SC safety analysis set by baseline SLEDAI-2K, immunosuppressant use, and OCS dose) and detailed discussion revealed no clear untoward effect of these baseline imbalances on the safety results and inferences made, and no further text amendments were deemed necessary to section 4.4 of the currently presented SmPC.

## Adverse events

The overall incidence of AE during the double-blind treatment period of the TULIP SC study was similar between the treatment groups, 74.4% in the anifrolumab 120 mg SC group and 71.2% in the placebo group. Most AEs were mild to moderate in intensity. Consistently with previous data and the mode of action of anifrolumab the most common AEs (frequency &gt; 5%) were nasopharyngitis (10.8% patients), COVID-19 (9.1% patients), and upper respiratory infection (8.0% patients) in anifrolumab 120 mg SC group  compared  with  nasopharyngitis  (9.4%  patients),  injection  site  erythema  (8.8%  patients), bronchitis (7.6% patients) and urinary tract infection (7.6% of patients) in placebo group.

## Related adverse events

Overall, also the incidence and type of ADR in the SC safety study appeared similar to that of the IV safety profile. No new ADRs , inherent to the new route of administration, wereidentified from the data available.

## AESIs

<div style=\"page-break-after: always\"></div>

In line with the known anifrolumab safety profile, the incidence of serious infections was higher in the anifrolumab treatment group than in the placebo group. Two events of serious infections resulted in discontinuation in the anifrolumab treatment group. No opportunistic infections were reported.

Also consistent with the known safety profile of anifrolumab 300 mg IV, patients in the anifrolumab SC group had an increased incidence of herpes zoster. Most events were cutaneous, localised, nonserious, mild or moderate in intensity, resolved with antiviral therapy, and did not lead to investigational product discontinuation.

A  total  of  2  AESIs  of  tuberculosis  were  reported,  one  in  the  anifrolumab  120  mg  SC  group  (latent tuberculosis), the only one of the two considered related to the study treatment, and one in the placebo group (extrapulmonary tuberculosis).

The 3 MACE events reported, 2 in the anifrolumab group (acute myocardial infarction, cerebrovascular accident) and one in the placebo group (acute myocardial infarction) were judged not to be related to the IMP.

No malignancies were reported during the 52-week double-blind treatment period.

Overall, the above-mentioned findings on these AESIs are adequately reflected in the proposed SC PI (please see Saphnelo SmPC).

The numbers of patients with the AESI of injection site reactions (ISR) were similar in the anifrolumab group  and  the  placebo  group.  All  injection  site  reaction  AESIs  were  nonserious,  mild/moderate  in intensity, and transient in nature. None resulted in discontinuation of investigational product. However, most  of  the  ISR  reported  meeting  narrative  criteria,  were  considered  related  to  the  anifrolumab treatment. This AESI inherent to the new route of administration is currently judged not related to the IMP.

The rate for hypersensitivity reactions with anifrolumab 120 mg SC was low (2 patients in the anifrolumab 120  mg  SC  group  and  no  patients  in  the  placebo  group).  One  of  the  hypersensitivity  AEs  led  to discontinuation of IP and was assessed by the investigator as possibly related to IP (see discontinuations below). This was incorrectly stated in the SC SmPC, but the text was subsequently corrected. In the anifrolumab SC SmPC a threshold of 5% was used for ADRs inclusion. The MAH explained that also the rarer TEAEs have undergone causality assessment and there is no need for revision of the PI texts. This was agreed on by the CHMP. There were no events of anaphylactic reactions in this patient sample.

## Serious adverse events

The proportions of patients with SAEs were low and similar between the anifrolumab and placebo groups with no clustering seen during the 52-week treatment period. The most common system organ class (SOC) with reported SAEs was 'Infections and infestations' in both the anifrolumab 120 mg SC and in the placebo groups.

## Deaths

Up to the date of the interim clinical data lock, one outcome of death (PT, gastrointestinal infection) was reported in the anifrolumab treatment group and none in the placebo group. The event (was assessed as not possibly related to anifrolumab treatment by the Investigator and considered to be related to the patient's underlying conditions. However, as SC administration is designed for at-home use, and any risk of unrecognised or unmanaged serious infection poses greater concern. The MAH discussed this case in further detail and justified acceptably that further precautionary texts were not considered necessary in the PI.

<div style=\"page-break-after: always\"></div>

## Laboratory and other findings

The clinical laboratory results as well as observations related to vital signs for the study pivotal study was consistent with the IV formulation and no clinically meaningful. There were no new safety concerns.

## Safety in special populations

- Intrinsic Factors: The AE and SAE profile of anifrolumab 120 mg SC QW was generally consistent across pre-defined subgroups (sex, age, race, BMI, disease-related factors, and ADA status) based on analyses of AEs by category, common AEs, and SAEs, although there were small numbers of patients in some subgroups.

Adverse Events by Anti-drug Antibody Status: Anifrolumab administered SC is poorly immunogenic in patients with moderate to severe SLE. There was no apparent effect of ADA-positive status on the overall incidence of AEs in TULIP SC, but due to very small numbers of ADA-positive patients, it is not possible to draw firm conclusions.

Extrinsic Factors: The AE and SAE profile of anifrolumab 120 mg SC QW was generally consistent across the pre-defined geographic region subgroups (Asia Pacific, Europe, Latin America, US/Canada, Rest of World) and concomitant medication use at baseline (immunosuppressant use) based on analyses of AEs by category, common AEs, and SAEs.

ADRs  in  special  populations:  According  to  the  MAH  incidences  of  ADRs,  with  anifrolumab  120 mg administered SC QW was consistent with the established safety profile of anifrolumab 300 mg Q4W administered by IV infusion. Collated data on the subgroups of special populations were not presented.

The  ADRs  identified  for  anifrolumab  are  not  based  on  route  of  administration  and  are  based  on  an evaluation of all studied populations. Based on all assessments and the rationale presented there is no reason to believe that any special population would be at any increased risk for any of the ADRs identified.

## Discontinuations

The proportions of patients with AEs leading to IP discontinuation were low, and slightly higher in the treatment group (5.1% in the anifrolumab group and 2.9% in the placebo group). By PT, they were single occurrence, thus untoward clustering was not evident. From further clarification by the MAH, no new safety concerns arose.

## Immunisations/Immune response

The MAH has, within this extension application, also provided a text update of sections 4.4 and 4.5 of the Saphnelo SmPC, to inform healthcare practitioners of the availability of the results from the NAÏVE study (a Post-Authorisation Safety Category 3 study). The provided results of this study showed that overall,  acknowledging  the  possible  limitations  of  the  study,  the  humoral  antibody  responses,  as measured by HAI titres and anti-influenza virus vaccine IgG concentrations, following the quadrivalent influenza virus vaccination appear similar between patients with moderately to severely active SLE who initiated anifrolumab at baseline in addition to SoC (n=19), or received SoC only (n=6).

Thetext update was a commitment from a previous variation EMEA/H/C/004975/II/0020. The proposed texts  concerning  the  results  of  the  NAÏVE  study  are  acceptable  verbatim  and  the  commitment  is recommended for approval. As per EMA advice during the previous variation, an update of the RMP to remove this Category 3 study following its completion, can be done at the next regulatory procedure affecting the RMP, after approval of this variation application.

<div style=\"page-break-after: always\"></div>

## ADA levels in SC studies

Taken together, data from both SC studies (TULIP SC and the Device bridging study) are consistent with the  previously  reported  low  immunogenicity  risk  profile  of  anifrolumab  in  IV  studies  and  they demonstrate a low immunogenicity of anifrolumab also when it is administered subcutaneously.

Due  to  the  low  level  of  immunogenicity  the  effect  of  ADA  on  PK,  efficacy  or  safety  could  not  be conclusively  assessed  (for  further  information  see  specific  sections  for  PK  on  clinical  pharmacology discussion 2.6.3., and discussion on clinical efficacy 2.6.7. and discussion on clinical safety 2.6.9.)

## Post-marketing experience

Overall, AEs received from post-marketing sources were generally consistent with those observed in clinical studies of anifrolumab. Arthralgia has been included as an ADR in the prescribing information (with unknown frequency) based on post-marketing information. On the data from the reporting period of the latest PSUR period, it was concluded that the benefit/risk profile of belimumab continued to be positive.

## Other

The safety profile of anifrolumab 120 mg SC QW appeared generally consistent with the established safety  profile  of  anifrolumab  300  mg  IV  Q4W,  acknowledging  the  inherent  limitations  of  post  hoc, between-study comparisons.

The results  of  the  safety  analysis  on  the  subset  of  AE  analyses  (the  analysis  set  for  assessment  of efficacy; N = 220), conducted for the population of 220 patients only (the SC 220 Safety Analysis Set) overall appeared to support the conclusions drawn from the comparison of SC and IV EAIR in a population where most patients had completed the 52 week double-blind treatment period i.e. in the patients with a wider range of exposure times (Safety Analysis Set).

## Human Factors Engineering (HFE)

Risk  review  concluded  positive  benefit-risk  profile  for  Accessorized  prefilled  syringe  (APSF).  Design verification  and  HFE  activities  demonstrated  that  the  design  input  requirements,  user  needs,  and intended uses have been met and that the product is safe and effective for its intended use. Device normal conditions of use was included in IFU.

Based on the outcome of the human factors evaluation of the autoinjector no training will be defined for the patients or caregivers besides the instructions outlined in the IFU. Human Factors summative study concluded that the AI can be used by the intended users without serious use errors or problems, for the intended use and under the expected use conditions.

The  MAH  provided  the  medical  device  document  (module  3.2.R)  and  notified  body  opinion  for  an Accessorised prefilled syringe (APSF) and Autoinjector (AI). These documents describe the engineering and optimization of the devices, user interface, instructions of use and risk minimisation of the use. Risk review concluded positive benefit-risk profile.  Based on these the APSF and AI can be used safely and effectively by the intended user populations in the expected use environments. No training will be defined for the patients or caregivers besides the instructions outlined in the IFU.

From the safety database all the adverse reactions reported in clinical studies and post-marketing have been included in the Summary of Product Characteristics.

<div style=\"page-break-after: always\"></div>

## 2.6.10. Conclusions on the clinical safety

In the pivotal phase 3 TULIP SC study, anifrolumab 120 mg SC QW appeared well tolerated during 52 weeks of treatment, in adult patients with moderate to severe, active SLE. No new safety concerns or ADRs were identified. The safety profile of anifrolumab 120 mg SC QW appeared generally consistent with the established safety profile of anifrolumab 300 mg IV Q4W, acknowledging the inherent limitations of post hoc, between-study comparisons.

As these results are based on an IA, the MAH provided a commitment of submitting the final full 52 weeks safety results of this study, a discussion on the results and an update of the PI, once available (1Q2026 ) .

The commitment of a Saphnelo SmPC text update (EMEA/H/C/004975/II/0020) with the results of a Post-Authorisation Safety Category 3 study, the NAÏVE study, has been submitted within this procedure and is considered acceptable and recommended for approval.

From a safety perspective the application for marketing authorisation for anifrolumab 120 mg SC QW in the proposed indication is approvable.

## 2.7. Risk Management Plan

## 2.7.1. Safety concerns

## Summary of safety concerns

## Table 30: Summary of safety concerns

| Summary of safety concerns   | Summary of safety concerns              |
|------------------------------|-----------------------------------------|
| Important potential risks    | Malignancy Serious infection            |
| Missing information          | Use in pregnant and breastfeeding women |

## 2.7.2. Pharmacovigilance plan

<div style=\"page-break-after: always\"></div>

Table 31: Ongoing and additional pharmacovigilance activities

| Study Status                                                                                                                                                                                             | Summary of objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Safety concerns addressed                                     | Milestones                                                    | Due dates                                                     |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                            | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities |
| D3461R00028 A Non- Interventional Multi- Database Post Authorisation Study to Assess Pregnancy- Related Safety Data from Women with SLE Exposed to Anifrolumab Ongoing D3461R00046 A non- interventional | The aim of this study is to describe the congenital malformations, adverse pregnancy and birth outcomes in pregnancies/offspring from women with moderate/severe SLE exposed to anifrolumab during pregnancy and to compare with outcomes in women with moderate/severe SLE who are exposed to other SOC but not anifrolumab. Adverse outcomes related to infant growth up to one year of age will also be investigated.                                                                                                                                             | Use in pregnant women                                         | Study protocol submission                                     | August 2022                                                   |
| D3461R00028 A Non- Interventional Multi- Database Post Authorisation Study to Assess Pregnancy- Related Safety Data from Women with SLE Exposed to Anifrolumab Ongoing D3461R00046 A non- interventional | The aim of this study is to describe the congenital malformations, adverse pregnancy and birth outcomes in pregnancies/offspring from women with moderate/severe SLE exposed to anifrolumab during pregnancy and to compare with outcomes in women with moderate/severe SLE who are exposed to other SOC but not anifrolumab. Adverse outcomes related to infant growth up to one year of age will also be investigated.                                                                                                                                             | Use in pregnant women                                         | Completion of the feasibility study                           | March 2023                                                    |
| D3461R00028 A Non- Interventional Multi- Database Post Authorisation Study to Assess Pregnancy- Related Safety Data from Women with SLE Exposed to Anifrolumab Ongoing D3461R00046 A non- interventional | The aim of this study is to describe the congenital malformations, adverse pregnancy and birth outcomes in pregnancies/offspring from women with moderate/severe SLE exposed to anifrolumab during pregnancy and to compare with outcomes in women with moderate/severe SLE who are exposed to other SOC but not anifrolumab. Adverse outcomes related to infant growth up to one year of age will also be investigated.                                                                                                                                             | Use in pregnant women                                         | Interim report 1                                              | Q4 2027                                                       |
|                                                                                                                                                                                                          | The aim of this study is to describe the congenital malformations, adverse pregnancy and birth outcomes in pregnancies/offspring from women with moderate/severe SLE exposed to anifrolumab during pregnancy and to compare with outcomes in women with moderate/severe SLE who are exposed to other SOC but not anifrolumab. Adverse outcomes related to infant growth up to one year of age will also be investigated.                                                                                                                                             | Use in pregnant women                                         | Interim report 2                                              | Q4 2030                                                       |
|                                                                                                                                                                                                          | The aim of this study is to describe the congenital malformations, adverse pregnancy and birth outcomes in pregnancies/offspring from women with moderate/severe SLE exposed to anifrolumab during pregnancy and to compare with outcomes in women with moderate/severe SLE who are exposed to other SOC but not anifrolumab. Adverse outcomes related to infant growth up to one year of age will also be investigated.                                                                                                                                             | Use in pregnant women                                         | Final report submission                                       | Q1 2032                                                       |
| multi- country post- authorisation safety study (PASS) to assess the incidence of serious infections & malignancies in systemic lupus erythematosus (SLE) patients exposed to anifrolumab.               | To compare hazard rates of new malignancies (as a composite outcome) in moderate/severe SLE patients initiating anifrolumab versus comparable moderate/severe SLE patients who do not initiate anifrolumab (exposed to SLE SOC). To compare hazard rates of the first occurrence of a serious infection (as a composite outcome) in moderate/severe SLE patients initiating anifrolumab versus comparable moderate/severe SLE patients who do not initiate anifrolumab (exposed to SLE SOC). To describe the demographic and clinical characteristics of patients in | Serious infection and malignancies                            | Study protocol submission                                     | August 2022                                                   |
| multi- country post- authorisation safety study (PASS) to assess the incidence of serious infections & malignancies in systemic lupus erythematosus (SLE) patients exposed to anifrolumab.               | To compare hazard rates of new malignancies (as a composite outcome) in moderate/severe SLE patients initiating anifrolumab versus comparable moderate/severe SLE patients who do not initiate anifrolumab (exposed to SLE SOC). To compare hazard rates of the first occurrence of a serious infection (as a composite outcome) in moderate/severe SLE patients initiating anifrolumab versus comparable moderate/severe SLE patients who do not initiate anifrolumab (exposed to SLE SOC). To describe the demographic and clinical characteristics of patients in | Serious infection and malignancies                            | Completion of feasibility study (Stage 1)                     | March 2023                                                    |
| multi- country post- authorisation safety study (PASS) to assess the incidence of serious infections & malignancies in systemic lupus erythematosus (SLE) patients exposed to anifrolumab.               | To compare hazard rates of new malignancies (as a composite outcome) in moderate/severe SLE patients initiating anifrolumab versus comparable moderate/severe SLE patients who do not initiate anifrolumab (exposed to SLE SOC). To compare hazard rates of the first occurrence of a serious infection (as a composite outcome) in moderate/severe SLE patients initiating anifrolumab versus comparable moderate/severe SLE patients who do not initiate anifrolumab (exposed to SLE SOC). To describe the demographic and clinical characteristics of patients in | Serious infection and malignancies                            | Interim report 1 (serious infections and malignancy)          | Q2 2027                                                       |
| multi- country post- authorisation safety study (PASS) to assess the incidence of serious infections & malignancies in systemic lupus erythematosus (SLE) patients exposed to anifrolumab.               | To compare hazard rates of new malignancies (as a composite outcome) in moderate/severe SLE patients initiating anifrolumab versus comparable moderate/severe SLE patients who do not initiate anifrolumab (exposed to SLE SOC). To compare hazard rates of the first occurrence of a serious infection (as a composite outcome) in moderate/severe SLE patients initiating anifrolumab versus comparable moderate/severe SLE patients who do not initiate anifrolumab (exposed to SLE SOC). To describe the demographic and clinical characteristics of patients in | Serious infection and malignancies                            | Final report of study results (serious infections)            | Q4 2028                                                       |
| multi- country post- authorisation safety study (PASS) to assess the incidence of serious infections & malignancies in systemic lupus erythematosus (SLE) patients exposed to anifrolumab.               | To compare hazard rates of new malignancies (as a composite outcome) in moderate/severe SLE patients initiating anifrolumab versus comparable moderate/severe SLE patients who do not initiate anifrolumab (exposed to SLE SOC). To compare hazard rates of the first occurrence of a serious infection (as a composite outcome) in moderate/severe SLE patients initiating anifrolumab versus comparable moderate/severe SLE patients who do not initiate anifrolumab (exposed to SLE SOC). To describe the demographic and clinical characteristics of patients in | Serious infection and malignancies                            | Interim report 2 (malignancy)                                 | Q2 2030                                                       |

<div style=\"page-break-after: always\"></div>

| Study Status                                                  | Summary of objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Safety concerns addressed                                     | Milestones                                                    | Due dates                                                     |
|---------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities |
| Ongoing                                                       | each study cohort (malignancy cohort and serious infection cohort) at index date, by exposure status (exposed to anifrolumab vs. exposed to SLE SOC). To compare hazard rates of new pre- specified malignancy sub-types (separately) in moderate/severe SLE patients initiating anifrolumab versus comparable moderate/severe SLE patients who do not initiate anifrolumab (exposed to SLE SOC). To compare hazard rates of the first occurrence of opportunistic serious infections, other serious infections, pneumonia (overall), fatal and non- fatal pneumonia (separately) in moderate/severe SLE patients initiating anifrolumab versus comparable moderate/severe SLE patients who do not initiate anifrolumab (exposed to SLE SOC), where feasible (ie, if sample size is sufficient). To compare the hazard rates of recurrent infections leading to hospitalisation in moderate/severe SLE patients initiating anifrolumab and in comparable moderate/severe SLE patients who do not initiate anifrolumab (exposed to SLE SOC), when feasible. |                                                               | Final report of study results (malignancies)                  | Q4 2032                                                       |

<div style=\"page-break-after: always\"></div>

## 2.7.3. Risk minimisation measures

## Table 32: Summary Table of Pharmacovigilance Activities and Risk Minimization Activities by Safety Concern

| Safety concern                          | Risk minimization measures                                                         | Pharmacovigilance activities                                                                                                                                                                                                                                                                                                                       |
|-----------------------------------------|------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important potential risks               | Important potential risks                                                          | Important potential risks                                                                                                                                                                                                                                                                                                                          |
| Malignancy                              | Routine risk minimization measures: • SmPC Section 4.4 • Package leaflet Section 2 | Routine pharmacovigilance activity: • Targeted safety questionnaire Additional pharmacovigilance activities: • Study D3461R00046 - A non- interventional multi-country post- authorisation safety study (PASS) to assess the incidence of serious infections & malignancies in systemic lupus erythematosus (SLE) patients exposed to anifrolumab. |
| Serious infection                       | Routine risk minimization measures: • SmPC Section 4.4 • Package leaflet Section 2 | Additional pharmacovigilance activities: • Study D3461R00046 - A non- interventional multi-country post- authorisation safety study (PASS) to assess the incidence of serious infections & malignancies in systemic lupus erythematosus (SLE) patients exposed to anifrolumab.                                                                     |
| Missing information                     | Missing information                                                                | Missing information                                                                                                                                                                                                                                                                                                                                |
| Use in pregnant and breastfeeding women | Routine risk minimization measures: • SmPC Section 4.6 • Package leaflet Section 2 | Additional pharmacovigilance activity: • D3461R00028, A Non-Interventional Multi-Database Post-Authorisation Study to Assess Pregnancy-Related Safety Data from Women with SLE Exposed to Anifrolumab                                                                                                                                              |

## 2.7.4. Conclusion

The CHMP considered that the risk management plan version 6.1 is acceptable.

## 2.8. Pharmacovigilance

## 2.8.1. Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the MAH fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

<div style=\"page-break-after: always\"></div>

## 2.8.2. Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.9. Product information

## 2.9.1. User consultation

The results of the user consultation for Saphnelo 120 mg solution for injection in pre-filled syringe submitted by the MAH show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

The bridging report for the pre-filled pen submitted by the MAH has been found acceptable.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

Systemic lupus erythematosus (SLE) is a complex, chronic, and heterogeneous autoimmune disease of unknown etiology that affects multiple organ systems.

Clinical manifestations of SLE include, but are not limited to, constitutional symptoms such as fatigue and fever, alopecia, rashes, serositis, arthritis, nephritis, vasculitis, lymphadenopathy, splenomegaly, hemolytic  anemia,  cognitive  dysfunction,  and  other  nervous  system  involvement.  These  disease manifestations cause a significant burden of illness and can lead to reduced physical function, loss of employment, and considerable health-related quality of life impairments. Increased hospitalizations and side effects of medications, including chronic oral corticosteroids (OCS) and other immunosuppressive treatments, add to the disease burden in SLE. There is considerable morbidity and reduced quality of life for many patients with SLE, and it is associated with cumulative and irreversible organ damage and early mortality.

The sought indication for SC anifrolumab was: ' Saphnelo is indicated as an add on therapy for the treatment  of  adult  patients  with  moderate  to  severe,  active  autoantibody  positive  systemic  lupus erythematosus (SLE),  despite  standard  therapy. ',  which  is  identical  to  the  approved  wording  for  IV anifrolumab.

## 3.1.2. Available therapies and unmet medical need

Until the approval of the 2 available targeted therapies for SLE (belimumab, IV or SC and IV anifrolumab), treatments were based on non-targeted therapies such as OCS and other immunosuppressive drugs. These  remain  a  major  component  of  SLE  therapy.  However,  chronic  steroid  use,  nonsteroidal  antiinflammatory drugs, and immunosuppressive agents have known safety concerns that contribute to longterm morbidity and mortality in SLE patients.

<div style=\"page-break-after: always\"></div>

There continues to be a need for improvement in SLE treatment through enhanced convenience for patients. The current application was a line extension for SC anifrolumab to the already approved IV administered anifrolumab.

## 3.1.3. Main clinical studies

The  anifrolumab  SC  clinical  programme  included  a  single,  pivotal,  global,  multicenter,  randomized, double-blind  (DB),  placebo-controlled,  Phase  III  study  (TULIP  SC).  TULIP  SC  was  an  ongoing  study during the procedure evaluating the safety and efficacy of anifrolumab SC administered by accessorised pre-filled syringe (APFS) in adults with moderate to severe SLE despite receiving standard of care.

## 3.2. Favourable effects

The primary endpoint, i.e. BICLA response rate at week 52 was 59.4% for anifrolumab and 43.9% for placebo (15.5% treatment difference, 95% CI 2.3, 28.6; p=0.0211). The results of the sensitivity and supplementary analyses were consistent with those of the primary analysis.

Overall, the secondary endpoints were numerically in favour of anifrolumab, supporting the beneficial effect of SC anifrolumab in the treatment of adult patients with moderate to severe, active autoantibodypositive SLE, despite standard therapy.

## 3.3. Uncertainties and limitations about favourable effects

The efficacy analysis is based on an IA of the first 220 patients of TULIP SC study. In the chosen IA strategy, only the primary endpoint was formally tested, while the key secondary endpoints will be tested in the multiple testing procedure when the full data on all 367 patients is available. Despite that the key secondary endpoints were all numerically in favour of SC anifrolumab this weakens the robustness and comprehensiveness of the efficacy results. Further efficacy results will become available when the MAH will submit the complete study report for all patients of the TULIP SC study by Q1 2026.

## 3.4. Unfavourable effects

Interim safety analysis (N= 346/367) of the pivotal phase 3 TULIP SC study (SC Safety Analysis Set)

Based on the 128.56 PY of treatment exposure to anifrolumab 120 mg SC (median duration of exposure 359.0 days), with 88 patients treated for one year, the overall incidence of AE during the double-blind treatment period of the TULIP SC study was 74.4% in the anifrolumab 120 mg SC group and 71.2% in the placebo group. Most AEs were mild to moderate in intensity.

The most common AEs (frequency &gt; 5%) were nasopharyngitis (10.8% patients), COVID-19 (9.1% patients), and upper respiratory infection (8.0% patients) in anifrolumab 120 mg SC group compared with  nasopharyngitis  (9.4%  patients),  injection  site  erythema  (8.8%  patients),  bronchitis  (7.6% patients) and urinary tract infection (7.6% of patients) in placebo group.

The  incidence  of  non-opportunistic  serious  infections  was  6.3%  (exposure-adjusted  incidence  rate [EAIR]: 8.84 per 100 PY) in the anifrolumab group and 3.5% (EAIR: 4.89 per 100 PY) in the placebo (EAIR difference of 3.95; 95% CI: -2.90, 11.50). Two events of non-opportunistic serious infections resulted in discontinuation of IMP.

No opportunistic infections were reported during the 52-week DB treatment period.Incidence of herpes zoster was (4.0% [EAIR: 5.62 per 100 PY]) in the anifrolumab treatment group compared with placebo

<div style=\"page-break-after: always\"></div>

(1.2% [1.61 per 100 PY]). Most events were cutaneous, localized, nonserious, mild or moderate in intensity, resolved with antiviral therapy, and did not lead to IMP discontinuation.

In all, 2 events of tuberculosis (including latent tuberculosis) were reported in the 52-week DB treatment period, one in the anifrolumab 120 mg SC group (latent tuberculosis) and one in the placebo group (extrapulmonary tuberculosis).

In all, 3 MACE events were reported, 2 in the anifrolumab 120 mg SC group (adjudication outcomes: acute  myocardial  infarction,  cerebrovascular  accident)  and  one  in  the  placebo  group  (adjudication outcome: acute myocardial infarction).

The proportions of patients with AESI of injection site reactions were similar in the anifrolumab group (27 patients [15.3%]) and in the placebo group (29 patients [17.1%]). All injection site reaction AESIs were nonserious, mild or moderate in intensity, and transient in nature, mostly considered related to the anifrolumab treatment by the investigator.

The most common system organ class (SOC) with reported SAEs was Infections and infestations in the anifrolumab 120 mg SC (6.8%) and in the placebo groups (3.5%).

No malignancies were reported during the 52-week double-blind treatment period.

One outcome of death (PT, gastrointestinal infection) was reported in the anifrolumab treatment group and none in the placebo group.

The clinical laboratory results as well as observations related to vital signs for the study pivotal study was consistent with the IV formulation and none considered clinically meaningful. There were no new safety concerns.

## 3.5. Uncertainties and limitations about unfavourable effects

The current submission is based on data from an interim analysis of the pivotal study TULIP SC study therefore data remains limited. Acknowledging the inherent limitations of between-study comparisons data showed that safety profile of anifrolumab 120 mg SC QW is generally consistent with the established safety profile of anifrolumab 300 mg IV Q4W. Further safety data will become available when the MAH will submit the complete study report for all patients of the TULIP SC study by Q1 2026.

## 3.6. Effects Table

<div style=\"page-break-after: always\"></div>

Table 33: Effects Table for anifrolumab 120 mg SC QW for the treatment of moderate to severe SLE [data cut-off: 23 July 2024 for the interim analysis)].

| Effect                             | Short Description                                               | Unit                    | Ani 120 SC              | Placebo                 | Uncertainties/ Strength of evidence                                       | Refere nces             |
|------------------------------------|-----------------------------------------------------------------|-------------------------|-------------------------|-------------------------|---------------------------------------------------------------------------|-------------------------|
| Favourable Effects                 | Favourable Effects                                              | Favourable Effects      | Favourable Effects      | Favourable Effects      | Favourable Effects                                                        | Favourable Effects      |
| BICLA RR                           | BICLA response rate at Week 52                                  | %                       | 59.4                    | 43.9                    | difference 15.5% (95 CI 2.3, 28.6); p=0.0211, IA of 220 patients          | TULIP SC                |
| BICLA RR with low/reduced OCS      | BICLA response rate at Week 52 with maintained low (or reduced) | %                       | 59.4                    | 39.5                    | difference 19.9% (95% CI 6.9, 32.9); nominal p=0.0027, IA of 220 patients | TULIP SC                |
| Time to sustained BICLA response   | Time to BICLA response sustained through Week 52                | %of respon se           | 39.8                    | 22.8                    | HR 2.038 (95% CI 1.248, 3.408); nominal p=0.0052, IA of 220 patients      | TULIP SC                |
| Time to first flare                | Time to first flare through Week 52                             | %of flare               | 39.3                    | 46.6                    | HR 0.757 (95% CI 0.499, 1.141); nominal p= 0.1841, IA of 220 patients     | TULIP SC                |
| Unfavourable Effects **            | Unfavourable Effects **                                         | Unfavourable Effects ** | Unfavourable Effects ** | Unfavourable Effects ** | Unfavourable Effects **                                                   | Unfavourable Effects ** |
| Number of patients                 | N=346 in all                                                    |                         | n=176                   | n=170                   |                                                                           |                         |
| AEs, all                           |                                                                 | n (%)                   | (74.4)                  | (71.2)                  | 52 week double-blind period                                               | TULIP SC                |
| AEs, most common                   | Nasopharyng itis                                                | n (%)                   | 19 (10.8)               | 16 (9.4)                |                                                                           | TULIP SC                |
| Any SAE                            |                                                                 | n (%)                   | 19 (10.8)               | 15 (8.8)                |                                                                           | TULIP SC                |
| Serious Infections                 |                                                                 | n (%)                   | 11 (6.3)                | 6 (3.5)                 | Two events resulted in discontinuation of IP                              | TULIP SC                |
| Deaths                             |                                                                 | n (%)                   | 1 (0.6)                 | 0                       | The single death was due to gastroenteritis                               | TULIP SC                |
| Discontinuati ons due to AEs       |                                                                 | n (%)                   | 9 (5.1)                 | 5 (2.9)                 |                                                                           | TULIP SC                |
| Local injection site reactions     |                                                                 | n (%)                   | 27 (15.3)               | 29 (17.1)               | No ADAs detected                                                          | TULIP SC                |
| Post- injection systemic reactions | Hypersensiti vity reactions                                     | n (%)                   | 2 (1.1)                 | 0                       | No ADAs detected                                                          | TULIP SC                |

<div style=\"page-break-after: always\"></div>

| Effect   | Short Description      | Unit   |   Ani 120 SC |   Placebo | Uncertainties/ Strength of evidence                                      | Refere nces   |
|----------|------------------------|--------|--------------|-----------|--------------------------------------------------------------------------|---------------|
|          | Anaphylactic reactions | n (%)  |            0 |         0 | One anaphylactic event was reported for IV anifrolumab 150 mg in study 5 | TULIP SC      |

Abbreviations:

Notes: ** Data reflect the IA (n=346/367) population, the Safety Analysis Set, of the pivotal TULIP SC study

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The efficacy of SC anifrolumab was evaluated in a single phase 3 study, TULIP SC. Given the approval of  IV  anifrolumab,  a  single  study  was  considered  sufficient  for  the  assessment  of  efficacy  of  SC anifrolumab in the same target population and the same indication. The primary endpoint BICLA response is a valid composite index to assess SLE disease activity and acceptable from the regulatory point of view as it is in line with the Guideline on clinical investigation of medicinal products for the treatment of systemic lupus erythematosus and lupus nephritis (EMA/CHMP/51230/2013 corr 1). The response rate of BICLA response at week 52 was 59.4% for SC anifrolumab and 43.9% for placebo, resulting in a 15.5% treatment difference. The efficacy observed with the sc formulation is comparable to the efficacy seen in pivotal IV anifrolumab studies, i.e. 16.3% treatment difference in the IV study 04 and 17.0% treatment difference in the IV study 05.

The key secondary endpoints were all numerically in favour of SC anifrolumab, including BICLA response at week 52 with maintained low (or reduced) use of OCS, time to BICLA response sustained through week 52, and time to flare through week 52. It was considered a major weakness that these endpoints were not hypothesis tested for the IA in the multiple testing procedure, which was planned only at the time of the final analysis.

In conclusion, the efficacy data as a whole, suggested a modest, but clinically relevant efficacy for SC anifrolumab  that  is  broadly  similar  to  the  efficacy  seen  with  the  approved  IV  anifrolumab.  SC administration will introduce a relevant new option for anifrolumab to be administered by the patient or by caregiver.

With  respect  to  safety,  in  the  single  pivotal  phase  3  TULIP  SC  study,  anifrolumab  120  mg  SC  QW appeared  well  tolerated  in  adult  patients  with  moderate  to  severe  active  SLE  during  52  weeks  of treatment. No new safety concerns or no new ADRs were identified. The safety profile of anifrolumab 120 mg SC QW appeared generally consistent with the established safety profile of anifrolumab 300 mg IV Q4W, acknowledging the inherent limitations of between-study comparisons.

## 3.7.2. Balance of benefits and risks

The benefit/risk balance of SC anifrolumab is positive.

## 3.7.3. Additional considerations on the benefit-risk balance

None

<div style=\"page-break-after: always\"></div>

## 3.8. Conclusions

The overall benefit /risk balance of 120mg SC anifrolumab is positive.

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of, Saphnelo 120mg, solution for injection for subcutaneous use is favourable in the following indication(s):

Saphnelo is indicated as an add on therapy for the treatment of adult patients with moderate to severe, active autoantibody positive systemic lupus erythematosus (SLE), despite standard therapy.

The CHMP therefore recommends the extension(s) of the marketing authorisation for Saphnelo subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

## Conditions and requirements of the marketing authorisation

## Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

- Risk Management Plan (RMP)

The Marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States.

Not applicable.